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Chronic Kidney Disease (CKD) affects million people worldwide and is a risk factor 
for morbidity and mortality. CKD patients have poor bone mineral density due to 
mineral metabolism imbalance and secondary hyperparathyroidism resulting in an 
increased fracture incidence. Bone, despite its well-known function on mineral 
storage and organ protection, plays an important role as endocrine organ controlling 
several system functions and metabolic pathways. In this respect, bone status have 
been associated with cardiovascular diseases and mortality in both, the general and 
CKD populations. Moreover, Fibroblast Growth Factor 23 (FGF23), a phosphaturic 
hormone secreted by osteocytes and mature osteoblasts has been associated with 
increased mortality and left ventricular hypertrophy. 
In clinical practice, mineral abnormalities are commonly treated with calcitriol, 
phosphate binders and calcimimetics, to maintain plasma parathyroid hormone 
(PTH) and phosphate levels within the normal range. Among the distinct types of 
phosphate binders available, those based on magnesium have additional benefits, 
preventing vascular smooth muscle cells calcification. 
As bone disorders are involved in adverse outcomes, we consider of interest the 
study of the abnormalities of mineral and bone disorders associated with CKD and 
how calcitriol, magnesium, calcimimetic and FGF23 affect bone cells and bone 
homeostasis in the context of renal insufficiency. 
To address this issue we used animal models of renal insuficiency and in vitro 
models of osteoblasts and osteoclasts and we found that 1) moderate doses of 
calcitriol decrease osteoblast acitivity and increase mineralization in vivo whereas 
high doses of calcitriol impair osteogenic differentiation in vitro; 2) dietary 
magnesium supplementation increases osteoblast activity and may impair 
mineralization in vivo and magnesium supplementation promotes osteogenic 
differentiation in vitro through Notch signaling activation; 3) treatment with 
calcimimetic maintains bone turnover despite the concomitant decrease in PTH 
concentration in vivo and increased osteogenesis and mineralization in vitro and 4) 
high FGF23 concentrations produce bone changes in a model of uni-nefrectomized 
rats and impair osteocyte maturation whereas promote osteoclast differentiation in 
vitro. 
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Altogether, our results demonstrate a potential role of these molecules on bone 














La Enfermedad Renal Crónica (ERC) afecta a millones de personas mundialmente 
y es un factor de riesgo para morbilidad y mortalidad. Los pacientes con ERC tienen 
pérdida de densidad mineral ósea debido al desequilibrio del metabolismo mineral 
y al hiperparatiroidismo secundario que resulta en un incremento del índice de 
fracturas. El hueso, además de sus conocidas funciones como almacén de 
minerales y soporte y protección de órganos, juega un importante papel como 
órgano endocrino controlando el funcionamiento de varios sistemas y procesos 
metabólicos. En este sentido, el estado del hueso ha sido asociado con 
enfermedades cardiovasculares y mortalidad tanto en la población general como en 
pacientes con ERC. Además, el Factor de Crecimiento Fibroblástico 23 (FGF23), 
una hormona fosfatúrica secretada por osteocitos y osteoblastos maduros ha sido 
asociada con el incremento de mortalidad y la hipertrofia de ventrículo izquierdo. 
En la clínica, el tratamiento con calcitriol, quelantes de fósforo y calcimiméticos es a 
menudo usado para controlar los niveles plasmáticos de hormona paratiroidea 
(PTH) y fósforo. Entre los distintos quelantes de fósforo, los que contienen magnesio 
ofrecen beneficios adicionales, previniendo la calcificación de células de músculo 
liso vascular. 
Ya que los trastornos óseos están implicados en eventos adversos, consideramos 
de interés el estudio de las alteraciones del metabolismo mineral y los trastornos 
óseos asociados con la ERC y como el calcitriol, magnesio, calcimimético y FGF23 
afectan las células del hueso y la homeostasis ósea en el contexto de la insuficiencia 
renal. 
Para abordar este trabajo usamos modelos animales de insuficiencia renal y 
modelos in vitro de osteoblastos y osteoclastos y encontramos que 1) dosis 
moderadas de calcitriol mejoran la mineralización y disminuyen la actividad 
osteoblástica in vivo mientras altas dosis bloquean la diferenciación osteogénica  in 
vitro; 2) el alto magnesio en la dieta incrementa la actividad osteoblástica y puede 
afectar la mineralización in vivo, mientras que in vitro el suplemento con magnesio 
promueve la diferenciación osteogénica a tráves de la activación de la ruta Notch; 
3) el tratamiento con calcimimético mantiene el remodelado óseo a pesar de la 
consecuente disminución de los nivels de PTH in vivo e incrementa la osteogénesis 
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y la mineralización in vitro y 4) altas concentraciones de FGF23 provocan cambios 
en el hueso en un modelo de ratas uninefrectomizadas mientras que in vitro inhiben 
la maduración de los osteocitos y promueven la diferenciación osteoclástica. 
En general, nuestros resultados demuestran el potencial papel de estas moléculas 















Chronic kidney disease (CKD) is a growing global problem affecting million people 
worldwide. In CKD patients, the loss of renal function leads to a mineral metabolism 
imbalance that compromises several organs. Due to mineral abnormalities, most of 
CKD patients develop secondary hyperparathyroidism (SHPT) resulting also in bone 
disorders. 
In addition to its mechanical and organs protection functions, bone orchestrates a 
wide number of interactions with other organs, acting as a sender/receptor of many 
hormones and cytokines that take part in physiological processes such as 
cardiovascular status1,2, glucose metabolism3, immune response4, gonadal sex 
steroid interaction5, brain function6,7, etc. 
In CKD, bone contribution to cardiovascular diseases has been largely studied. For 
example, bone mineral density has been associated inversely to vascular 
calcification. Other specific bone factors such as fibroblast growth factor 23 (FGF23), 
has been also associated with the induction of left ventricular hypertrophy and heart 
failure8–10. Additionally, bone health is dramatically compromised in CKD patients. In 
this respect, the terminus CKD-Mineral and Bone Disorders (MBD) has been 
proposed to include the systemic abnormalities of mineral metabolism due to CKD. 
Due to the fact that bone is an important contributor to mineral and cardiovascular 
disorders associated with CKD, we consider that the study of bone is key to 
understand globally the pathophysiology of CKD-MBD and propose new therapeutic 
tools. 
In the introduction of this thesis, we summarize the current knowledge about the 
mineral metabolism alterations in CKD, focused on the abnormalities in bone 
structure and bone cells.  
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1. Calcium and phosphate stores in the body 
 
The major reservoir in the body for calcium (Ca) and phosphate (P) is bone, 
containing 99% and 85% of the total content respectively in the form of 
hydroxyapatite. In the extracellular fluid, the amount of these elements only 
represents a very small part of the total body content. 
In healthy individuals, blood Ca concentration varies from ~8.6 to 10.4 mg/dL. The 
40% is protein-binding Ca and the 6% is linked to P, citrate and bicarbonate. The 
metabolic actions of Ca are attributed to its ionized form, which represents the 54% 
of the total blood Ca and it is tightly ranged between ~4.4 and 5.4 mg/dL (1.1-1.35 
mM). 
Plasma P concentration is around 3.0-4.5 mg/dL and, in normal conditions, it is 
inversely correlated to plasma Ca concentration. P levels vary depending of age, 
gender, diet and acid-base status. P is necessary to catalyze a wide number of 
reactions; it forms part of organic molecules and cellular structures and plays a 
critical role in intermediary metabolism and energy-transfer mechanisms (protein 
phosphorylation, ATP synthesis, etc)11. The distribution of the content of Ca and P 
in the body is shown in Table 1. 
 
  
 Extracellular Fluids Cells Bone Total body content* 
Calcium 1% negligible 99% 1000grs 
Phosphate 0.1% 15% 85% 542grs 
Table 1. Calcium and phosphate content and distribution in the body. 
*Content in a 70kg adult human. Data from Favus MJ. Primer of the Metabolic Bone Disease 
and Disorders of Mineral Metabolism. 6th edition, 200610. 
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2. Bone and bone cells 
 
Bone is the principal store of Ca and P in the body and commonly it is considered as 
an individual organ. The term bone could be controversial, due to it may be referred 
to the mineralized tissue (hard tissue), the sum of mineralized bone and the not-yet-
mineralized collagen matrix or osteoid (sometimes called as pre-bone), and the 
whole organ including bone marrow and soft tissues. The American Society for Bone 
and Mineral Research (ASBMR) adopted the term bone as the sum of both, 
mineralized bone and osteoid. 
Structurally, bone compartments are divided in two types, cortical bone that is the 
hard-outer layer and represents approximately the 80% of total bone mass in the 
adult human skeleton, and trabecular bone, also referred as spongy or cancellous 
bone which is an internal bone that forms a skeletal porous network. The thin 
structures which form the trabecular bone are called trabeculae. Figure 1 shows the 
bone structures of a longitudinal section of the mouse distal femur. 
 
 
Figure 1. Goldner’s trichrome image showing cortical and trabecular bone in the distal 








The growth plate, or epiphyseal plate, is the area of growing tissue near the ends of 
the long bones (fuchsia band). It is constituted by chondrocytes embedded into 
cartilaginous matrix which became mineralized in the zone close to the bone marrow 
(ossification zone). Bone is formed by several types of cells with different functions. 




Osteoblasts are bone forming cells. This term is strictly referred to the cells, generally 
with cuboidal morphology, which produce bone matrix (osteoid), mainly composed 
by collagen fibers. The flat cells that remain quiescent are called lining cells. The 
osteoblast progenitor cells are mesenchymal stem cells (MSC) and they are found 
into the bone marrow12. Furthermore, MSC are also chondrocyte and adipocyte 
progenitors. In the bone marrow, it has been well studied that MSC differentiation 
into osteoblasts is inversely related to MSC differentiation into adipocytes13,14. With 
aging, bone marrow MSC tend to be differentiated into adipocytes instead of 
osteoblasts and it is a feature in the process of osteoporosis15.The main stimulus for 
osteoblast differentiation and activity is PTH16. In this regard, the pharmaceutical 
companies have developed human recombinant PTH analogues (fragment 1-34 and 
1-84) as osteoanabolic agent for the treatment of osteoporosis17. 
Osteoblast differentiation is characterized by the expression of specific bone 
proteins. Figure 2 illustrates the gene expression profile changes during 
osteoblastic/osteocytic differentiation. In early stages of differentiation, when MSC 
are led to be committed osteoprogenitor cells, there is an increase in the expression 
of Collagen Type I (COL1A1), Alkaline Phosphatase (ALP) and Runx2 genes, 
generating preosteoblasts. Then, preosteoblasts upregulate the expression of 
Osterix, an important transcription factor for osteoblast maturation18, and 
Osteocalcin, a protein secreted into the bone matrix and blood stream, which 
participates in bone development and also has an important role in energy balance19, 
and they achieve the state of mature osteoblasts. Some of the osteoblasts may be 
trapped into the mineralized matrix and differentiated into osteocytes, the terminal 
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stage of osteogenic differentiation20. Osteocytes highly express specific genes such 
as SOST, the gene responsible for the production of sclerostin. 
  
 
Figure 2. Transitional stages during osteocyte differentiation (a and b). 1 = preosteoblast; 2 = 
osteoblast; 3 = embedding osteoblast; 4 = osteoid osteocyte; 5 = mineralizing osteocyte; 6 and 
7 = mature osteocytes. Scale bar = 25 μm. Marker genes for the different stages of osteogenic 








Osteocytes are the main cell type in the adult bone and represent about the 90% of 
the bone cells. They can live for decades into the bone matrix and they are one of 
the longest-lived cells in the body and are important endocrine cells participating in 
mineral homeostasis and other processes. Furthermore, they act as 
mechanosensors and regulate bone formation and strength21. Osteocytes express 
high amounts of some specific proteins such as Dentin Matrix Protein 1 (DMP1), 
which participates in bone mineralization, Sclerostin, an endogenous inhibitor of Wnt 
signaling or Fibroblast Growth Factor 23 (FGF23), a potent regulator of phosphate 
metabolism. The study of the bone effects of FGF23 will be a key point in this thesis. 
In spite of they are embedded into the mineralized bone, osteocytes are very well 
connected to whole body signals. Actually, the harvesian system or osteon (Fig.3 a) 
is a very organized structure found in compact bone, measuring 0.2 mm of diameter 
approximately and several millimeters of length. In the center of the system exists a 
tunnel where blood capillaries and nerves, which transport nutrients and signals to 
the cells and collect waste and signals from the bone cells to the circulation. Around 
the harvesian canal, osteocytes are disposed in concentric circles, called lamellae. 
Harvesian system can contain up to 20 lamellae. Osteocytes (Fig.3 b) are embedded 
into mineralized bone, each one into their own cavity, named lacuna. Osteocytic 
lacunae are connected by canals, named canaliculi and they spread their dendrites 
along the canaliculi to connect with the dendrites of the neighbor osteocytes forming 
gap junctions, which only allow the transport of small molecules (intracellular signals 
as Ca2+, cAMP, IP3). Bone canaliculi are not completely occupied by the osteocytes, 
the remaining space is called periosteocytic space and contains fluid and large 
molecules22. Altogether, osteocytes are tightly connected to the systemic signals and 
form an extremely organized network to convey information from the whole body to 





Osteoclasts are the bone resorbing cells. The osteoclast progenitor cells are 
monocytes/macrophages24. Several monocytes fuse to form a large multinucleated 
cell termed osteoclast. Although osteoclasts are multinucleated, containing from 2 to 
several nuclei, in a histological preparation of bone we may observe osteoclasts with 
only one or no nucleus because of the sectional view of the slice. Osteoclasts contain 
abundant lysosomes and tartrate-resistant acid phosphatase (TRAP), which is 
typically used as histochemical staining for osteoclast identification25. Osteoclast life 
spam is a few days26. Osteoclasts differentiation and their activity are regulated by 
the osteoblasts and osteocytes, which produce receptor activator of nuclear factor 
kappa-Β ligand (RANKL) that binds the receptor activator of nuclear factor kappa-Β 
(RANK) in the monocyte surface and promotes their recruitment and fusion to form 
osteoclasts27. Osteoblasts also produce Osteoprotegerin (OPG), a soluble receptor 
for RANKL that intercept the protein and inhibits its ability to bind RANK, preventing 
osteoclast differentiation and activity28,29 (Fig.4). 
 
Figure 3. In (a) is shown a microphotograph of the harvesian system. In the middle is 
found the harvesian canal. Surrounding the harvesian canal, it can be appreciated a very 
organized network of osteocytes connected by cannaliculi (Image adapted from the gallery 
of the Bone Research Society). In (b) is shown a scanning electron microscopy (SEM) 
microphotograph of a mouse osteocyte showing filopodia by Bonewald LF. (Image from 





Figure 4. Stages of osteoclast differentiation. Monocytes/macrophages are cells from 
hematopoietic lineage. The binding of the RANKL secreted by osteoblasts to the receptor 
RANK in the osteoclast surface activates pathways such as NFκB and NFATc1 that lead 
to monocyte recruitment and osteoclast differentiation. OPG prevents RANKL actions. At 
contrary, estrogen and TGFβ induce osteoclast apoptosis. 
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In bone resorption, osteoclasts mainly release two enzymes, Cathepsin K (CTSK) 
which degrades the osteoid30, and TRAP which decreases the pH level and 
promotes the hydroxyapatite crystals dissolution31. 
The typical situation of bone remodeling is a set of osteoblasts in a row forming bone 
following an osteoclast resorbing bone ahead. In a healthy bone, osteoclasts are not 
abundant and bone remodeling remains almost quiescent. Figure 5 shows 
osteoblasts in the process of bone formation and an osteoclast during bone 
resorption.
 
3. Signaling pathways involved in osteoblast differentiation 
 
Among others biochemical pathways, Wnt/β-catenin or Notch signaling have a 
critical role during MSC differentiation into osteoblasts. Following, both signaling 
pathways are briefly described. 
 
Figure 5. Example of a Goldner’s trichrome staining picture showing high bone 







3.1. Notch signaling pathway 
 
In addition to the Wnt/β-catenin pathway, Notch signaling activation has been 
associated with bone formation. Notch signaling is also a conserved pathway in 
multicellular organisms and it is critical in proliferation, differentiation and cell polarity 
in embryonic and postnatal development. To activate Notch signaling, a 
communication between two adjacent cells is needed. Notch receptor is a single 
pass transmembrane receptor consistent in an extracellular domain, a 
transmembrane domain and a Notch Intracellular Domain (NICD)32. When the 
extracellular domain of a receiving cell binds the surface ligand Delta or Jagged of a 
sender cell, the Notch receptor is cleaved intracellularly by a γ-secretase and the 
NICD fragments are translocated into the nucleus activating the transcription factor 
CSL (CBF1, Suppressor of Hairless, Lag-1), responsible for the Notch target genes 
expression, such as HES (hairy and enhancer of split-1) and HEY (Hairy/enhancer-
of-split related with YRPW motif) genes33. See Figure 6. 
 
 
Figure 6. Simplified scheme of Notch signaling pathway. NICD: Notch intracellular 













In vitro, it has been reported that Notch signaling activation increases mineralization 
and osteoblastic differentiation34,35. In vivo, it was demonstrated that Notch signaling 
regulates osteoblast differentiation by maintaining the osteoblast progenitor cell 
pool36,37. Additionally, it has been shown that specific ablation of Notch in osteocytes 
decreases sclerostin and increases trabecular bone volume. In these mice, cortical 
and trabecular bone were indistinguishable, indicating that Notch exerts functions in 
osteocytes to determine the structure of the different bone compartments38.  More 
recently, other studies have confirmed an osteoanabolic response of Notch 
activation in osteocytes39–41, suggesting that there exists controversy about the role 
of Notch signaling during osteogenesis. 
 
3.2. Wnt-β/catenin pathway 
 
Wnt signaling pathways are highly conserved evolutionarily. The common feature of 
all of them is that they depend of the binding of the Wnt ligands to the receptors of 
the Frizzled family. The Wnt signaling pathway that involves β-catenin nuclear 
translocation and the activation of the target genes via T cell factor/lymphoid 
enhancer binding factor (TCF/LEF) transcription factors is termed canonical Wnt 
pathway. Its co-receptors are Lipoprotein-receptor related protein 5 (LRP5) and 
LRP6 and mainly participates in proliferation and differentiation. The non-canonical 
Wnt pathways are those not dependent of β-catenin-TCF/LEF and the most studied 
branches are the non-canonical Wnt/Ca2+ pathway, which participates in cell fate 
and migration, via intracellular Ca2+; and the non-canonical Wnt planar cell polarity 
(PCP) signaling pathway which controls morphogenesis, cell polarity and 
migration42. In addition to its role in embryonic development, the canonical Wnt/β-
catenin signaling pathway is critical in bone formation in adults, since mutations 
affecting the functionality of the LRP5 receptor have been identified as causes for 
skeletal disorders43,44. In general, sustained activation of the Wnt/β-catenin pathway 
in osteoblasts leads to an increase of bone mineral density. 
For the canonical pathway, in the absence of soluble Wnt protein ligands, the protein 
Axin forms a complex with the proteins adenomatous polyposis coli (APC), Casein 
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kinase 1 isoform α (CK1α) and glycogen synthase kinase 3 (GSK3). Axin and APC 
act as scaffold proteins for GSK3β that binds and phosphorylates β-catenin, which 
is degraded by the proteasome. The activation of the Wnt/β-catenin pathway occurs 
with the binding of the Wnt ligands to the receptor Frizzled and the co-receptor LRP5 
or LPR6, following the recruitment of the protein Dishevelled that sequesters Axin 
and prevents the complex formation. In these conditions, β-catenin is not 
phosphorylated and is stabilized, promoting its nuclear translocation. In the nucleus, 
it activates the transcription of the Wnt target genes through the interaction with the 
transcription factors TCF/LEF45. 
There exist a number of proteins that regulate the Wnt/β-catenin pathway by 
inhibition of the binding between the Wnt ligands and the co-receptors. The members 
of the secreted frizzled related protein (sFRP) are proteins that contains a cysteine-
rich domain homologous to the putative Wnt-binding site of Frizzled proteins. 
Crystallographic resolution and biochemical analysis have shown that sFRPs are 
able to prevent the bound of the Wnt proteins to the Frizzled receptors by a) binding 
to the cysteine-rich domain of the Frizzled proteins and forming inactive homo or 
heterodimers complexes or b) binding the Wnt ligands acting as antagonist and 
impeding the activation of the canonical Wnt pathway46,47. 
Other proteins as Sclerostin (the product of the SOST gene) and Dickkopf related 
proteins (DKK), interact with LRP5/6 working as Wnt signaling inhibitors. Sclerostin 
binds the LRP5/6 receptors, impairs the LRP5/6-Frizzled interaction and the 
interaction of the Wnt signaling proteins to the receptors48,49. DKK binds also the 




Historically, the participation of the Wnt-β-catenin pathway in bone disorders have 
been widely documented. In 1955, a rare case of osteopetrosis was defined by Van 
Buchem as “Hyperostosis Corticalis Generalisata Familiaris”, nowadays called Van 
Buchem syndrome. Van Buchem Syndrome patients show extremely increased 
bone mineral density with hyperostosis of the jaw and syndactyly51. In 2001, a loss-
of-function mutations in the SOST gene, was identified as the cause leading to the 
development of the Van Buchem syndrome52,53. Thus, the canonical Wnt pathway is 
 
Figure 7. Simplified scheme of the Wnt/β-catenin signaling pathway. In the presence of 
the Wnt ligand (left), the protein Dishevelled (DVL) binds the Frizzled receptor and 
sequester the protein complex for β-catenin degradation, which in turn translocates into 
the nucleus and activates the TCF/LEF transcription factor. In the absence of the Wnt 
ligand or under the action of the Wnt inhibitors (right), β-catenin is phosphorylated and 






















critical in bone formation and its modulation could be beneficial for the treatment of 
bone disorders. 
In CKD, two inhibitors of the canonical Wnt pathway have been investigated: DKK1 
and Sclerostin54. Paradoxically, despite to both molecules inhibit Wnt ligand-LRP5/6-
Fzd interaction, the downstream responses are different, unrevealing the complexity 
of this pathway. In CKD patients, the correlation of serum DKK1 with mineral and 
bone parameters is inexistent in the most studies55,56, suggesting that DKK1 might 
have a weak relation with renal osteodystrophy. Nevertheless, the serum sclerostin 
levels increase early in CKD before renal osteodystrophy is established. It is 
associated with increased expression in osteocytes, which indicates a relationship 
between bone and kidney in CKD patients57. Serum sclerostin levels increase as 
glomerular filtration rate declines in CKD patients, and also correlate with gender 
and age58. The effects of these elevated levels of sclerostin on bone are unknown 
and the causes and consequences whereby the levels of serum sclerostin increase 
in CKD are not well understood. Paradoxically, it has been reported a positive 
association of serum sclerostin levels with bone mineral density in hemodialysis 
patients59. Additionally, the treatment with neutralizing antibodies against sclerostin 
in a murine model of CKD only resulted beneficial in low PTH conditions60. 
In vitro studies in our laboratory have reported the involvement of the canonical Wnt 
pathway also in pathologic processes as vascular smooth muscle cells calcification61 
and renal cells deterioration62. 
Altogether, Wnt/β-catenin pathway is largely involved on the regulation of bone 
formation. Considering that Wnt inhibitors are increased in CKD, it is a very attractive 
mechanism to look for treatments for the management of renal osteodystrophy. 
Similarly, it results of interest to study the relationship between bone metabolism 
parameters altered during CKD and the activation or inhibition of this important pro-
osteogenic pathway.  
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4. Calcium and phosphate balance in health 
 
Kidneys, gut, parathyroid glands and bone are the organs responsible for the tight 
regulation of Ca and P levels in the body. Thus, the main mechanisms involved in 
Ca and P homeostasis are intestinal absorption, renal reabsorption and bone 
turnover. These processes are regulated by a set of key elements, including 
parathyroid hormone (PTH), 1,25-hydroxyvitamin D or calcitriol (1,25(OH)2D3), 
fibroblast growth factor 23 (FGF23), and receptors, as calcium sensing receptor 
(CaSR), PTH receptor (PTHR, mainly PTHR1), Vitamin D receptor (VDR) and the 
complex FGFR1-α-klotho. 
Parathyroid glands are the responsible organ for PTH production and secretion and 
the control of Ca concentration. Mechanistically, the parathyroid glands sense the 
Ca concentration in the blood through the CaSR, a G protein coupled-receptor that 
detects ionized calcium (iCa) concentration and activates a downstream signaling 
that regulates the PTH production and secretion63. When plasma Ca concentration 
decreases, the CaSR downstream signaling is inactivated and PTH releasing is 
increased (Fig.8). 
 
Circulating PTH targets the kidneys and the bone, binds the PTH receptor 1 (PTHR1) 
and exerts its actions to normalize blood Ca concentration. In the kidney, PTH 
promotes Ca reabsorption through activation of the Transient Receptor Potential 
 








Vanilloid 5 (TRPV5)64. Additionally, PTH induces the expression of the renal 25-
hydroxyvitaminD-1-α-hydroxylase (1α-OHase), the enzyme responsible for the 
hydroxylation of the 25-hydroxyvitamin D to 1,25(OH)2D3. Active vitamin D acts in 
the gut to promote the absorption of Ca through the TRPV6 channels, and P 
absorption through the NaPi-IIb65. 
In the bone, PTH increases the osteoclastic differentiation, proliferation and activity, 
by decreasing osteoprogerin (OPG) and increasing RANKL in osteoblasts, which 
subsequently targets the monocytes (osteoclast precursors) and promotes their 
recruitment and differentiation into osteoclasts66. Consequently, osteoclasts 
increase bone reabsorption and mobilize Ca from the bone-mineralized matrix to the 
bloodstream. At the same time, osteoblasts produce protein-bone matrix or osteoid 
(mainly collagen) which works as scaffold for hydroxyapatite crystals67. The process 
by which osteoblasts and osteoclasts form and resorb mineralized bone is called 
bone turnover or bone remodeling. Finally, the CaSR in the parathyroid glands 
senses again normal Ca concentrations and its activation decreases the PTH 
secretion, closing the loop. 
In normal adults, the Ca content in the bone is net, nevertheless, this content  
decreases in processes such as aging or in the pathological process called 
osteoporosis where participate other mechanisms68. 
It is interesting to note that in normal conditions, plasma P and Ca concentrations 
are indirectly correlated. As well as low iCa concentration, high plasma P levels also 
increase PTH secretion that triggers actions in the kidneys increasing 
phosphaturia69. The ex vivo studies using intact parathyroid glands have been key 
to reveal the direct effects of P and other molecules on PTH releasing70,71. However, 
in addition to PTH, other molecules such as FGF23 has been also involved in the 
maintenance of P homeostasis and bone is thought to be the organ responsible for 
FGF23 production72. In osteocytes and mature osteoblasts, stimuli such as PTH or 
calcitriol, promote FGF23 production and secretion to the bloodstream to maintain P 
homeostasis through its action in the target organs73. The bone actions of both, 
calcitriol and FGF23 will be examined in this thesis. 
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In pathologic conditions, such as loss of kidney functionality, the regulation of the Ca 
and P levels is severely compromised, finding an imbalance of the mineral 
metabolism, which disrupts the hormonal equilibrium and leads to decreasing bone 
mineral density, high incidence of fractures and cardiovascular complications. 
In the next section, the disorders in mineral metabolism due to kidney dysfunction 
are summarized. 
 
5. Chronic Kidney Disease-Mineral and Bone Disorders 
 
Nowadays, CKD is a worldwide problem without cure and only palliative treatments 
are used until the patients receive a renal transplant or die. After organ 
transplantation, treatment with immunosuppressive drugs is needed to prevent 
organ rejection and graft-versus-host disease. In the most cases, the transplanted 
organ is rejected in less than 10 years74, therefore the problem is still far from being 
solved. An epidemiologic study about the incidence of CKD in Europe reported a 
prevalence in CKD (stages 1 to 5) from 3.3% in Norway to 17.3% in Northeast 
Germany75. In Spain, the EPIRCE study reported an overall prevalence of CKD 
(stages 1 to 5) of 9.09%76. 
The principal causes for CKD establishment are diabetes mellitus, hypertension and 
glomerulonephritis77. There are not specific symptoms at the beginning of the 
disease and often it remains undetectable until serum creatinine or proteinuria is 
increased. The progression of this pathology leads to alterations and changes in 
other organs such as heart, parathyroid glands or bone. Actually, cardiovascular 
complications are very common in uremic patients and are inversely associated with 
the decreased renal function78. In this respect, bone abnormalities contributes 
importantly to the development of mineral and cardiovascular disorders in CKD79. 
The main focus of this thesis will be the study of bone changes associated with CKD 
and the implications of potential treatments such as magnesium (Mg), calcimimetic 
and calcitriol on the development of bone disorders. Furthermore, the study of the 
bone effects of FGF23 in early CKD will be also addressed. 
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The CKD-MBD syndrome is a broad group of abnormalities related to a mineral 
metabolism imbalance in the context of renal disease. The progression of CKD leads 
to alterations in the mineral metabolism and its severity increases as the disease 
advances. One of the first pathophysiological events that occurs in the early stages 
of CKD, when the loss of glomerular filtration rate is still marginal, is a renal α-klotho 
down-regulation80. The causes for this renal α-klotho reduction is unclear yet 
although they are largely attributed to kidney deterioration. It has been suggested 
that plasma FGF23 concentration increases progressively, in part promoted by a 
FGF23-resistance caused by a loss of its co-receptor α-klotho which is decreased, 
at least in part, by an excessive P load in the renal tubular cells62,81.  In Figure 9 are 




Figure 9. Changes in plasma and renal parameters with CKD progression (From Drueke 
T. and Massy Z.)82. 
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The loss of the renal function and the high FGF23 levels decrease the renal 1α-
hydroxylase expression and activity and reduces the active 1,25(OH)2D3 synthesis83. 
Consequently, the lower 1,25(OH)2D3 levels induce a decrease in the plasma iCa 
and stimulate the secretion of PTH, which additionally increases the FGF23 
concentration that further suppress the expression of the renal 1α-hydroxylase and 
1,25(OH)2D3 production. Serum FGF23 concentration increases before PTH and 
becomes extremely high in end-stage renal disease (ESRD) patients84. 
The high levels of plasma PTH in uremia are not able to produce sufficient active 
1,25(OH)2D3 due to the loss of the functional renal mass and plasma Ca levels fall 
below the normal range while plasma P concentration becomes abnormally high. 
Moreover, FGF23 is unable to decrease PTH releasing due to the loss of the FGFR1 
and α-klotho receptors in the hypertrophic parathyroid glands85. Furthermore, there 
is a feedback response by bone cells to high PTH levels that induces a direct 
increase of FGF23 in osteoblasts73. These alterations lead to the development of 
SHPT that dramatically affects bone homeostasis86. The lack of a functional kidney 




                
 
Figure 10. Scheme of endocrine interactions in the regulation of mineral metabolism in 
health (a) and renal dysfunction (b). 
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Bone disorders in CKD are heterogeneous. To provide basic understanding, the next 
section summarizes the main types of bone abnormities found during CKD and their 
potential causes. 
 
5.1. Renal osteodystrophy 
 
Renal osteodystrophy is the term that includes the different skeletal abnormalities in 
the CKD context87. Bone disorders associated with albuminuria were recognized in 
the year 188388, but it was since 60’s when skeletal abnormalities emerged due to 
the beginning of the dialysis and the increased lifespan of the patients89. Nowadays, 
renal osteodystrophy represents a serious health problem worldwide and both, the 
bone contribution to renal disease progression and its relationship with 
cardiovascular disorders constitute a challenge in the nephrology field. 
Bone disorders in renal insufficiency are largely attributed to both, the high PTH 
levels or the lack of responsiveness to PTH90. Due to the lower plasma levels of 
1,25(OH)2D3 and iCa, plasma PTH concentration increases and consequently also 
bone turnover. In these conditions, osteoclast activity may be higher than osteoblast 
activity, thus bone volume is reduced. Extremely high PTH levels promote also the 
differentiation of pre-osteoblasts into fibroblasts and lead to the development of 
osteitis fibrosa91. 
On the other hand, bone resistance to PTH and the increased levels of uremic toxins 
in early stage of renal disease lead to low bone turnover and low bone volume, this 
form of renal osteodystrophy is named adynamic bone disorder92. 
Renal osteodystrophy have been divided into different types based on bone 
turnover, bone volume and bone mineralization. The classification of the types of 
renal osteodystrophy is following detailed. 
 
5.1.1. Adynamic bone disease 
 
Nowadays, adynamic bone is the most common form of renal osteodystrophy93. 
Adynamic bone is a form of renal osteodystrophy characterized by decreased bone 
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volume, normal mineralization and very low or inexistent bone turnover. Both, PTH 
over-suppression due to an excessive pharmacological control, and the reduction in 
the PTHR1 expression in bone cells in CKD patients, contribute to the development 
of adynamic bone disorder94. To avoid this fact, guidelines recommend maintaining 





Other type of bone abnormaties associated with CKD are those related to defective 
mineralization such as Osteomalacia. Osteomalacia is defined by an abnormal 
mineralization (mineralization lag time > 100 days and Osteoid thickness > 12.5µm) 
and low bone turnover. It commonly appears due to inadequate Ca-P ratio, 
insufficient 1,25(OH)2D3 or factors that impair hydroxyapatite crystal formation (e.g. 
Aluminum). In bone histology, osteomalacia is appreciated as a high accumulation 
of osteoid due to impaired mineralization of the new bone matrix (See Figure 11). 
  
 
Figure 11. Goldner trichrome staining of trabecular bone showing osteomalacia in a rat 
with renal insufficiency (5/6Nx) for 14 days. Note the accumulation and thickness of 
osteoid (red). Image from our laboratory. 
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5.1.3. Mixed uremic osteodystrophy 
 
On the other hand, high levels of PTH accompanied by defective mineralization may 
also cause Mixed Uremic Osteodystrophy, where increased osteoid, unmineralized 
bone matrix, and a high activity of bone cells co-exist. Mixed uremic osteodystrophy 
is variably defined internationally. Table 2 summarizes the different types of bone 
disorders in CKD. 
 
6. Fractures Prevalence in CKD 
 
CKD is an important risk factor for hip fracture independently of age and gender, and 
the incidence ratios increase according to the time since the first dialysis treatment95. 
In addition to the risk factors in the general population, peripheral vascular disease 
was also independently associated with hip fractures in hemodialysis patients96. This 
risk of fractures increases as CKD progresses97 (See Figure 12) being higher in 
dialysis patients98. 
 Volume Turnover Mineralization 
Adynamic Bone ↓↓↓ ↓↓↓ normal 
Mild Hyperparathyroidism ↓ ↑↑ normal 
Osteotis Fibrosa ↓ ↑↑↑ normal 
Osteomalacia ↓ ↓ ↓↓↓ 
Mixed Uremic Osteodystrophy ↓ ↑↑ ↓↓ 
Table 2. Classification of the different forms of renal osteodystrophy according to bone 
turnover, mineralization and volume (TMV turnover/mineralization/volume) classification. 
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Nickolas TL et al showed that the decrease of glomerular filtration rate (GFR) below 
60 mL/min significantly increases the prevalence of hip fracture, particularly in 
younger patients99. In a retrospective study in CKD men, it has been showed that 
the increased fractures risk was dependent to the CKD stage and the age. 
 
In CKD patients, out of range plasma PTH levels (high or low) have been associated 
with fractures100,101, so there must be other additional factors that contribute to the 
development of fractures in CKD. Altogether indicates that low bone mineral density 
and fractures are very common in CKD and optimal control of PTH levels must be a 
potential factor to reduce fracture and to improve survival, yet not the only one. 
Of note, there exist a close relationship between the increased risk of fractures and 
mortality in elderly adults102–104, and the incidence of all-cause mortality and overall 
survival for hip fracture is comparable to those for myocardial infarction or stroke105. 
Therefore bone analysis is critical in order to avoid fractures and complication in 
renal disease patients. 
In the diagnosis and classification of the types of renal osteodystrophy, bone biopsy 
is the gold standard. Although it is not extensively used in the clinic, considering that 
 
Figure 12. Hip fracture incidence have a higher incidence with age and progressive CKD 
increases this incidence. (From Moe SM. and Nickolas T.)97. 
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it is an invasive technique and requires specialized processing, bone 
histomorphometry is a very useful tool in clinical research, giving information about 
bone turnover, mineralization and volume. Moreover, the new KDIGO Guidelines 
2017 Update indicates performing a bone biopsy prior to antiresorptive and other 
osteoporosis therapies in CKD patients from CKD-3 to CKD-5D106. 
 
7. Bone histomorphometry for evaluation of renal osteodystrophy 
 
In 1987, Parfitt AM. et al107, reported for the first time a set of parameters and 
nomenclature to encourage bone researchers to standardize the manner in which 
data are reported in the field of bone histology. To study bone histomorphometry 
accurately, specific parameters comprising bone cells number and surface, bone 
structure and mineralization should be included. In 2013 the guidelines were updated 
in by Dempster DM et al with scarce changes108. 
The specific measurement must be related to a referent and the most commonly 
used are Tissue Volume (TV), Bone Volume (BV), Bone Surface (BS), Osteoid 
Surface (OS) and their corresponding two-dimensional areas and perimeters. The 
three dimensional/Surface ratios are commonly referred to TV or BV. 
For some case, a subdivision of bone surface is needed as a referent for bone cell 
number and activity. Thus, Osteoblast surface (Ob.S), the surface of bone covered 
by osteoblasts, and the mineralizing surface are often related to osteoid surface, 
while for osteoclasts, osteoid as referent is avoided. Osteoid thickness should be 
also specified. Eroded surface (ES) is the irregular bone surface as result of 
osteoclasts resorption and comprises the osteoclasts surface (Oc.S) and the 
reversal surface (Rv.S). Unfortunately, bone resorption cannot be measured directly 
by histomorphometry, however can be estimated indirectly as the bone formation 
rate increased or decreased by an assumed or measured rate of change of bone 
volume. 
Respect to, derived indices can be either structural or kinetic. The structural ones 
are Trabecular number (Tb.N), Trabecular Separation (Tb.S) and Trabecular 
thickness (Tb.Th). To obtain a value for derived kinetic indices, a labeling of the 
63 
surface active in mineralization at a time of the label administration is needed. 
Double labeling provide information about the mineralized bone deposition. The 
most commonly used fluorochromes for labeling in bone histomorphometry are 
tetracycline and calcein compounds (See Figure 13). 
The term Mineralizing Surface (MS) is the mean of the double labels and the half of 
the single labels. MS can be expressed as MS/OS, equivalent to the fraction of 
osteoid seam life span during which mineralization occurs or to the BS. Bone 
Formation Rate (BFR) relative to BV determines bone age-dependent properties. 
The mineral apposition rate (MAR) is a parameter of bone formation that represents 
the distance between labels divided by the time between both labeling. In addition, 
the concept of Adjusted Apposition Rate (Aj.AR) is the MAR*MS/OS and represents 
the best estimate available in a biopsy of the mean rate of osteoid (or matrix) 
apposition in the absence of osteomalacia. Others parameters are used to express 
the timing of mineralization. The interval between osteoid secretion and its 
subsequent mineralization, in days, is the mineralization lag time (Mlt). The MS is 
 
Figure 13. Image shows double calcein labeling in rat trabecular bone. Interlabel period: 




also used to calculate bone formation rate (BFR) and the volume of mineralized bone 
formed per unit time. BFR relative to BS seems most logical when are being 
considered hormonal effects on bone remodeling. The principal parameters for bone 
histomorphometry are displayed in Table 3. 
Despite bone histomorphometry could be applied to many types of materials, the 
most common are cylindrical biopsies of iliac crest in humans and sections of long 
bones in experimental murine models, usually femurs. Surgical biopsy for bone 
histomorphometry analysis is a painful intervention and is only used for diagnosis of 
renal osteodystrophy and research. However, as it has been already mentioned, 
KDIGO guidelines for CKD-MBD suggests a more extended use of bone biopsy to 
consider with more precision the pathophysiological alterations of bone in CKD106. 
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Parameter Abbreviation Units 
Cortical Thickness Ct.Th µm 
Trabecular Thickness Tb.Th µm 
Osteoid Thickness O.Th µm 
Trabecular Separation Tb.Sp µm 
Trabecular Number Tb.N /mm 
Bone Volume BV/TV % 
Osteoid Volume OV/TV % 
Osteoid Surface OS/BS % 
Osteoblast surface Ob.S/BS % 
Osteoblast Number N.Ob/B.Pm /mm 
Eroded Surface ES/BS % 
Osteoclast Surface Oc.S/BS % 
Osteoclast number Oc.N/B.Pm /mm 
Mineralizing Surface MS/BS % 
Mineralizing Surface per Osteoid MS/OS % 
Mineral Apposition Rate MAR µm/day 
Adjusted Apposition Rate Aj.AR µm/day 
Mineralization lag time Mlt Days 
Osteoid Maturation Time Omt Days 
Bone Formation Rate BFR/BS µ/day 
Bone Formation Rate BFR/BV %/year 
 
Table 3. Nomenclature and units for bone histomorphometry parameters 
according to the ASBMR guidelines107,108. 
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8. Treatments for the management of CKD-MBD 
 
The causes for the establishment of the broad spectrum of bone disorders in CKD 
are poorly understood. Nevertheless, the maintenance of mineral metabolism 
parameters in CKD-MBD is critical to avoid bone abnormalities. In clinical practice, 
the use of calcitriol, CaSR agonists (calcimimetics) and P binders is frequent to 
maintain the mineral parameters within a narrow range in CKD patients. 
Due to the fact that 1,25(OH)2D3 levels are very low in CKD patients with the high 
levels of PTH, the most if not all the CKD patients are treated with any form of vitamin 
D, vitamin D receptor (VDR) agonists or calcimimetics in order to decrease PTH 
levels. However, despite of its effects on PTH regulation are well studied, those 
effects independent of PTH on bone are unknown. Therefore, both calcitriol and 
calcimimetic are particularly important in this thesis, and their PTH-independent 
effects on bone will be studied. 
Regarding to P binders, there is a growing interest in the effects of Mg-based P 
binders on mineral metabolism. This thesis is aimed on the study of the direct actions 
of calcitriol, calcimimetic and magnesium on bone homeostasis in CKD, and in bone 
cells. To attempt this proposal we performed in vivo experiments using animal 
models of renal insufficiency, and in vitro models of osteoblasts and osteoclasts. 
On the other hand, as mentioned above, besides PTH levels, FGF23 concentration 
is also deregulated in CKD and, although some direct actions of FGF23 on bone 
cells has been reported, its contribution to bone abnormalities in CKD have not been 
clearly studied yet. Another key point raised in this thesis will be the study of FGF23 
effects on bone. 
Following a brief introduction to the role of calcitriol, calcimimetic, magnesium, and 





Calcitriol or 1,25(OH)2D3 is the active form of vitamin D. In 1971, it was discovered 
the pivotal role of the kidney in the activation of 1,25(OH)2D3 109, and the reduction 
of 1,25(OH)2D3 induced by the loss of renal mass proposed a feasible explanation 
for the frequency of rickets in patients with renal insufficiency. Afterwards, patients 
with CKD were treated with exogenous 1,25(OH)2D3, resulting in the elevation of 
serum Ca and the lowering of PTH levels110. Nowadays, 1,25(OH)2D3 is commonly 
used to reestablish the 1,25(OH)2D3 deficiency and control the SHPT. The 
metabolism of the vitamin D is shown in Figure 14. 
The effects of vitamin D on renal osteodystrophy have been largely described. In 
1977, an experiment using dogs with experimental renal insufficiency showed that 
restriction of P, decreased the levels of PTH and ameliorated the osteoid 
accumulation, however, when P restriction was accompanied by treatment with 
vitamin D, PTH levels further decreased and signs of renal osteodytrophy were not 
observed, although the animals became hypercalcemic. In that moment, the 
reduction of the PTH levels was attributed to the high levels of plasma Ca111. 
However, after the discovery of the existence of the VDR in the parathyroid glands, 
a direct action of 1,25(OH)2D3 in the regulation of PTH levels was demonstrated in 
dialysis patients112. 
It has been reported that, in addition to the kidneys, bone cells also possess the 
enzyme 1-α hydroxylase, responsible for the 1,25(OH)2D3 synthesis113. Of note, it is 
known since the birth of vitamin D that calcitriol increases bone reabsorption114, 
however there exists controversy about its actions in bone in renal disease patients. 
Long-term treatment with calcitriol also decreased bone alkaline phosphatase 
without changes in PTH levels in eight ESRD patients, but only four showed 
improvement of bone mineral density that remained below normal115, suggesting 




Figure 14. Scheme for Vitamin D synthesis. Vitamin D is synthesized in the skin by the action of 
the ultraviolet light of the sun. Calcidiol is produced in the liver by 25-hydroxylation of Vitamin 
D3. Calcitriol is the active form of the vitamin D and is mainly produced in the kidney by 1α-
hydroxylation of the 25-hydroxyvitamin D3. 24-hydroxylation of calcitriol or calcidiol is performed 
in the kidney and it has been proposed that this product is excreted. 
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Nowadays, calcitriol is widely used in the general population, alone or in 
combination, for the treatment of osteoporosis. In the most cases calcitriol 
supplementation prevents or even reverses the loss of bone mineral density, and 
these effects could be related to its calcemic function116. At contrary, a meta-analysis 
review about the association between vitamin D and bone mineral density showed 
that vitamin D supplementation has marginal effects in bone mineral density when 
administered to individuals who do not present Vitamin D deficiency117. In animals, 
it has been showed that very high calcitriol treatment to rats with normal renal 
function increases cortical porosity118. 
In summary, the previous information illustrates the controversial effects of calcitriol 
on bone. Whether calcitriol effects on bone cells are mediated by its direct actions 
through VDR or by the modulation of plasma PTH and Ca levels are unknown. This 
issue will be studied in vivo in an experimental model of uremia with clamped PTH 
and in vitro during osteogenesis of mesenchymal stem cells and osteoclastogenesis 
of hematopoietic cells. 
It is well known that Vitamin D enhances blood Ca concentration by increasing the 
Ca uptake in gut119. Due to the fact that the CaSR is also expressed in bone, we 
hypothesized that the activation of this receptor, by both, Ca or calcimimetics, might 
participate in the transduction of the Ca signaling, orchestrating bone homeostasis. 
In this context, CaSR activation may contribute to bone turnover in CKD and the 
effects of calcimimetic in bone independently of its action on PTH secretion in vivo 
and in vitro in bone cells must be clarified. 
 
8.2. CaSR and bone 
 
In 1993, the CaSR was identified by the first time in bovine parathyroid glands63. In 
this sense, positive and negative allosteric modulators of the CaSR have been 
developed for the management of the PTH secretion120–122. Additionally, CaSR is 
also expressed in the kidney, and there it regulates calciuria123. In addition to iCa, 
the CaSR can be activated in a minor intensity by other divalent ions as Mg124. 
Activation of CaSR by its ligands triggers a rapid respond via MAPK125,126, which 
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promotes the transcription of the specific target genes. Figure 15 shows a scheme 
of the downstream pathways of CaSR in cells. 
 
An interesting study by Miao D. et al suggested a regulation of the 1α-hydroxylase 
by Ca independently of PTH. They observed that PTH knockout mice developed a 
phenotype similar to that found in hypoparathyrodism (i.e. hypocalcemia, 
hyperphosphatemia and low levels of circulating 1,25(OH)2D3) when feed in a normal 
 
Figure 15. Summary figure showing the principal downstream pathways of the CaSR. 
Ionized Ca2+ in blood, binds the homodimeric CaSR and rapidly activates Gq/11 and Gi/o 
pathways (2-5 minutes). The Gq/11 activates mainly phospholipase C (PLC) that 
metabolizes phosphatidylinositol 4,5-biphosphate (PIP2) into inositol triphosphate (IP3) 
and diacylglycerol (DAG). DAG activates protein kinase C (PLC) and mitogen-activated 
protein kinase (MAPK). IP3 binds the IP3 receptor in the endoplasmic reticulum (ER) and 
promotes calcium releasing into the cytoplasm, which can also activate the MAPK 
pathway. The activation of the Gi/o that inhibits the adenylate cyclase (AC), leading to 
decreasing cAMP levels and protein kinase A (PKA) activation. The reduction in PKA 
activity prevent the inhibition of MAPK and further increases the MAPK pathway. Adapted 
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P diet. However, PTH-KO mice fed on a low Ca diet increased the synthesis of 
1,25(OH)2D3, consistent with a higher expression of the renal 1α-hydroxylase127. 
In vitro studies have also demonstrated the existence of the CaSR in osteoblasts128, 
and its activation promotes proliferation and chemotaxis, suggesting a key role of 
CaSR in the organization and mobilization of the osteoblasts to the site of 
resorption129. In addition, it has been observed in calvaria cells and others models of 
osteoblasts, that high Ca concentration (1.25-1.8mM) or gadolinium, a trivalent 
cation with similar ionic radius to Ca, activate the CaSR downstream signaling and 
increase the mineralized bone formation130. 
The role of a functional CaSR in bone tissue has been also studied in vivo. Mice with 
conditional ablation of the CaSR in osteoblasts show delayed osteoblast 
differentiation and defective mineralization. In addition, in these mice RANKL was 
also increased, and consequently the number of osteoclasts131. Other studies have 
shown that mice with specific ablation of the CaSR under the promotor of Col (II) or 
Osterix displayed important defects in bone development, demonstrating the crucial 
role of CaSR in osteoblasts at different stages132. 
In this respect, calcimimetics and Ca, through the activation of CaSR, might also 
exerts relevant actions directly in bone cells in CKD although this issue has not been 
clearly studied. 
 
8.2.1. Calcimimetics in CKD 
 
Calcimimetics are positive agonist of the CaSR and are used in the clinic to decrease 
PTH secretion133,134. These molecules induce a conformational change in the 
extracellular domain of the CaSR and make the receptor more sensitive to plasma 




In hemodialysis patients with established SHPT, administration of the calcimimetic 
R-568 also reduced PTH plasma concentration121. In CKD patients, several clinical 
studies have demonstrated that hemodialysis patients treated with the second 
generation of calcimimetics Cinacalcet (Mimpara) showed decreased PTH levels as 
well as lower serum P concentration122,136,137. In 2004, FDA approved the clinical use 
of Cinacalcet for the treatment of hyperparathyroidism. 
Generally, the effects of calcimimetics in bone in CKD are largely attributed to its 
action on PTH regulation138. The hypothesis that CaSR activation promotes bone 
changes independently of PTH has not been explored or quantified yet. More 
recently, the expression of the CaSR have been also confirmed in a variety of tissues 
and calcimimetic may exert its functions in others cells. Thus, CaSR modulation is 
being investigated in other fields “not related” to calcium metabolism, as cancer139–
141, hypertension142,143, asthma144 or inflammation145 among others. 
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The bone effects of calcimimetic have been widely documented. Yajima A. et al146, 
in a histomorphometric study, reported that treatment with cinacalcet during 1 year 
decreased bone turnover markers and fibrosis in four hemodialysis patients. 
Undoubtedly, these results could be influenced by the lower PTH levels after 
treatment. In the EVOLVE study, cinacalcet vs placebo was compared in a cohort of 
hemodialysis patients with established SHPT. At the beginning, the study was 
planned to investigate the effects of cinacalcet in cardiovascular diseases and 
mortality and the authors recognized limitations in the bone study. However, they 
observed a significant decrease in the incidence of fractures when adjusted for 
differences in baseline characteristics, multiple fractures, and/or events prompting 
discontinuation of the study drug. Nevertheless, the action of cinacalcet as 
suppressor of PTH releasing may be involved in the reduction of fracture events147. 
In the same way, in the Bonafide study, bone cells activity decreased according to 
the reduction of PTH levels after treatment with calcimimetic138. In a recent study, 
the administration of the novel second generation calcimimetic Etelcalcetide 
(Parsabiv) maintained the bone turnover in rats that underwent subtotal Nx despite 
of the decrease in serum PTH levels148. Therefore, these studies suggest a specific 
role of CaSR activation, although it is difficult to separate a direct effect of CM from 
the decreased levels of PTH. In this way, directs effects of the calcimimetics on bone 
during CKD must be evaluated. 
Another critical issue in CKD is to maintain plasma P levels within the normal range. 
In this respect, it has been reported that the control of P absorption in the gut 
decreases plasma P concentration in CKD patients149 and dietary intervention has 
showed beneficial effects150. However, poor adherence to P restriction diet is 
frequent in patients with renal disease151. To solve this problem, P binders have been 
developed for managing plasma P levels in CKD patients. Particularly, Mg-based P 
binders have shown important beneficial effects. Another key item in this thesis is 
the evaluation of the bone effects of dietary magnesium as P binder in a murine 
model of renal insufficiency and vascular calcification. Furthermore, the in vitro 
effects of magnesium on osteogenesis and osteoclastogenesis will be also 
examined in this thesis.  
74 
8.3. Phosphate Binders 
 
The control of P levels in CKD patients is a key challenge nowadays. High plasma 
levels of P have been associated with mortality and morbidity in people with 
normal152 and reduced renal function153. The plasma P concentration is highly 
associated with the P content in the diet and even the source of P154. The benefits 
of P restriction in the diet for the management of SHPT in renal insufficiency were 
firstly examined by Slatopolsky E. et al155 in 1973. They observed that P restriction 
in the diet prevents the increase of plasma PTH concentration at different ranges of 
Glomerular Filtration Rate (GFR) in a model of renal insufficiency in dogs. More 
recently the benefits of dietary P restriction in CKD patients have been also 
demonstrated150. However, due to the fact that the management of the diet in 
patients with CKD is difficult, pharmaceutical corporations have developed 
compounds capable to decrease P absorption in the gut, thus reducing plasma P 
levels; these drugs are called P binders and there are a wide variety of them (i.e. 
Aluminum Hydroxide, Calcium carbonate, Calcium acetate, Calcium acetate-
Magnesium carbonate, Lanthanum carbonate, Sevelamer Hydrochloride). 
At the beginning, aluminum-based P binders showed to be efficient reducing serum 
P levels, however, the clinical use of aluminum was stopped after the discovery of 
its implication in the “uremic encephalopathy” and osteomalacia, due to the 
accumulation of aluminum in the cerebral and osseous tissues respectively156. 
Magnesium hydroxide was proposed as an alternative for aluminum157,158, 
nevertheless later was changed to calcium carbonate because of its poor 
gastrointestinal tolerability and laxative effects159. Nowadays other magnesium-
based P binders are efficiently used in the control of hyperphosphatemia160. In 
addition, Mg has other beneficial effects regarding vascular calcification and SHPT. 
In this respect, Mg results of interest for our studies due to the fact that its effects on 
bone homeostasis and osteogenesis have not been investigated in depth. In this 
thesis, we attempt to shed light on the actions of Mg in bone homeostasis.  
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8.3.1. Magnesium and bone 
 
About the 66% of the total Mg in the body is located in bone, nevertheless the impact 
of Mg supplementation on bone in the context of CKD has been poorly studied. In 
1973, Alfrey CA suggested that the accumulation of Mg in bone might be involved in 
the development of renal osteodystrophy161. Additionally, in vitro studies have 
reported that a concentration of 2 mM of Mg promotes amorphous hydroxyapatite 
crystal formation162 which could contribute to the development of osteomalacia and 
defective mineralization. More recently, in the CALMAG study, the authors compared 
the effects of Mg-based P binder (Calcium Acetate/Magnesium Carbonate) or 
Sevelamer on serum bone turnover markers in a cohort of hemodialysis or online 
hemodiafiltration patients. Calcium Acetate/Magnesium Carbonate administration 
increased the levels of serum Ca and Mg after 9 weeks of treatment and reduced 
serum P. In this period, Mg-based P binder administration decreased the serum β-
crosslap collagen type I C-telopeptides, a marker of bone resorption, and increased 
the bone-specific alkaline phosphatase. These effects were not observed in the 
sevelamer group, despite the fact that both groups showed lower PTH levels, 
indicating that Mg may affect bone cells activity163. 
In the other side of the spectrum, several studies have reported a deleterious effect 
of Mg deficiency on bone. Rude et al reported that Mg depletion in the diet by the 
50% increased the number of osteoclasts in rats164. In elderly men and women, Mg 
intake has been related to higher bone mineral density165. 
However, despite the fact that the use of Mg supplementation seems to be beneficial 
for the treatment of CKD, there exist controversy about its effects in bone. One key 
point in this thesis will be the study of the effects of dietary Mg supplementation on 
bone in an animal model of renal insufficiency and vascular calcification and in vitro 
on the differentiation of mesenchymal stem cells into osteoblasts. 
Finally, despite FGF23 is not properly a treatment, we consider of interest the study 
of the role of this molecule on bone homeostasis. FGF23 plays a critical role on P 
metabolism and, importantly FGF23 levels increase according to the loss of the 
glomerular filtration rate.  As FGF23 is a key participant in mineral metabolism 
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homeostasis by regulating PTH production and secretion in parathyroid glands and 
renal vitamin D metabolism,  we hypothesized that it may also exerts actions in bone 
cells, considering relevant the study of the effects of FGF23 in bone. Following, a 
brief introduction to this molecule is detailed. 
 
8.4. FGF23. Definition, functions and contribution to mineral metabolism 
 
Before FGF23 identification, the existence of molecules responsible for the 
regulation of P levels, in addition to PTH and Vitamin D, was supposed. These 
molecules were called “phosphatonins”. In 1994, a potent phosphatonin was 
identified as a low molecular weight and heat-sensitive protein, released by a 
sclerosing hemangioma which induces osteomalacia, decreases serum P and 
1,25(OH)2D3 levels and increases P wasting by inhibition of the apical expression of 
the NaPi-IIa and NaPi-IIc in the renal proximal tubule. After excision of the tumor, P 
and 1,25(OH)2D3 levels became within the normal range166. Therefore, this protein 
was considered as a key factor to maintain P homeostasis. Subsequently, Shimada 
identified FGF23 as the causative protein for hypophosphatemia in Tumor Induced 
Osteomalacia. In this way, subcutaneous implantation of cells overexpressing 
FGF23 induced a decrease in serum P and renal 1α-hydroxylase expression, and 
increased phosphaturia, bone alkaline phosphatase, osteoid accumulation and the 
widening of the growth plate. Characterization of FGF23 showed a soluble secreted 
protein of approximately 30 KDa, however, two fragments resulting from FGF23 
cleavage were also identified72. The tumor responsible for osteomalacia showed an 
elevated FGF23 expression in bone, although this was also detected in at lesser 
extent in other tissues such as heart, liver, lymph node and thymus72. 
At bone level, it has been described that the disruption of FGF23 production 
promotes pathologic bone features with defective mineralization and decreased 
bone turnover. Using FGF23-null mice, Shimada et al showed that the absence of 
FGF23 increased 1,25(OH)2D3 production due to 1α-hydroxylase activation in the 
kidney. Moreover, plasma P and Ca were increased and PTH levels decreased83. 
FGF23 also acts on the parathyroid glands and inhibits PTH production and 
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secretion through FGFR/α-klotho/MAPK signaling activation167. Furthermore, FGF23 
directly participates in the Ca homeostasis, increasing Ca reabsorption by activation 
of the TRPV5 apical expression in the distal renal tubules168.  
Mutations affecting the FGF23 metabolism have been studied in hypophosphatemic 
cases (i.e X-linked hypophosphatemia (XLH)169, autosomal dominant 
hypophosphatemic rickets (ADHR)170 and hyperphosphatemic (i.e 
hyperphosphatemic familial tumoral calcinosis (HFTC)171 disorders, leading to bone 
defects. The Phosphate-regulating neutral Endopeptidase, X-linked (PHEX) is an 
enzyme that participates in the cleavage of FGF23 in two fragments172. Loss-of-
function mutations in the PHEX gene develop XLH, the most common of the 
hypophosphatemic rickets affecting 1:20000. In XLH patients, due to the high plasma 
intact FGF23 levels, serum P concentration is low because of the increased renal P 
wasting. Additionally, hypophosphatemia is not solved due to the resulting low 
1,25(OH)2D3 and PTH levels. These patients developed severe rickets at early age 
and ectopic calcification in adulthood173.  Similarly, ADHR is caused by a mutation in 
the FGF23 gene resulting in a site of cleavage unable to be identified for PHEX, 
protecting FGF23 from proteolysis and leading to increased levels of plasma intact 
FGF23174. FGF23 degradation by PHEX may be prevented by intact FGF23 O-
glycosylation, in the site of cleavage. The enzyme responsible for this process is the 
polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3). Loss-of-function 
mutations in the gene encoding GalNAc-T3 result in HFTC, characterized by 
increased cleavage of the FGF23 protein, hyperphosphatemia and ectopic 
calcifications175. Additionally, the Family with Sequence Similarity 20, Member C 
(FAM20C or DMP4) is a kinase that phosphorylates FGF23 and inhibits the action 
of GalNAc-T3, yet proteolysis is enhanced176. Figure 17 shows the different 
fragments of FGF23 found in the blood (Fig.17 a) and the principal enzymes 
participating on FGF23 processing (Fig.17 b). The previous findings reveal the 
complexity in the FGF23 metabolism.  
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Overall there exists a direct role of high FGF23 on bone turnover and mineralization, 
however, whether FGF23 could contribute to renal osteodystrophy is still unclear. 
There are a growing number of evidences suggesting that FGF23 triggers different 
effects in bone cells177,178. The in vivo e in vitro effects of high levels of FGF23 will 
be explored during this thesis.  
 
 
Figure 17. Scheme for FGF23 processing. a) FGF23 is synthesized as a pro-protein. The 
1-24 signal peptide is excised and the protein become active. The intact FGF23 can 
undergo proteolysis at the site 176-Arg-His-178-Thr-179-Arg-Ser-180, resulting in two 
inactive fragments N-terminal, (12 KDa) and C-terminal (18 KDa). b) Intact FGF23 can be 
O-Glycosylated by the enzyme GALNT3 in various sites and also in theThr-178 preventing 
the proteolysis. At contrary, the kinase FAM20C phosphorylates FGF23 at the Ser-180 
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The main aim of this thesis is the study of the potential effects of treatments generally 
used in CKD patients (such as CTR, calcimimetic or Mg) and molecules abnormally 
altered in renal insufficiency (such as FGF23) on bone alterations. Following, the 




1. To evaluate the direct effects of calcitriol on bone histomorphometry in a 
model of renal insufficiency with parathyroidectomy and subcutaneous 
constant infusion of PTH 
 
2. To determine in vitro the effects of calcitriol supplementation on the 
differentiation of mesenchymal stem cells into osteoblasts and on 




3. To investigate the role of calcimimetic on bone histomorphometry in a model 
of parathyroidectomy and subcutaneous constant infusion of PTH in rats 
with normal of reduced renal function. 
 
4. To study in vitro the direct effects of CaSR modulation by calcimimetic and 
calcilytics in a cell line of osteoblast and on bone marrow mesenchymal stem 




5. To evaluate the preventive effects of dietary magnesium supplementation 
as phosphate binder in a rat model of renal insufficiency and its involvement 
in the development of vascular calcification, renal deterioration and bone 
disorders. 
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6. To investigate the direct effects of magnesium supplementation in the 
differentiation of the bone marrow mesenchymal stem cells into osteoblasts 




7. To analyze the role of high FGF23 levels on pathophysiological changes in 
bone turnover in a rat model of early CKD. 
 
8. To study in vitro the effects of high concentrations of FGF23 on bone marrow 
mesenchymal stem cells differentiation into osteoblasts and on osteoclast 














This part has been divided into four separate sections for each elements/molecules 
that we have considered as potential contributors to bone alterations associated with 
CKD. 
Every section comprises in vivo experiments using a rat model of renal insufficiency 
as well as in vitro experiments using different types of bone cells. 
 
Therefore, methodology will be described as follows: 
 
Section 1: Calcitriol and bone 
Section 2: Calcimimetic and bone 
Section 3: Magnesium and bone 
Section 4: FGF23 and bone 
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Animal care and proceedings 
10-12-week old male Wistar rats weighing 250–300 g were used to carry out the in 
vivo experiments. This strain was chosen on the basis of its feasibility to resemble 
CKD features. Animals were purchased from Charles River (Wilmington, 
Massachusetts) and individually housed in 33.5 x 56 x 19 cm cages with 450 cm2 
floor area per rat, applying a 12h/12h light/dark cycle. Before starting the 
experiments, all rats were given ad libitum access to a standard diet (Ca 0.6%, P 
0.6% and Mg 0.1%) and tap water. Appropriate measures were taken to ensure 
animal welfare and to address the basic behavioral and physiological needs of the 
animals. All experimental protocols were reviewed and approved by the Ethics 
Committee for Animal Research of IMIBIC in accordance with the ethical guidelines 
of the Institution and the EC Directive 86/609/EEC for animal experimentation and 
the University of Cordoba, and all rats received humane care in compliance with the 
guiding principles in the “Guide for the Care and use of laboratory animals: Eight 
edition”. 
Research ethics to obtain human samples 
Human bone marrow mesenchymal stem cells were obtained from bone marrow 
aspirates taken from the iliac crest of adult donors after written informed consent. 
Donors were patients of the Hematology Service of the Reina Sofia University 
Hospital on diagnosis or follow-up. All protocols were approved by the Ethical 
Committee of Reina Sofia University Hospital in agreement with the ethical principles 
of the Declaration of Helsinki. 
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SECTION 1: CALCITRIOL AND BONE 
1.1. IN VIVO EXPERIMENTS 
 
As previously detailed, calcitriol (CTR) administration is widely used for the treatment 
of SHPT, thus increasing plasma Ca concentration and decreasing PTH levels. To 
examine in vivo the bone effects of CTR independently of PTH, we used an 
experimental model of uremia based on 5/6 nephrectomy and total 
parathyroidectomy. 
 
1.1.1. Model of 5/6 nephrectomy in rats 
Uremia was induced by 5/6 nephrectomy (5/6Nx), a two-step procedure that reduces 
the original functional renal mass by five-sixths. On the basis of our previous 
studies179, animals were anesthetized using sevoflurane (Sevorane, Abbott 
laboratories, Chicago, IL, USA). In the first step of the nephrectomy, a 5 to 8 mm 
incision was made on the left mediolateral surface of the abdomen. The left kidney 
was exposed, and the two poles (2/3 of renal mass) were ablated. The kidney was 
inspected and returned to an anatomically neutral position within the peritoneal 
cavity. The abdominal wall and skin incisions were closed with sutures, and the rat 
was placed back into its home cage. After 1 week of recovery, the animal was 
reanesthetized and a 5 to 8 mm incision was made on the right mediolateral surface 
of the abdomen. The right kidney was exposed and unencapsulated, the renal 
pedicle was clamped and ligated, and the kidney was removed. The ligated pedicle 
was returned to a neutral anatomical position and the abdomen and skin incisions 
closed with suture materials. Fentanyl 0.01mg/kg; i.p (Fentanest, Kern Pharma, 
Barcelona, Spain) was used as analgesic agent. 
1.1.2. Parathyroidectomy and PTH clamp in rats 
Total parathyroidectomy (PTx) was performed using a dissecting microscope as 
previously reported180, Briefly, rats were anesthetized with sevoflurane, a surgical 
incision was made in the skin of the ventral part of the neck and subsequently 
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another incision was made carefully in the muscular tissue until the thyroid was 
exposed. Using a stereoscopic microscope, parathyroid glands were removed from 
the thyroid gland, vessels were cauterized and both surgical cuts were stitched with 
absorbable suture. After surgery, rats received analgesia using fentanyl (0.01mg/kg; 
i.p.). One day after PTx, rats were re-anesthetized using sevoflurane and blood (0.7 
ml) was drawn by puncture of the jugular vein to measure serum Ca levels. PTx was 
considered successful in rats with iCa levels below 0.8mM. 
Subsequently, a miniosmotic pump (ALZET model 2004 purchased from Charles 
River Laboratories, Barcelona, Spain) was implanted subcutaneously between the 
shoulders. The osmotic pump was loaded with rat recombinant PTH (1-34 fragment) 
(Sigma-Aldrich CO, St. Louis, MO, USA) diluted in isosmotic saline with 2% cysteine 
(pH 1.4) in aseptic conditions. As a decrease in plasma iCa levels was expected due 
to the reduction in the renal mass, these groups of rats received a constant infusion 
of a 6-fold the dose of the rat recombinant PTH 1-34 necessary to maintain plasma 
iCa levels in rats with normal renal function (0.132 µg/100g/hr)181. 
1.1.3. Experimental design for the in vivo study 
To evaluate the PTH-independent effects of CTR in bone, we used male wistar rats 
that underwent 5/6Nx and total PTx. As PTH requirements in uremic conditions must 
be higher than in normal conditions, it was administered a constant infusion of rat 
recombinant PTH higher than the necessary dose to maintain plasma iCa 
concentration in PTx rats with normal renal function (1-34 fragment; 0.132 
µg/100g/hr). In addition, CTR (Calcijex, Abbott Laboratories, Chicago, IL, USA) was 
administered at 20, 40 or 60 ng/kg/48h; i.p. during 28 days. Calcein (Sigma-Aldrich, 
25mg/kg; i.p.) was administered 9 and 2 days before sacrifice to evaluate bone 
mineralization. Animals were fed with a 0.6% Ca and 0,9% P diet (Altromin GmbH & 
CO. KG, Lage, Germany).Rats receiving a simulated surgery (Sham) were included 
in all the experiments as control animals. Sham operation consist of the exposition 
of the target organs to be mobilized and then returned to the animal. Sham rats were 
fed on a diet containing Ca 0.6%, P 0.6%, and Mg 0.1% (Altromin GmbH & CO. KG) 
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and were not treated with calcitriol or any other treatment different of those used in 
the surgery. 
The experimental groups were as follows: 
1. Sham Operated (n=5) 
2. 5/6Nx (n=7) 
3. 5/6Nx plus PTx and PTH replacement (Nx+PTx+PTHx6+Vehicle, n=9) 
4. Nx+PTx+PTHx6+CTR 20ng/kg (n=10) 
5. Nx+PTx+PTHx6+CTR 40ng/kg (n=5) 
6. Nx+PTx+PTHx6+CTR 60ng/kg (n=9) 
At the end of the study, blood was obtained by aortic puncture under general 
anesthesia with sodium thiopental 50mg/kg (B. Braun, Melsungen, Germany) and 
femurs were dissected to evaluate bone histomorphometry. A visual timeline of the 
experiment is shown in Fiure 18. 
 
 





















1.1.4. Plasma biochemical analysis 
To confirm the PTx, blood for measurements of iCa levels was collected in 
heparinized syringes and immediately analyzed using a Ciba- Corning 634 ISE 
Ca2+18 /pH analyzer (Ciba-Corning, Essex, UK) or a Spotlyte Ca2+/pH Analyzer 
(Menarini Diagnostics, Barcelona, Spain). Afterwards, blood samples were 
centrifuged 2000 x g for 10 minutes at 4ºC for plasma separation, aliquoted and 
stored at -20ºC for biochemical analysis.  
At the end of the study, blood was obtained by aortic puncture under general 
anesthesia with sodium thiopental (50mg/kg; i.p.). Plasma P, Mg and creatinine were 
measured by spectrophotometry using commercially available kits (BioSystems SA, 
Barcelona, Spain). 
Plasma levels of circulating intact FGF23 were determined using a rat FGF23 
sandwich enzyme-linked immunosorbent assay (ELISA) kit (Kainos Laboratories, 
Tokyo, Japan). In this ELISA kit, wells are coated with an antibody against N-terminal 
FGF23 length that capture both intact and N-terminal FGF23; then another 
monoclonal HRP-conjugated antibody is added to detect the C-terminal length, thus 
only intact FGF23 is recognized by the measurement. 
Plasma CTR concentration was measured with a radioimmunoassay (RIA) kit 
(Immunodiagnostic Systems (IDS) Ltd, Boldon, UK). Briefly, plasma samples was 
delipidated and 1,25(OH)2D3 extracted from potential cross-reactants by incubation 
for 3 hours with a highly specific solid phase monoclonal antibody against 
1,25(OH)2D3. The immunoextraction gel is then washed and purified 1,25(OH)2D3 
eluted directly into glass assay tubes. Reconstituted eluates and calibrators are 
incubated overnight with a highly specific sheep anti-1,25(OH)2D3. Then, 125I-
1,25(OH)2D3 is added and incubation continued for 1 hour. Separation of bound from 
free is achieved by a short incubation with Sac-Cel®, a binder reagent developed by 
the company, followed by centrifugation, decantation and counting. Bound 
radioactivity is inversely proportional to the concentration of 1,25(OH)2D3. 
Plasma intact PTH concentration was quantified according to the manufacturer’s 
instructions using a rat PTH (1–84) sandwich ELISA kit (Immutopics, San Clemente, 
CA, USA). To detect intact PTH the ELISA kit uses two antibodies, the capture 
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antibody is a polyclonal rat avidin-biotin-conjugated antibody against the PTH (39-
84) fragment coated in wells and for detection was used a PTH (1-34) polyclonal 
antibody raised against epitopes in the PTH (1-34) fragment. 
Infused rat recombinant PTH (1-34 fragment) was not recognized by the intact PTH 
assay. To determine the plasma concentration of PTH (1-34) fragment, we used a 
specific competitive ELISA kit (Phoenix Pharmaceuticals, Inc. Burlingame, CA, 
USA). In this kit, the plate is pre-coated with a capture antibody that binds both the 
biotinylated antibody and the PTH (1-34) peptide at the same time. The antigen and 
antibody therefore “compete” for the binding sites. The biotinylated peptide interacts 
with streptavidin-horseradish peroxidase which catalyzes the substrate solution, thus 
the intensity of the yellow is inversely proportional to the amount of the PTH (1-34) 
peptide. The amount of the PTH (1-34) peptide was determined by extrapolation with 
a standard curve. 
Plasma sclerostin concentration was measured with a sandwich ELISA kit (R&D 
System, Inc. Minneapolis, USA), consistent in a pre-coated microplate with a murine 
monoclonal antibody against sclerostin for protein capture and once rinsed, a 
polyclonal HRP-conjugated antibody specific for murine sclerostin was added for 
detection by colorimetry. 
 
1.1.5. Bone histomorphometry 
After sacrifice, right femurs were dissected, adjacent soft tissues were removed and 
bones were placed into 10 ml crystal bottles with 70% ethanol and then femurs were 
dehydrated with 100% ethanol. Each ethanol solution was replaced every 24 hours 
during three days at room temperature. Subsequently, samples were cleared with 
xylene overnight at room temperature, and bones were embedded in 75% methyl 
methacrylate (Merck KGaA, Darmstadt, Germany), 25% dibutyl phthalate (Sigma-
Aldrich) (Solution A), then in Solution A plus 1% w/v benzoyl peroxide (Merk) and 
finally in Solution A plus 2.5% w/v benzoyl peroxide. Each methyl methacrylate 
solution was replaced every 24 hours during three days and stored at 4ºC. After the 
last replacement, samples were maintained at 37ºC. Once solution became solid, 
93 
crystal bottles were broken and the blocks with the embedded samples were cutting 
with a tungsten knife.  
5μm sections of the undecalcified distal femurs were stained with a modified 
Masson-Goldner trichrome method as previously reported182. In detail, slices were 
fixed with 50% ethanol and slides were maintained at 37ºC overnight. Samples were 
rehydrated and stained with 1:1 hematoxylin-ferric chloride during 10 minutes and 
subsequently rinsed with tap water for 5 minutes. Then, slices were cleared with 1% 
HCl, and turned blue with a solution of saturated LiCO3. After rinsing with water, 
slices were stained with Goldner trichrome dye for 20 minutes and then rinsed with 
1% acetic acid. Subsequently, samples were dehydrated with 95% ethanol (twice, 
1.5 minutes each), and stained with an ethanol solution of 1% w/v saffron for 5 
minutes. Afterward slices were subsequently rinsed with 95% and 100% ethanol, 1 
minutes each, and cleared with xylene. A non-aqueous xylene-containing mounting 
medium was used to adhere to the coverslips. Green stained areas were considered 
as mineralized bone and red stained areas measuring at least 1.5 µm were 
considered as osteoid. 
Bone histomorphometric parameters were assessed in cancellous bone within the 
secondary spongiosa (0.25 mm distance from endocortical bone and growth plate) 
under 200x magnification as previously described183 using OsteoMeasure™ 
software (OsteoMetrics, Decatur, IL, USA) and derived indices were determined by 
standard calculations108.  
The following parameters were analyzed: BV/TV: Bone Volume/Tissue Volume, 
OV/TV: Osteoid Volume/Tissue Volume, OS/BS: Osteoid Surface/Bone Surface, 
Ob.S/BS: Osteoblast Surface/Bone Surface, ES/BS: Eroded Surface/Bone Surface, 
Oc.S/BS: Osteoclast Surface/Bone Surface, BFR/BS: Bone Formation Rate/Bone 
Surface, MS/BS: Mineralizing Surface/Bone Surface. 
The bone dynamic parameters were calculated by measurement of the single and 
double fluorescent calcein labelling lines in undecalcified 10 μm serial sections. 
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1.2. IN VITRO EXPERIMENTS 
1.2.1. In vitro study of the effects of calcitriol on osteogenesis of rat bone 
marrow MSC 
The effects of CTR on osteogenesis of bone marrow mesenchymal stem cells (MSC) 
were also analyzed. Thus, different concentrations of calcitriol (10-12, 10-11, 10-10, 10-
9 and 10-8 M) were used. 
1.2.1.1. Isolation and primary culture of rat bone marrow MSC 
2-month male Wistar rats weighting 200-250 g were euthanized by aortic puncture 
under general anesthesia with pentobarbital sodium (50 mg/kg; i.p.). Tibiae and 
femurs were cut at the epiphyses and subsequently perfused with alpha minimal 
essential medium (α-MEM; Sigma-Aldrich) containing 15% FBS (Lonza Inc., 
Walkersville, MD, USA), 1% ultraglutamine (Lonza), 100 U/ml penicillin and 100 
µg/ml streptomycin. Cell aggregation was reduced by filtration through 70 µm cell 
strainer (BD Biosciences, San Jose, CA, USA). Following centrifugation and washing 
with α-MEM, bone marrow cells were cultured in 25 cm2 flasks (NUNC A/S, Roskilde, 
DE, USA) with α-MEM containing 15% FBS, 1% ultraglutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin and 1 ng/ml rat recombinant basic fibroblast growth factor 
(bFGF; PeproTech EC Ltd., London, UK) in a humidified atmosphere with 5% CO2 
at 37ºC. MSC were isolated according to their plastic adherence properties. Fresh 
α-MEM with 10% FBS, 1% ultraglutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin and rat recombinant 1 ng/ml bFGF was added after 24 hours and 
replaced every 3 days. Once 85-90% confluence was reached, cells were collected 
using Trypsin-EDTA (Lonza). Briefly, supernatant was discarded and cells were 
rinsed with saline twice. 1.5 ml of Trypsin-EDTA was added per 25 cm2 flask and 
cells were maintained at 37ºC in the incubator for 5 minutes. After we had checked 
that adherent cells were detached from the surface, trypsin was inactivated with 5 
ml of supplemented α-MEM and cells were collected. Subsequently, cells were 
centrifuged at 450 x g, 4 ºC for 10 minutes and pellets suspended in supplemented 
α-MEM. Cells were counted using a Neubauer chamber in a Motic AE31 inverted 
microscope (MoticEurope S.L.U, Barcelona, Spain). Cells were seeded in 6-well 
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plates (NUNC) at 13000 cells/cm2. Treatments were started as described below 
when cells reached 90% confluence. 
1.2.1.2. Osteogenic differentiation of MSC and treatments 
MSC were cultured in α-MEM with 10% FBS, 1% ultraglutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin and an osteogenic stimuli based on the addition of 1 µM 
dexamethasone (Sigma-Aldrich), 10 mM β-glycerol phosphate (Sigma-Aldrich) and 
0.2 mM ascorbic acid (BAYER, Barcelona, Spain). Cells were maintained in 
osteogenic medium during 21 days. Undifferentiated MSC at 0 and 21 days were 
used as control cells. CTR was added throughout osteogenic differentiation of rat 
bone marrow MSC at concentrations of 10-12, 10-11, 10-10, 10-9 and 10-8 M. 
Osteoblastic differentiation and mineralization of in vitro cultures were evaluated 
through the measurement of the expression of specific osteogenic genes, alkaline 
phosphatase activity, Ca content and alizarin red staining. In addition, the role of pro-
osteogenic pathways was also analyzed through confocal microscopy. Methodology 
is shown in Figure 19. Experiments were performed at least three times. 
 
Figure 19. Experimental design for the in vitro study of the effects of calcitriol on 





























1.2.1.3. RNA isolation from cell cultures 
Total RNA from cell cultures was extracted using TRI Reagent® (Sigma-Aldrich). 
Briefly, cells were lysed and collected with 1 ml of TRI Reagent® and stored at -80 
ºC until procedure.  
To isolate total RNA, 200 µl of chloroform was added, samples were mixed with 
vortex and then centrifuged at 15000 x g, 4 ºC for 15 minutes. Following, clear 
supernatant containing the RNA fraction was separated and mixed with 500 µl of 
isopropanol and maintained at -80ºC for 10 minutes to allow RNA precipitation. Then, 
samples were centrifuged at 15000 x g, 4 ºC for 10 minutes and the resultant pellet 
was rinsed with 1 ml of 70% ethanol and centrifuged at 15000 x g, 4 ºC for 5 minutes. 
Ethanol was discarded, pellet was air-dried and RNA was dissolved in RNAse- and 
DNAse-free water. 
Final RNA concentration was quantified by spectrophotometry (ND-1000, Nanodrop 
Technologies, Wilmington, DE, USA).  
1.2.1.4. RNA treatment with DNase 
1 µg of RNA was treated with a DNase I amplification grade kit (Sigma-Aldrich) to 
eliminate possible DNA contamination.  Then, RNA concentration was quantified 
again. Briefly, 1 µg of RNA was suspended in a final volume of 10 µl containing 0.1 
unit of DNase I, 20mM Tris-HCl, 2 mM MgCl2 and incubated for 25 minutes at room 
temperature. Then, 1 µl of 50 mM EDTA was added to prevent metal ion catalyzed 
hydrolysis of the RNA and samples were heated at 70 ºC for 10 minutes to denature 
both DNase I and RNA. Subsequently, samples were placed into ice, RNA was 
quantified by spectrophotometry and then stored at -80 ºC until analysis. 
1.2.1.5. Two-step RT-PCR 
In these experiments, RT-PCR was performed using a two-step protocol. Firstly, 
cDNA was synthesized from total RNA and, in a second step, quantitative PCR was 
performed. Briefly, total RNA was extracted with 1 ml of TRI Reagent® and quantified 
by spectrophotometry. cDNA was synthesized from 1 μg of total RNA with a first 
strand cDNA synthesis kit (Qiagen, Hilden, Germany) in the presence of random 
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hexamers in a final volume of 20 μl at 25 °C for 10 minutes, followed by 42 °C for 15 
minutes and 95 °C for 3 minutes. PCR SYBR Green kit (Qiagen N.V., Hilden, 
Germany) was used to quantify mRNA expression levels. Primers for Runx2, 
Osterix, Osteocalcin and 18S were synthesized with Oligo software and used at a 
final concentration of 1 µM. Primers sequences are listed in Table 4. The expression 
of these genes was evaluated by quantitative RT-PCR using Lightcycler 480 (Roche 
Diagnostics, Basel, Switzerland). The relative expression was calculated by the 2-
ΔΔCt method, using ribosomal 18S RNA expression as housekeeping control. 
 
1.2.1.6. Enriched fractions of cytosolic and nuclear proteins isolation 
Enriched fraction of cytosolic proteins was isolated from cells in lysis buffer A, 
containing 10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM 
Dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 15 µL/ml 
Protease Inhibitor Cocktail and 0.5% Igepal CA-630, pH 7.9. All the reagents were 
purchased from Sigma-Aldrich. The suspension was centrifuged at 15000 g, 4º C for 
3 minutes, and the supernatant (cytosolic extract) was stored at -80ºC. Nuclear 
extracts were obtained by incubating the pellet obtained from the cytosolic extract in 
 Primer sequences NCBI gene ID 
Rat Runx2 Fw 5’-CGGGAATGATGAGAACTACTC-3’ 
Rv 5’-CGGTCAGAGAACAAACTAGGT-3’ 
367218 
Rat Osterix Fw 5’-GTACGGCAAGGCTTCGCATCTGA-3’ 
Rv 5’-TCAAGTGGTCGCTTCGGGTAAAG-3’ 
300260 
Rat Osteocalcin Fw 5’-TCTGAGTCTGACAAAGCCTTCATG-3’ 
Rv 5’-TGGGTAGGGGGCTGGGGCTCC-3’ 
25295 




Table 4. Sequences of the primers used in the in vitro study of the effects of calcitriol on 
osteogenesis. 
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lysis buffer B for 20 minutes, containing 20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 1 
mM EGTA, 1 mM DTT, 0.5 mM PMSF and 15 µL/ml Protease Inhibitor Cocktail, pH 
7.9. Suspension was centrifuged at 15000 g, 4º C for 5 minutes. Supernatants were 
collected and stored at -80ºC. Protein concentration was determined by Bradford 
assay (Bio-Rad Laboratories, Hercules, CA, USA). 
1.2.1.7. Western blot analysis 
To analyze the amount of specific cytosolic or nuclear protein, cell lysates were 
analyzed by immunoblotting. Briefly, loading buffer containing glycerol, sodium 
dodecyl sulfate (SDS), β-mercaptoethanol and bromophenol blue were added to 
protein samples and denaturalization was carried out at 70 ºC for 10 minutes. 
Following, samples were placed in ice and samples were loaded in polyacrylamide 
gels. Electrophoresis were performed in a commercial chamber (Bio-Rad 
Laboratories) at 150 V, 90 mA until the blue front line reached the end of the gel. A 
pre-stained ladder (Bio-Rad Laboratories) was used as an indicator of molecular 
weight. Thereafter, proteins were transferred from gel to nitrocellulose membranes 
using a trans-blot turbo (Bio-Rad Laboratories). Then, membranes were blocked in 
TBS-T with 5% dry milk to avoid unspecific binding and subsequently incubated with 
primary antibodies against proliferating cell nuclear antigen (PCNA; Santa Cruz 
Biotechnology / SC-56; 1:100 dilution) and Cyclin D1 (Cell signaling Technology / 
#2978; 1:500 dilution). Following, primary antibodies were removed, membranes 
were rinsed with TBS-T three times and incubated with HRP-conjugated goat anti-
mouse and goat anti-rabbit (Santa Cruz Biotechnology) as secondary antibodies. 
Antibody for detection of Transcription factor II B (TFIIB; Cell signaling Technology / 
#4169; 1:1000 dilution) were used for loading control. 
 ECL Advance Detection Reagents (GE Healthcare Bio-Sciences, Uppsala, 
Sweden) were used to detect chemiluminiscence in a LAS 4000 imager (GE 
Healthcare Europe GmbH, Barcelona, Spain). Band areas were quantified with 
Image J software. 
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1.2.1.8. Immunofluorescence analysis  
Cells were cultured upon glass coverslips in 6-well plates. After 14 days of treatment 
cells were fixed with cold methanol for 20 minutes and subsequently rinsed with PBS 
three times. Fixed cells were incubated in the diluted antibodies in 1% BSA (Sigma-
Aldrich) in PBS. β-catenin primary antibody (BD Biosciences; dilution 1:75) was 
incubated for 1 hour at 4ºC. Subsequently, cells were washed with PBS and 
incubated with Alexa Fluor 488 anti-mouse (Invitrogen, Ltd., Paisley, UK. / Ref 
A21204; 1:500 dilution) diluted in 1% BSA in PBS. Cell nuclei were visualized with 
the nuclear stain 4’,6-diamino-2-phenylindole dihydrochloride (DAPI; Invitrogen). 
Pictures were obtained at 400x in a Zeiss LSM 710 inverted confocal microscope 
(Carl Zeiss, Jena, Germany). ImageJ software (National Institutes of Health, 
Bethesda, MD, USA) was used to analyze the confocal images. Co-localization 
analysis was performed by quantifying the mean of intensity of fluorescence (β-
catenin-488 Green) in each nucleus of the different treatments. Briefly, channels for 
both colors were split into separate images and blue channel (DAPI) was used to 
select a region of interest (ROI) comprising the nuclei. Then, ROI were placed onto 
the green image (β-catenin) and pixels into the region were measured. Values are 
showed as fold change vs undifferentiated MSC control. 
1.2.1.9. Quantification of alkaline phosphatase activity 
2 µg of cytoplasmic cell lysates were incubated in 2 mM p-nitrophenyl phosphate 
(Sigma-Aldrich) for 30 minutes at 37 °C. The reaction was stopped by adding 3 M 
NaOH, and alkaline phosphatase (ALP) activity was measured by quantifying 
absorption at 405 nm. ALP activity was expressed as µmol of hydrolyzed p-
nitrophenyl phosphate per min and per mg of protein versus undifferentiated control 
cells. 
1.2.1.10. Alizarin red S staining 
In differentiated MSC treated or not with the different CTR concentrations, matrix 
mineralization was evaluated by alizarin red S staining. Cells were washed twice with 
PBS, fixed with 2% para-formaldehyde and 1% sucrose for 15 minutes and 
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subsequently washed 3 times with PBS. Then, cells were stained with 40 mM Alizarin 
Red S pH 4.1 Sigma-Aldrich for 20 minutes, and washed 4 times for 5 minutes with 
water at pH 7. Finally, water was removed and samples were dried at room 
temperature. Plates were scanned in a WIFI OKI Scanner (Madrid, Spain). 
1.2.1.11. Measurement of calcium content in cell cultures 
Demineralization of the calcified matrix was carried out by incubating cell cultures 
with 0.6 M HCl for 24 hours. Ca content in the supernatant was determined by the 
phenolsulfonphthalein method using a commercial assay (QuantiChrom™ Calcium 
Assay Kit, BioAssay Systems, CA, USA). Cells were washed three times with PBS 
(Sigma Aldrich) and protein content was isolated with a 0.1 M NaOH and 0.1% SDS 
solution. Protein content was quantified using the Bradford method and Ca content 
was normalized according to total protein and expressed as µg Ca/mg protein. 
1.2.2. In vivo study of the effects of calcitriol supplementation on 
osteoclastogenesis 
The effects of CTR (10-11 and 10-9 M) were determined in an in vitro model of 
osteoclasts. 
1.2.2.1. Osteoclast differentiation of hematopoietic bone marrow cells 
10 Male wistar rats weighing 250 g approximately were anesthetized with sodium 
thiopental (50mg/kg; i.p) and sacrificed by aortic puncture. Rat femurs and tibias 
were extracted, the adjacent soft tissues were removed and bones were placed in 
α-MEM. In a laminar flow chamber, bones were cut at the epiphyses and bone 
marrow was extracted by perfusion with α-MEM supplemented with 10% FBS with a 
sterile syringe as described in the section 1.2.1.1. Bone marrow cells from each rat 
were isolated separately to avoid immune response among different animals. Cell 
aggregation was prevented by filtration using a 70 µm cell strainer. Then, cells were 
centrifuged at 450 x g for 5 minutes at room temperature and the resultant pellet was 
re-suspended in ACK lysing buffer, incubated for 2-3 minutes at room temperature 
and centrifuged at 450 x g for 5 minutes at room temperature. Subsequently, 
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supernatant was removed and cell pellets were re-suspended in α-MEM with 10% 
FBS plus rat recombinant 10 ng/ml M-CSF (PeproTech) and incubated at 37 ºC, 5% 
CO2 with saturated humidity. After 24 hours, non-adherent cells were collected and 
centrifuged at 450 x g for 5 minutes at room temperature and cell pellets were re-
suspended in supplemented α-MEM with 10% FBS. At this time, a fraction of the 
cells was collected for characterization by flow cytometry and the remaining cells 
were seeded on 6-well plates and incubated at 37%, CO2 5% with saturated humidity 
with supplemented α-MEM with 10% FBS containing rat recombinant 30 ng/ml M-
CSF. After 3 days, adherent cells were collected carefully using a scrapper, counted 
in a Neubauer chamber and seeded on 24-well plates at 4x104 cells/cm2 with α-MEM 
with FBS 10% containing rat recombinant 30 ng/ml M-CSF and rat recombinant 100 
ng/ml RANKL. Additionally, CTR was added at concentrations of 10-11 and 10-9 M. 
Cells were incubated at 37%, CO2 5% with saturated humidity for 5 days. Medium 
was replaced every 2 days. At the end of the experiments cells were processed for 
determination of osteoclastic gene expression (Cathepsin K) or tartrate-resistant 
acid phosphatase (TRAP) staining, commonly used as histochemical marker for 
osteoclasts. Figure 20 summarizes the methodology of this study. Experiments were 
performed at least three times.  
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1.2.2.2. Characterization of non-adherent osteoclast-precursor cells 
Non-adherent cells were processed for characterization by flow cytometry using a 
MACs Quant cytometer (Miltenyi Biotec S.L., Madrid, Spain). Briefly, cells were 
suspended in 800 µl of PBS at 4x106 per tube and subsequently labeled with FITC-
conjugated anti-rat CD34, FITC-conjugated anti-rat CD45, FITC-conjugated anti-rat 
Sca-1 or an isotype control antibody (Negative control IgG) for 15 minutes protected 
from light exposure. The expression of the cell surface proteins CD34, CD45 and 
Sca-1 is used for characterization of bone marrow cells. Dilution for all the antibodies 
was 1:150. Then, cells were centrifuged at 450 x g, 4 ºC for 5 minutes, the 
supernatant was discarded and cell pellets were re-suspended in PBS for acquisition 
in the cytometer using the software BD CellQuest™ (BD Biosciences, San Jose, CA, 
USA). 
1.2.2.3.  RNA isolation and DNase treatment 
RNA isolation and treatment with DNase was carried out as aforementioned in 
sections 1.2.1.3 and 1.2.1.4, respectively.  
1.2.2.4.  RT-PCR (one-step protocol) 
A one-step RT-PCR kit was used for quantification of Cathepsin K (CTSK) mRNA 
expression, using GAPDH as housekeeping gene. Cathepsin K is a protease highly 
expressed in osteoclasts. Cathepsin K is secreted by osteoclasts to degrade bone 
collagen matrix. RT-PCR was performed with 50 ng of DNase-treated RNA using 
SensiFAST SYBR No-ROX One-Step Kit (Bioline Reagents Limited, London, UK) as 
indicated by the manufacturer. Primers for PCR are shown in Table 5. Final 
concentration of the forward and reverse primer mix was 1 µM. Primer sequences 
were designed with the Oligo software or pre-designed oligonucleotides were 
purchased from IDT (Integrated DNA Technologies Inc., Coralville, IA, USA). PCR 
amplification was performed using Lightcycler 480 (Roche Molecular Systems, Inc., 
Indianapolis, USA). The expression of target genes was normalized with the 2-ΔΔCt 
method using GAPDH as housekeeping gene. 
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1.2.2.5. TRAP staining 
Osteoclasts are TRAP-positive cells. TRAP is an enzyme highly expressed by 
osteoclasts. It is secreted to bone surface by osteoclasts and participates in bone 
resorption. 
For TRAP staining, a commercially available kit was used (Sigma–Aldrich) with 
modifications. Briefly, cells were fixed according to manufacturer instructions with a 
citrate-paraformaldehyde-acetone solution for 30 seconds at room temperature. 
Then, fixative solution was removed and cells were rinsed three times with 37 ºC 
pre-warmed deionized distillated water (ddH2O). Subsequently, ddH2O was removed 
and cells were incubated in TRAP-staining solution as indicated by the manufacturer 
(0.25 M Acetate, 0.7 mg/ml Diazotized Fast Garnet GBC, 1.25 mg/ml Naphtol AS-BI 
phosphate and 0.67 M tartrate) at 37ºC. After 1 hour, TRAP-staining solution was 
removed and cells were rinsed with ddH2O twice. Then, cells were counterstained 
with hematoxylin for 2 minutes, rinsed with tap water and air-dried. 
 Primer sequences NCBI gene ID 
Rat CTSK Fw 5’-TCTCTGTACCCTCTGCACTTAG-3’ 
Rv 5’-ATTGACTCTGAAGACGCTTACC-3’ 
29175 




Table 5. Primers sequences used in the study of the calcitriol effects on osteoclastogenesis 
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SECTION 2: CALCIMIMETIC AND BONE 
2.1. PTH-INDEPENDENT EFFECTS OF CALCIMIMETICS IN BONE: IN VIVO 
STUDIES 
Calcimimetics (CM) are used alone or in combination with CTR to reduce PTH levels 
and treat SHPT. The effects of CM independently of their action in parathyroid glands 
are unknown. To examine in vivo the PTH-independent effects of CM in bone we 
used rats with normal renal function and an experimental model of uremia based on 
5/6 nephrectomy. Both rat models underwent total parathyroidectomy and received 
constant infusion of rat recombinant PTH (1-34 fragment) capable of maintaining 
plasma Ca and P levels. 
2.1.1. Experimental procedure for the in vivo study 
Firstly, CM effect was evaluated in PTx rats with normal renal function. 
Parathyroidectomy was performed according to the protocol described in 1.1.2. 
Subsequently, two subgroups of PTx rats received a physiological dose of 1-34 PTH 
(0.022 µg/100g per hour) released from miniosmotic pumps. Additionally, the PTx 
rats with PTH (1-34) infusion were divided in two subgroups, one of them received 
calcimimetic AMG 641 (1.5 mg/kg/48h; subcutaneously) and the other one received 
vehicle. The physiological dose of PTH (0.022 µg/100g per hour) was previously 
defined by its ability to maintain serum iCa within a normal range (1.15-1.25 mM) in 
PTx rats fed a 0.6% Ca and 0.6% P diet181. The calcimimetic AMG 641 was 
reconstituted in 12% p/v Captisol (Ligand Pharmaceuticals, Inc. San Diego, CA), pH 
3. The dose of AMG 641 administered to the rats was demonstrated to be efficient 
decreasing PTH levels in Nx rats184. In these conditions animals were maintained on 
a 0,6% Ca and 0,9% P diet for 28 days. The experimental groups of animals for the 
study with normal renal function were as follows: 
1. Sham-operated (Sham, n=6) 
2. PTx rats (PTX, n=7) 
3. PTX rats with PTH replacement (PTX-PTH, n=5) 




To assess the effects of the CM on bone in the context of CKD, a second experiment 
was performed in uremic PTx rats. Uremia was induced by 2-step subtotal 
nephrectomy (5/6Nx) as described in section 1.1.1. After the second surgery, the 
standard diet was switched to a moderately high P diet (Ca 0.6% and P 0.9%). An 
additional group of Nx rats was treated with CM (1.5 mg/kg/48h; subcutaneously). 
As a decrease in plasma iCa levels was expected due to the reduction in the renal 
mass, these groups of rats received a constant infusion of a 6-fold (0.132 µg/100g 
per hour) or 9-fold (0.198 µg/100g per hour) the dose of rat recombinant PTH 1-34 
needed to maintain plasma iCa levels within a normal range in rats with normal renal 
function through ALZET osmotic pumps in combination with vehicle or CM (1.5 
mg/kg/48h, subcutaneously). Therefore, experimental groups were the following: 
5. Sham (Sham, n=6) 
6. 5/6 Nx rats (5/6Nx, n=7) 
6. 5/6 Nx rats and CM (5/6Nx, n=6) 
7. 5/6 Nx-PTx and PTH replacement x6 (5/6Nx-PTx-PTHx6, n=8) 
8. 5/6 Nx-PTx, PTH replacement x6 and CM (5/6Nx-PTx-PTHx6-CM, n=5) 
9. 5/6 Nx-PTx and PTH replacement x9 (5/6Nx-PTx-PTHx9, n=5) 
10. 5/6 Nx-PTx, PTH replacement and CM x9 (5/6Nx-PTx-PTHx9-CM, n=6).  
 
Figure 21. Experimental design of the in vivo experiment of the effects of calcimimetic 


















To evaluate bone mineralization, double calcein labeling was performed by 
administering calcein (25 mg/kg; i.p.) at days 9 and 2 before sacrifice. On day 28, 
twenty-four hours after the last dose of CM, animals were sacrificed by aortic 
puncture under general anesthesia with sodium thiopental (50mg/kg, i.p). Blood 
samples were collected in heparinized tubes for biochemistry and femurs were 
collected to study bone histomorphometry. 
2.1.2. Plasma and biochemistry 
Blood ionized Ca concentration was determined using a Spotlyte Ca2+/pH Analyzer. 
Plasma was separated by centrifugation at 2000 x g for 10 minutes at 4 ºC, and P, 
creatinine, CTR, intact PTH and intact FGF23 concentrations were measured as 
described in section 1.1.4. The plasma concentration of the PTH (1-34) fragment, 
was measured with a specific ELISA kit (Phoenix Pharmaceuticals, Inc. Burlingame, 
CA, USA). 
2.1.3. Bone histomorphometry 
Bone histomorphometric analysis of distal left femurs was assessed as previously 
described in section 1.1.5. The following parameters were analyzed: BV/TV: Bone 
 
Figure 22. Experimental design for the study of the effect of calcimimetic on bone in rats 
with renal insufficiency. 
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Volume/Tissue Volume, OV/TV: Osteoid Volume/Tissue Volume, OS/BS: Osteoid 
Surface/Bone Surface, Ob.S/BS: Osteoblast Surface/Bone Surface, ES/BS: Eroded 
Surface/Bone Surface, Oc.S/BS: Osteoclast Surface/Bone Surface, BFR/BS: Bone 
Formation Rate/Bone Surface, MS/BS: Mineralizing Surface/Bone Surface, Osteoid 
Thickness (O.Th), Mineralizing Surface related to Osteoid Surface (MS/OS), mineral 
apposition rate (MAR), adjusted apposition rate (Aj.AR), mineralization lag time (Mlt) 
and osteoid maturation time (Omt). 
2.1.4. Bone immunohistochemistry 
To confirm the activation of the CaSR in bone cells, ERK1/2 phosphorylation, a 
CaSR downstream signaling pathway, was examined. Tissue phospho-ERK1/2 
expression was evaluated in decalcified 5-μm bone sections. Briefly, bone sections 
were deacrylated in a 1:1 mixture of xylene and chloroform for 30 minutes and 
rehydrated with graded ethanol to tap water. Subsequently, slices were decalcified 
with 14% EDTA, pH 7.4 for 1 hour and rinsed with distilled water for 10 minutes. 
Then, immunohistochemistry was performed using the Novolink Polymer detection 
System kit (Leica Biosystems Newcastle Ltd, UK) according to the manufacturer’s 
instructions. Briefly, endogenous peroxidase was neutralized with hydrogen 4% 
peroxidase for 5 minutes and rinsed twice with PBS. Then, protein was blocked with 
0.4% casein for 5 minutes to avoid non-specific binding of primary antibody and 
polymer and rinsed twice with PBS. Subsequently, slices were incubated with anti-
phospho-p44/42 MAPK (Cell signaling Technology / Ref. #4370; 1:400 dilution) at 
37 ºC for 2 hours. To localize osteoblasts in bone tissue, the distribution of the 
osteoblast marker osteocalcin was determined using a monoclonal antibody against 
rat osteocalcin (R&D Systems Inc. MN, USA / Ref. MAB1419; 10 µg/ml dilution). 
Then, samples were rinsed twice with PBS and a post-primary antibody (rabbit anti 
mouse; <10 µg/ml) was added for 30 minutes. Then, slices were incubated with a 
polymer solution (poly-HRP-conjugated antibody raised against rabbit; <25 µg/ml), 
rinsed twice with PBS and protein detection was performed by incubating with 3, 3 -
diaminobenzidine (DAB) for 5 minutes. Subsequently, slices were rinsed with water 
and counterstained with hematoxylin for 15 minutes. Finally, samples were rinsed 
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with tap water, dehydrated with ethanol, cleared with xylene and mounted with 
coverslips using a non-aqueous mounting medium. Images were taken with a Leica 
DM2000 LED microscope with a Leica MC190 HD camera using the Leica 
Application Suite 4.8.0 software. 
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2.2. IN VITRO EXPERIMENTS 
2.2.1. Effects of calcimimetic on osteogenesis 
The in vitro effects of AMG641 were evaluated in UMR-106 cells and in osteogenesis 
of bone marrow mesenchymal stem cells. 
2.2.1.1. Effects of calcimimetic in UMR-106 cells 
To test the effects of the treatment with CM in mature osteoblasts, we used the rat 
osteosarcoma cell line UMR-106 (ATCC, Manassas, VA, USA) which displays 
osteoblastic properties. UMR-106 cells were cultured in a Ca-free DMEM (Gibco™, 
Grand Island, NY, USA), supplemented with 10% FBS, 2 mM ultraglutamine, 1 mM 
sodium pyruvate, 20 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin. CaCl2 
(Sigma-Aldrich) was used to adjust the Ca concentration at 0.5 mM (low Ca 
conditions). Once cells reached ~90% confluence, CM was added at 1 µM and 100 
µM. Protein and RNA samples were collected after 6 and 24 hours, respectively. 
To further confirm that the CM actions are mediated by the CaSR, Calhex 231, a 
negative allosteric modulator of the CaSR was added at 1 µM and 10 µM to UMR 
cells cultured in Ca-free DMEM (Gibco™) supplemented with CaCl2 to achieve a Ca 
concentration of 1.8mM (high Ca conditions). Cells were processed for protein 
isolation after 6 hours and for RNA isolation after 24 hours. Experiments were 
performed at least three times. 
2.2.1.2.  In vitro study  of the calcimimetic effects on osteogenesis of human 
bone marrow MSC 
Additionally, human MSC were obtained from excess bone marrow collected during 
diagnosis or routine follow-up of patients in the Hematology service of Reina Sofía 
University Hospital. Human samples of bone marrow MSC were collected from 
patients after obtaining the corresponding signed informed consent. These MSC 
from the iliac crest were isolated by their plastic adherence properties. Briefly, 750 
µl of total bone marrow aspirate were cultured in 75 cm2 flasks with α-MEM 
containing 15% FBS, 2 mM ultraglutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 1 ng/ml human recombinant bFGF (PeproTech). Cells were 
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incubated in a humidified atmosphere of 5% CO2 at 37ºC. Fresh α-MEM 
supplemented as above and with 10% FBS was added after 24 hours and replaced 
every 3 days. Once 85-90% confluent, cells were collected using Trypsin-EDTA, 
seeded in 6-well plates at a density of  
13000 cells/cm2 and cultured with Ca-free DMEM supplemented as described above 
and under osteogenic stimuli based on dexamethasone, β-glycerol phosphate and 
ascorbic acid. Additionally, 100 µM of CM were added to osteogenic media with low 
0.5 mM Ca throughout the differentiation period. After 21 days, cells were processed 
for analysis of protein and mRNA expression. A graphical scheme sumarizing the 
methodology of this experiment is shown in Figure 23. Experiments were carried out 
at least three times. 
 
2.2.1.3. Total protein isolation 
Total protein was isolated from cells in a lysis buffer, containing 20 mM Tris/HCl, 150 
Mm NaCl, 1 Mm EDTA, 0.5 Mm PMSF, 70 µg/ml Protease Inhibitor Cocktail, 0.5% 
Igepal CA-630, 1 µl/ml Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich) and 1 µl/ml 
Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich), Ph 7.6. Suspension was 
centrifuged and supernatant (protein extract) was stored at -80 ºC. Protein 
concentration was determined by Bradford assay (Bio-Rad Laboratories). 
 
Figure 23. Experimental design for the in vitro study of the effects of calcimimetic on 



























2.2.1.4. Western blotting 
50 µg of total protein were analyzed by immunoblotting as described in the section 
1.2.7 using antibodies for CaSR (Abcam plc, Cambridge, UK. Ref. ab19347; 2 µg/ml 
dilution), p44/42 MAPK (total ERK1/2; Cell signaling Technology / Ref. #4695; 
1:1000 dilution) and phospho-p44/42 MAPK (phospho-ERK1/2; Cell signaling 
Technology  Ref. #4370; 1:2000 dilution) as primary antibodies, and horseradish 
peroxidase-conjugated goat anti-mouse and goat anti-rabbit (Santa Cruz 
Biotechnology) as secondary antibodies. β-actin (Antibody for detection Santa Cruz 
Biotechnology / Ref. SC-47778; 1:500 dilution) was used as loading control . 
2.2.1.5. RNA extraction, DNAse treatment and RT-PCR 
RNA isolation, DNase treatment and RT-PCR analysis for rat Runx2, Osterix and 
Osteocalcin and human Runx2, Osterix, Osteocalcin and BMP2 were determined as 
described in sections 1.2.1.3, 1.2.1.4 and 1.2.2.4, respectively. GAPDH expression 
was used as housekeeping gene. Primers sequences are listed in Table 6. 
2.2.1.6. Calcium content in the matrix of the cell cultures 
At the end of the experiment with MSC differentiated into osteoblasts, Ca 
concentration in the mineralized matrix was quantified as in section 1.2.11. 
Representative microphotographs showing nodules of calcifications were taken 






 Primer sequences NCBI gene ID 
Rat Runx2 Fw 5’-CGGGAATGATGAGAACTACTC-3’ 
Rv 5’-CGGTCAGAGAACAAACTAGGT-3’ 
367218 
Rat Osterix Fw 5’-GTACGGCAAGGCTTCGCATCTGA-3’ 
Rv 5’-TCAAGTGGTCGCTTCGGGTAAAG-3’ 
300260 
Rat Osteocalcin Fw 5’-TCTGAGTCTGACAAAGCCTTCATG-3’ 
Rv 5’-TGGGTAGGGGGCTGGGGCTCC-3’ 
25295 
Rat GAPDH Fw 5’-AGGGCTGCCTTCTCTTGTGAC-3’ 
Rv 5’-TGGGTAGAATCATACTGGAACATGTAG-3’ 
24383 
Human Runx2 Fw 5’-CCGGAGTGGACGAGGCAAGAGTT-3’ 
Rv 5’-AGCTTCTGTCTGTGCCTTCTGGG-3’ 
860 








Human BMP2 Fw 5’-AGGAGGCAAAGAAAAGGAACGGAC-3’ 
Rv 5’-GGAAGCAGCAACGCTAGAAGACAG-3’ 
650 




Table 6. Primers sequences for RT-PCR in the experiments with calcimimetics in vitro. 
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2.2.2. Effects of calcimimetic on osteoclastogenesis: In vitro study 
The effects of low calcium concentration (0.5mM) and calcimimetic (10 and 100 µM) 
during osteoclastic differention of bone marrow hematopoietic cells were also 
examined as indicated previously in the section 1.2.2. 
  
 
Figure 24. Scheme of the in vitro experiment for the study of the effects of calcium and 
calcimimetic on the osteoclastic differentiation of rat bone marrow hematopoietic cells. 
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SECTION 3: MAGNESIUM AND BONE 
3.1. IN VIVO EXPERIMENTS 
Mg-based compounds are commonly used as P binders to reduce serum P levels 
and vascular calcifications. Moreover, Mg-based phosphate binders also increase 
serum Mg levels, with unknown effects on bone homeostasis. In this section, we 
studied the effects of Mg supplementation in bone in vivo in a rat model of renal 
osteodystrophy and in vitro on osteogenesis of mesenchymal stem cells and 
osteoclast differentiation of bone marrow hematopoietic stem cells. 
3.1.1. In vivo experimental procedure 
To induce uremia in rats, the 5/6 nephrectomy model was used (detailed in section 
1.1.1). One day after the second kidney surgery, rats were fed a high P diet (Ca 0.6% 
and P 1.2%). 5/6Nx animals received CTR (80ng/kg/48h; i.p). Rats were randomly 
divided into groups (n=10-14) which were fed with diets containing different Mg 
content: 0.1, 0.3 or 0.6% for 14 days. All diets were purchased from Altromin 
(Altromin GmbH, Lage, Germany).  
The following animal groups were studied in this section: 
 1. Sham operated (n=15) 
2. 5/6Nx+P 1.2%+Mg 0.1% (n=21)  
3. 5/6Nx+P 1.2%+Mg 0.3% (n=22) 
4. 5/6Nx+P 1.2%+Mg 0.6% (n=24) 
 
At the end of the experiments rats were euthanized and exsanguinated by aortic 
puncture under general anesthesia with sodium thiopental (50mg/kg; i.p.). Blood 
samples were collected, processed for plasma separation and subsequently stored 
at -80 ºC until determination of biochemical parameters. Femurs were placed into 
ethanol 70% for histomorphometric analyses. 
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3.1.2. Plasma and urine biochemistry 
Three days before sacrifice, rats were housed into metabolic cages for urine 
collection and maintained on the same diet. Urine samples from the two first days 
were discarded and only urine from the 24h before sacrifice was used to determine 
Ca, P, Mg and creatinine by spectrometry using commercial kits (Biosystem S.A.). 
Blood samples were collected during the sacrifice in heparinized tubes and 
processed to obtain plasma by centrifugation at 2000 x g, 4 ºC for 10 minutes. 
Samples were divided in aliquots and stored at -20ºC. 
Creatinine, ionized Ca, P, Mg, PTH, CTR and FGF23 plasma concentrations were 
measured as described in section 1.1.4. 
3.1.3. Bone histomorphometry 
Femurs were dehydrated, embedded in methyl-methacrylate and processed for 
histomorphometric analysis as detailed in section 1.1.5. Bone volume, turnover and 
were assessed using Osteometrics™ software according to the established 
system108. 
 





















CTR (80ng/kg/48h; i.p.) 




3.2. IN VITRO EXPERIMENTS 
3.2.1. Magnesium effects on  MSC osteogenic differentiation 
The in vitro effects of Mg supplementation were evaluated on osteogenesis of bone 
marrow MSC. 
3.2.1.1. Experimental design 
Basal Mg2+ concentration in α-MEM was 0.8 mM. To increase Mg2+ content in the 
pro-osteogenic medium, α-MEM was supplemented as indicated in section 1.2.1.2 
and MgCl2 (Carlo ErbaReagentiSpA, Milano, Italy) was added to achieve final Mg2+ 
concentrations of 1.2 and 1.8 mM during the osteogenic stimulus. Fresh medium 
alone or osteogenic medium supplemented with MgCl2 was replaced every 3 days.  
Furthermore, 2-aminoethoxydiphenyl borate (2-APB; 50 µM; Tocris Bioscience, 
Bristol, UK), was added to the osteogenic medium containing 0.8 mM of Mg2+ during 
differentiation to determine the effects of inhibiting the Mg2+ channel Transient 
Receptor Potential cation channel, subfamily M, member 7 (TRPM7). To examine 
the direct effects of Mg2+, MgCl2 at 1.2 and 1.8Mm, or 2-APB at 50 µM was added 
for 24 hours to undifferentiated MSC, to MSC at early osteogenic differentiation (first 
24 hours of osteogenic stimuli) or to MSC at a late stage of differentiation (last 24 




                   
Figure 26. Design for the in vitro study of the effects of magnesium on osteogenesis 
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3.2.1.2. Protein isolation and western blotting 
Isolation of enriched fractions of cytoplasmic and nuclear proteins was carried out 
as previously described in section 1.2.1.6. Protein expression of cleaved Notch, β-
catenin, PCNA and Cyclin D1 was measured by western blotting as described in 
section 1.2.1.7 using 20 µg of nuclear-enriched protein extracts. Primary antibodies 
were anti Cleaved Notch1 (Val1744) (Cell signaling Technology / Ref. #2421; 1:200 
dilution), anti-β-catenin (Cell signaling Technology / Ref. #9562; 1:1000 dilution), 
anti-PCNA (Santa Cruz Biotechnology / Ref. SC-56; 1:100 dilution) and anti-Cyclin 
D1 (Cell signaling Technology / Ref. #2978; 1:500 dilution). TFIIB protein expression 
was used as loading control (Cell signaling Technology / Ref. #4169; 1:1000 
dilution). All experiments were repeated at least three times. 
3.2.1.3. RNA isolation and RT-PCR (two-step protocol) 
RNA samples were obtained at the end of the experiments and treated with DNase 
as previously described in sections 1.2.1.3 and 1.2.1.4 respectively. For these 
experiments RT-PCR was performed for the osteogenic genes Runx2, Osterix, 
Osteocalcin using a two-step protocol as indicated previously in 1.2.1.5. Ribosomal 
18S RNA expression was used as housekeeping control. Primers sequences are 
listed in Table 7. 
3.2.1.4. Quantification of ALP activity 
Determination of ALP activity was conducted as described in the section 1.2.1.9 
using the p-nitrophenyl phosphate method. 
3.2.1.5. Alizarin red S staining 
Matrix mineralization was assessed by alizarin red staining. Protocol and image 
processing were performed as previously detailed in section 1.2.1.10. 
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3.2.1.6. Immunoflurescence analysis 
Protein amount and location for Notch intracellular domain and β-catenin were 
analyzed by confocal microscopy as previously described in section 1.2.1.8. 
3.2.1.7. Decellularization of rat bones for scaffold preparation 
Bone scaffolds were obtained as it was previously reported Shahabipour185. Briefly, 
rat femurs and tibiae were cut longitudinally in 5 mm pieces. Subsequently, bone 
pieces were boiled 4 times for 5 minutes to remove fat tissues. Pieces were stored 
overnight at -20ºC before decellularization. Bone specimens were thawed at room 
temperature, washed with PBS and placed in liquid nitrogen for 2 minutes. Then, 
pieces were maintained in distilled water at room temperature and washed with PBS. 
The freeze-thaw process was repeated five times to lysate the cells. Bone scaffolds 
were decellularized in 2.5% SDS (Sigma-Aldrich) for 24h at 37 ºC with gentle 
shaking. Then, bone specimens were washed twice with PBS for 15 minutes to 
 Primer sequences NCBI gene ID 
Rat Runx2 Fw 5’-CGGGAATGATGAGAACTACTC-3’ 
Rv 5’-CGGTCAGAGAACAAACTAGGT-3’ 
367218 
Rat Osterix Fw 5’-GTACGGCAAGGCTTCGCATCTGA-3’ 
Rv 5’-TCAAGTGGTCGCTTCGGGTAAAG-3’ 
300260 
Rat Osteocalcin Fw 5’-TCTGAGTCTGACAAAGCCTTCATG-3’ 
Rv 5’-TGGGTAGGGGGCTGGGGCTCC-3’ 
25295 
Rat HEY2 Fw 5’-TCCAATGCTCATAAAGTCCGT-3’ 
Rv 5’ -TCTGCAAATGACAGTGGATCA-3’ 
155430 




Table 7. Sequences for primers used in the in vitro experiments with magnesium. 
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remove SDS, washed in ethanol (70%) and maintained in PBS (Sigma-Aldrich) for 
30 minutes with shaking at room temperature. Pictures shown the processing and 
the resulting decellularized scaffolds are shown in Figure 27. 
 
Figure 27. Photograph of processing and resulting decellularized rat bone scaffolds. Rat 
bones were cut using a saw (a), and processed for decellularization. Decellularized rat 
bones pictures were taken with a conventional camera using different zoom (b and c). 
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3.2.1.8. Transmission Electron Microscopy (TEM) 
Bone marrow MSC were cultured in the presence of different concentrations of 
MgCl2 (0.8, 1.2 and 1.8 Mm) on rat femur scaffolds. After 21 days of culture, the 
cellular layer was removed from the surface of the bone scaffolds and they were 
analyzed by electronic microscopy. For the ultrastructural study, randomly selected 
samples of decellularized bone scaffolds were primarily fixed in a glutaraldehyde 2% 
solution in phosphate buffer 0.1 M pH 7.4 overnight at 4ºC and then re-fixed in 
osmium tetroxide 1% in phosphate buffer 0.1 M pH 7.4 for 30 minutes. After 
dehydration in graded ethanol series and embedding in an epoxy adhesive, semi-
thin and ultra-thin sections were cut with a LKB ultramicrotome. Ultra-thin sections 
were viewed and photographed in a Philips CM10 transmission electron microscope. 
3.2.1.9. Scanning Electron Microscopy (SEM) 
Bone marrow MSC were cultured in the presence of different concentrations of 
MgCl2 (0.8, 1.2 and 1.8 Mm) on rat femur scaffolds. After 21 days of culture, 
decellularized bone fragments without MSC, differentiated cells and differentiated 
cells plus MgCl2 were kept in glutaraldehyde 2.5%. Bone scaffolds were mounted on 
the SEM specimen stubs with carbon tape and were carbon-coated. Samples were 
analyzed and photographed with a Hitachi S520 SEM (Hitachi, Tokyo, Japan). 
3.2.2. Effects of magnesium on osteoclastogenesis 
The effects of high doses of Mg were determined in an in vitro model of osteoclasts. 
3.2.2.1. Experimental design 
Osteoclast differentiation was performed as abovementioned in section 1.2.2.1. 
Magnesium chloride was added at the time of osteoclastic differentiation to achieve 
concentrations of 1.4 and 2.6 mM (Fig. 28). After 5 days of differentiation and once 
the presence of multinucleated cells was confirmed in an inverted microscope, cells 




3.2.2.2. RNA isolation and RT-PCR 
RNA isolation and DNAse treatment was determined as aforementioned in sections 
1.2.1.3 and 1.2.1.4, respectively. mRNA expression of CTSK was quantified using a 
one-step protocol as indicated previously in section 1.2.2.4. 
3.2.2.3. TRAP staining 
TRAP staining was performed at the end of the experiment as previously described 
in section 1.2.2.4. 
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Collection of adherent 
cells by scraping and 
seeding into 6-well plates  
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SECTION 4: FGF23 AND BONE 
4.1.  IN VIVO STUDIES 
Serum levels of FGF23 increase dramatically during CKD. This hormone is produced 
mainly by mature osteoblasts and osteocytes; however, currently it is unknown 
whether FGF23 controls osteogenesis or whether excessive FGF23 promotes 
changes in bone homeostasis. In this section, the effect of FGF23 on bone at early 
stage of CKD will be evaluated.  
A heminephrectomy model with modifications in the P content of the diet was 
performed to generate a uremic model with a low and high FGF23 levels without 
additional changes in other important parameters of mineral metabolism. 
4.1.1. Experimental procedure 
Male wistar rats weighing 250 g approximately were anesthetized using sevoflurane 
and underwent total right kidney ablation (1/2Nx). Briefly, rats were anesthetized with 
sevoflurane, an excision was made in the right lateral side of the abdomen and the 
right kidney was exposed, the vessels and the ureter were ligated and the kidney 
was ablated. A group of rats received sham-operation in which the right kidney was 
exposed, moved and returned to approximately the same place in the abdominal 
cavity. Animals were analgesized with fentanyl 10 µg/kg/i.p. After surgery, rats were 
housed using a 12h/12h light/dark cycle and given ad libitum access to tap water. All 
animals fed a 1.2% P, 0.6% Ca diet (Fig.29). Therefore, the following groups of rats 
were studied:  
1. Sham+ P 1.2% (n=8) 
2. 1/2Nx+P 1.2% (n=13). 
After three weeks, rats were euthanized and exsanguinated by aortic puncture under 
general anesthesia by sodium thiopental (50mg/kg; i.p.). Blood samples were 
collected in heparinized tubes and right femurs were placed in 70% ethanol for bone 
histomorphometry. Right tibias were also stored at -80 ºC for RNA isolation and 
quantification of gene expression. 
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4.1.2. Plasma and urine biochemistry 
Plasma determinations of ionized Ca, P, creatinine, intact PTH, intact FGF23 and 
sclerostin concentrations were assayed as previously described in section 1.1.4. 
4.1.3. Bone histomorphometry 
Bone histomorphometric analysis was performed in undecalcified right femurs as 
previously described in section 1.1.5. 
4.1.4. Bone RNA isolation and RT-PCR 
To prevent tissue degradation, frozen tibias were cut and the proximal parts were 
used for RNA isolation. Samples were maintained in liquid nitrogen during tissue 
homogenization using a mortar. Then, the ground tissue was placed in 1 ml of TRI 
Reagent® and homogenized using a vortex during at least 10 seconds. RNA 
isolation and DNase treatment were performed as shown in sections 1.2.1.3 and 
1.2.1.4, respectively. 
RT-PCR was performed for the genes Runx2, Osterix, Ostecalcin, DMP1 and SOST 
as described in the section 1.2.2.4, using GAPDH as housekeeping gene. Primer 
sequences are listed in Table 8. 
 







Diet 0.6%Ca, 1.2%P Sacrifice
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 Primer sequences NCBI gene ID 
Rat Runx2 Fw 5’-CGGGAATGATGAGAACTACTC-3’ 
Rv 5’-CGGTCAGAGAACAAACTAGGT-3’ 
367218 
Rat Osterix Fw 5’-GTACGGCAAGGCTTCGCATCTGA-3’ 
Rv 5’-TCAAGTGGTCGCTTCGGGTAAAG-3’ 
300260 
Rat DMP1 Fw 5’-GGCTGTCCTGTGCTCTCC-3’ 
Rv 5’-ACTGCTGTCCGTGTGGTC-3’ 
25312 




Table 8. Primer sequences for RT-PCR in the study of the effects of FGF23 on bone 
homeostasis in vivo. 
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4.2.  IN VITRO STUDIES 
4.2.1. Effects of FGF23 on osteogenesis of bone marrow MSC 
The effects of high FGF23 on osteogenic differentiation of bone marrow MSC or in 
mature osteoblasts/osteocytes were investigated in vitro. 
4.2.1.1. Experimental design 
Bone marrow MSC isolation and osteogenic differentiation was performed as 
previously detailed in sections 1.2.1.1 and 1.2.1.2, respectively. A high rat 
recombinant FGF23 (R176Q) (rFGF23, 15 ng/ml) concentration was added during 
osteogenic differentiation to assess the effects along differentiation, or 24 hours 
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A) Effects of FGF23 during osteogenesis

























At the end of the experiments cells were processed for RNA or protein isolation. 
Experiments were repeated at least three times. 
4.2.1.2. RNA isolation and RT-PCR 
RNA isolation, DNAse treatment and the quantification of  Runx2, Osterix, 
Osteocalcin, DMP1, SOST, OPG and RANKL mRNA expressions, using GAPDH as 
housekeeping gene, was performed as previously described in sections 1.2.1.3, 
1.2.1.4 and 1.2.2.4, respectively. Primers sequences are shown in Table 9. 
 
 Primer sequences NCBI gene ID 
Rat Runx2 Fw 5’-CGGGAATGATGAGAACTACTC-3’ 
Rv 5’-CGGTCAGAGAACAAACTAGGT-3’ 
367218 
Rat Osterix Fw 5’-GTACGGCAAGGCTTCGCATCTGA-3’ 
Rv 5’-TCAAGTGGTCGCTTCGGGTAAAG-3’ 
300260 
Rat Osteocalcin Fw 5’-TCTGAGTCTGACAAAGCCTTCATG-3’ 
Rv 5’-TGGGTAGGGGGCTGGGGCTCC-3’ 
25295 
Rat DMP1 Fw 5’-GGCTGTCCTGTGCTCTCC-3’ 
Rv 5’-ACTGCTGTCCGTGTGGTC-3’ 
25312 
Rat OPG Fw 5’-CACCAGAACACTCAGCCAAT-3’ 
Rv 5’-CCGGAAACAGAGAAGCAACT-3’ 
25341 
Rat RANKL Fw 5’-ACGAACCTTCCATCATAGCTG-3’ 
Rv 5’-GAAGACACAGAAGCACTACCT-3’ 
117516 
Rat SOST Commercially acquired from Qiagen 
Ref. QT00418558 
80722 
Table 9. Sequences of the primers used for RT-PCR analysis in the in vitro study of the 
effects of FGF23 on osteogenesis. 
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4.2.1.3. ALP activity quantification 
As protein extracts were not collected in these experiments, ALP activity was 
measured in the supernatants. At the end of the experiment, supernatants were 
collected and 20 µl were incubated in 2 mM p-nitrophenyl phosphate using the 
protocol detailed in section 1.2.1.9. 
4.2.1.4. Immunofluorescence analysis 
Confocal microscopy analysis for the location and quantification of β-catenin was 
performed as described in section 1.2.1.8. 
4.2.2. Effects of FGF23 on osteoclastogenesis 
The effects of high doses of rFGF23 (0.1 and 10 ng/ml) were determined in an in 
vitro model of osteoclasts. 
4.2.2.1. Experimental design 
Osteoclast differentiation was performed as described previously in section 1.2.2.1. 
Additionally rFGF23 was added at 0.1 and 10 ng/ml along with the osteoclastogenic 
stimuli. Cells were incubated at 37 ºC, 5% CO2 with saturated humidity for 5 days. 
Figure 31 shows a visual timeline of this study. 
 Medium was replaced every 2 days. At the end of the experiments cells were 
processed for determination of mRNA expression and TRAP staining. Experiments 
were performed at least three times. 
4.2.2.2. RNA isolation and RT-PCR 
RNA isolation, DNAse treatment and quantification of CTSK mRNA expression were 
carried out as described in sections 1.2.1.3, 1.2.1.4 and 1.2.2.4. 
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4.2.2.3. TRAP staining 
 
TRAP staining was performed at the end of the experiment as previously detailed in 
section 1.2.2.4. 
 
4.2.2.4. Length measurement of osteoclasts 
As an increase in the size of the osteoclasts was observed in the cells treated with 
high rFGF23, we considered to measure the length of differentiated osteoclasts. 
Osteoclast differentiation was evaluated using an inverted microscope Nikon eclipse 
Ti-S. Intense red-stained (TRAP-positive) cells with more than 3 nuclei were 
considered osteoclasts. Cells nuclei were counted and the length of the minor and 
major axis were measured using Image J software.  
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SECTION 1: CALCITRIOL 
1.1 IN VIVO STUDY OF THE CALCITRIOL EFFECT ON BONE  
 
In these experiments, the effect of different concentrations of CTR (20, 40 and 60 
ng/kg) were evaluated in 5/6 nephrectomized (5/6Nx) and parathyroidectomized 
(PTx) rats, receiving a constant infusion of rat recombinant PTH (1-34 length) 
through Alzet pumps and fed on a 0.9% P diet. Thus, the actions of CTR on bone 
were separated from those mediated by CTR-dependent PTH modulation. Sham 
rats and 5/6Nx-PTx-PTH rats receiving vehicle were also included. 
 
1.1.1. Plasma biochemistry 
Biochemical data of this study are shown in Table 10. As compared with Sham 
animals, 5/6Nx rats showed a significant increase in plasma creatinine, P, PTH and 
intact FGF23, while plasma iCa was significantly decreased. In 5/6Nx rats with PTx 
and PTH replacement by 6-fold (5/6Nx-PTx-PTHx6), plasma iCa levels were similar 
to those observed in the 5/6Nx group. Administration of CTR dose-dependently 
increased plasma P and iCa, being statistically significant at the dose of 60 ng/kg. 
The group receiving the dose of CTR 60 ng/kg also showed higher plasma creatinine 
than the others 5/6Nx groups. Furthermore, it was found that plasma FGF23 and 
sclerostin levels resulted significantly increased according to CTR dose. Exogenous 


















Creatinine (mg/dl) 0.49±0.03 0.88±0.06a 0.91±0.03 a 1.02±0.05 a 1.03±0.06 a 1.46±0.15 a,b,c,d,e 
P (mg/dl) 6.2±0.2 8.73±0.39 a 7.77±0.43 a 8.49±0.66 a 9.28±0.65 a 13.6±2.17 a,b,c,d 
iCa (mM) 1.21±0.02 1.10±0.02a 1.02±0.03 a 1.04±0.03 a 1.23±0.04 c,d 1.32±0.01 b,c,d 
Intact PTH (pg/ml) 47±4.4 540±96 a n.a n.a n.a n.a 
FGF23 (pg/ml) 130±31 1522±217 a 471±105 a,b 908±138 a,b,c 5143±2264 a,b,c 28930±9608 a,b,c,d,e 
Sclerostin (pg/ml) 215±20 261±43 288±39 253±24 374±112 713±179 a,b,c 
 
Table 10. Plasma biochemistry. Values are mean ±SEM. One-way ANOVA with tukey test. a: p<0.05 vs Sham; b: p<0.05 vs 5/6Nx; c: p<0.05 vs 5/6Nx-
PTx-PTHx6; d: p<0.05 vs 5/6Nx-PTx-PTHx6-CTR20; e: p<0.05 vs 5/6Nx-PTx-PTHx6-CTR40. Sham rats fed a 0.6%P, 0.6%Ca Diet. 5/6Nx groups fed 
a 0.9%P, 0.6%Ca diet. 
1.1.2. Bone histomorphometry 
Bone histomorphometry parameters were evaluated in the trabecular bone of the 
distal right femurs (Fig.32). 5/6Nx rats showed reduced BV/TV (Fig.32 a) and 
increased OV/BV, OS/BS (Fig.32 b and c respectively) and osteoblast activity 
(Fig.32 d) as compared with Sham animals. The ES/BS and the bone surface 
covered by osteoclasts were increased in the 5/6Nx group as compared with Sham 
rats (Fig.32 e and f). 5/6Nx-PTx-PTHx6 rats receiving vehicle showed similar BV/TV 
and OV/BV than the 5/6Nx group (Fig.32 a and b respectively), while bone cell 
activity was lower as assessed by the OS/BS and ES/BS (Fig.32 c and e) and the 
bone surface covered by osteoblasts and osteoclasts (Fig.32 d and f). CTR 
administration at 40 ng/kg body weight prevented the decrease in BV/TV. However, 
CTR at the dose of 60 ng/kg did not further increased the BV/TV. Osteoid amount 
was reduced by CTR administration at 20 and 40 ng/kg, consistent with a decrease 
in the bone surface covered by osteoblasts (Fig.32 d). It is interesting to note that 
the highest dose of CTR (60 ng/kg body weight) increased the osteoid amount 
respect to lower CTR doses. In 5/6Nx-PTx-PTHx6, CTR administration did not 
induce significant effects on osteoclast activity (Fig 32.e and f). 
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Figure 32. Effect of CTR on bone volume and turnover. CTR induces alterations in bone 
volume and bone cell activity independently of PTH in uremia. One-way ANOVA with Tukey 
test. a: p<0.05 vs Sham; b: p<0.05 vs 5/6Nx; c: p<0.05 vs 5/6Nx-PTx-PTH-vehicle; d: p<0.05 
vs 5/6Nx-PTx-PTH-CTR 20 ng/kg; e: p<0.05 vs 5/6Nx-PTx-PTH-CTR 40 ng/kg. Sham rats 
fed a 0.6%P, 0.6%Ca Diet. 5/6Nx groups fed a 0.9%P, 0.6% Ca diet. 
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5/6Nx rats showed higher trabecular separation (Fig.33 c) and decreased trabecular 
number (Fig.33 d) than Sham animals. Bone structural parameters in 5/6Nx-PTx-
PTHx6 were similar to those in 5/6Nx group. There was a significant increase in the 
osteoid thickness in 5/6Nx-PTx-PTHx6 rats treated with CTR at the dose of 60 ng/kg 
as compared with all the groups (Fig.33 b). A tendency to prevent the loss of 
trabecular bone was observed according to CTR administration. Trabecular 
thickness remained similar in all experimental groups (Fig.33 a). 
 As compared with Shan animals, bone mineralization assessed by calcein labelling 
showed higher mineralizing surface (MS/BS, Fig.34 a) and bone formation rate 
Figure 33. Effect of CTR on bone microstructure. CTR produces changes in bone structure and 
thickness independently of PTH. One-way ANOVA with Tukey test. a: p<0.05 vs Sham; c: 
p<0.05 vs 5/6Nx-PTx-PTHx6; d: p<0.05 vs 5/6Nx-PTx-PTHx6-CTR20; e: p<0.05 vs 5/6Nx-PTx-
PTHx6-CTR40. Sham rats fed a 0.6%P, 0.6%Ca Diet. 5/6Nx groups fed a 0.9%P, 0.6%Ca diet. 
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(BFR/BS, Fig.34 c) in the 5/6Nx group. A tendency to increase the time of 
mineralization was observed in the 5/6Nx group respect to Sham animals (Fig.34 d). 
5/6Nx-PTx-PTHx6 rats showed significantly lower BFR/BS than 5/6Nx and a 
tendency to decrease MS/BS. CTR administration at 60 ng/kg body weight produced 
a significant increase in the mineral apposition rate (MAR) as compared with the 
other 5/6Nx-PTx-PTHx6 groups (Fig.34 b). CTR administration did not modify bone 
formation significantly (Fig.34 c). Mineralization lag time was similar among all 
groups, however CTR administration at 20 and 40 ng/kg showed a tendency to 
decrease the time of mineralization, while it was observed delayed mineralization 
with the dose of 60 ng/kg (Fig.34 d), consistent with the accumulation of osteoid. 
 
 
Figure 34. Bone formation and mineralization is affected by 1,25(OH)2D3 at the same plasma 
PTH levels. One-way ANOVA with Tukey test. a: p<0.05 vs Sham; b: p<0.05 vs 5/6Nx; c: 
p<0.05 vs 5/6Nx-PTx-PTHx6; d: p<0.05 vs 5/6Nx-PTx-PTHx6-CTR20; e: p<0.05 vs 5/6Nx-





Figure 35 shows representative pictures of Goldner’s trichrome staining and calcein 
labeling of trabecular bone for each group. Note the increased resorption in the 
5/6Nx group (Fig.35 b) and the increased bone formation (Fig.35 e) as compared 
with Sham animals (Fig.35 a and d). CTR administration by 20 ng/kg ( Fig.35 g and 
j) and 40 ng/kg (Fig.35 h and k) decreased the osteoid amount as compared with 
vehicle (Fig.35 c and f), however, CTR at 60ng/kg increased osteoblast activity and 
osteoid amount (Fig.35 i and l). CTR did not exert significant effects on osteoclast 
activity and bone formation, however decreased bone mineralization and increased 




Figure 35. Representative pictures of Goldner’s trichrome staining and calcein labeling of 
trabecular bone. 5/6Nx rats (b and e) showed an increased bone remodeling and bone 
formation as compared with Sham animals (a and d). PTH replacement maintained bone 
formation in parathyroidectomized rats receiving vehicle (c and f). CTR administration by 20 
(g and j) and 40 ng/kg (h and k) decreased the osteoid amount in 5/6Nx-PTx-PTHx6 rats, 
while CTR at 60 ng/kg induced an increase in osteoblast activity and diffuse bands of calcein 
were observed (i and l). Sham rats fed a 0.6%P, 0.6%Ca Diet. 5/6Nx groups fed a 0.9%P, 
0.6%Ca diet. Double-headed arrows indicate distance between both calcein labels. 
Ob: Osteoblasts. Arrowhead: Osteoclast. Magnification: 200x. Bars represent 100µm. 
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1.2.  IN VITRO STUDY OF THE CALCITRIOL EFFECTS ON OSTEOGENESIS 
 
The direct actions of CTR supplementation were studied in vitro on osteogenesis 
and osteoclastogenesis models with bone marrow stem cells. Firstly, our in vitro 
model of osteoblast differentiation was based on rat bone marrow mesenchymal 
stem cells (MSC) treated with dexamethasone, β-glycerol-phosphate and ascorbic 
acid for 21 days. To evaluate whether CTR acts directly on osteogenesis, we 
measured its effects at different doses, from 10-12 to 10-8 M, during osteogenic 
differentiation of MSC. 
 
1.2.1. Effects of calcitriol supplementation on MSC osteogenesis 
 
As expected, osteogenic stimuli in the culture medium promoted MSC differentiation 
into osteoblast-like cells (OB), increasing the amount of mineralized matrix (Fig.36 
a). Alizarin red staining at 21 days showed lower intensity at high doses of CTR, 
supporting the previous results. At the concentration of CTR 10-8 M mineralization 
was inexistent. Of note, the addition of CTR suppressed MSC differentiation dose-
dependently, as confirmed by decreased calcium content in the mineralized matrix 




In addition, treatment with CTR at doses from 10-10 to 10-8 M decreased the 
expression of the osteogenic master genes Osterix and Osteocalcin (Fig.37 a and b 
respectively), however CTR addition at lower dose (10-11 and 10-12 M) increased the 
 
 
Figure 36. Effect of CTR on mineralization during osteogenesis in vitro. Representative pictures 
of alizarin red staining and microphotographs of MSC cultured with different experimental 
conditions after 21 days (a). UC: undifferentiated control. CTR dose-dependently decreased 
the amount of Ca in the mineralized matrix (b) and ALP activity (c). Bars are mean ± SEM. 
One-way ANOVA with Tukey test. a: p<0.05 vs UC; b: p<0.01 vs OB; c: p<0.001 vs OB+CTR 
10-12 M; d: p<0.001 vs OB+CTR 10-11 M; e: p<0.01 vs OB+CTR 10-10 M. ALP: Alkaline 















expression of both genes, resembling a reverse J-shaped curve that suggests a 
hormetic dose-response. Similar results were observed respect to the expression of 
the Vitamin D receptor (VDR) (Fig.37 c). 
 
Moreover, high doses of CTR during osteogenic differentiation reduced the cellular 
proliferation, assessed by the decreased protein amount of PCNA and Cyclin D1 in 
western blot analysis (Fig.38). 
 
Figure 37. CTR administration during 
osteogenic differentiation of MSC decreases 
the expression of osteogenic master genes 
such as Osterix (a), Osteocalcin (b) and 
VDR (c). UC: undifferentiated control. One-
way ANOVA with Tukey test. a: p<0.05 vs 
UC; b: p<0.01 vs OB; c: p<0.001 vs 
OB+CTR 10-12 M; d: p<0.001 vs OB+CTR 
10-11 M; e: p<0.01 vs OB+CTR 10-10 M; f: 




1.2.2. Effects of calcitriol on β-catenin nuclear translocation during 
osteogenesis of MSC 
In order to evaluate the mechanism whereby high doses of CTR achieve its anti-
osteogenic effect, the participation of the canonical Wnt/β-catenin pathway was 
examined by confocal microscopy. 
High doses of CTR during osteogenic differentiation decreased the nuclear 
traslocation of β-catenin. Co-localization analysis of the confocal microphotographs 
clearly showed that the number of green pixels (β-catenin labeling) overlapping with 
blue pixels (DAPI, nuclear labeling) were lower in MSC differentiated into osteoblasts 
as CTR concentration increases (Fig.39). 
 
Figure 38. Effects of CTR supplementation on proliferation during MSC osteogenesis. 
CTR addition throughout osteogenesis decreased the amount of nuclear PCNA and 
Cyclin D1. TFIIB was used as housekeeping protein. 
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Figure 39. Representative pictures of β-catenin immunofluorescence. Submask images 
were performed for clearly identifying the co-localization for blue and green pixels co-
localization. Green: β-catenin-488. Blue: DAPI. 
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1.3. IN VITRO EFFECTS OF CALCITRIOL ON OSTEOCLASTOGENESIS 
To develop the in vitro model of osteoclast differentiation, we isolated non-adherent 
bone marrow hematopoietic stem cells from rat tibias and femurs, subsequently 
monocyte-macrophage differentiation was induced with M-CSF and differentiated 
into osteoclasts with M-CSF and RANKL during 5 days approximately. CTR was 
added along the differentiation process. 
1.3.1. Osteoclast differentiation of bone marrow hematopoietic cells 
Firstly, we characterized by immunophenotyping the osteoclast precursor cells. At 
the time of characterization, the non-adherent osteoclast precursor cells showed the 
immunophenotype of rat hematopoietic stem cell (Table 11). 
Undifferentiated control cells were mono-nuclear TRAP-negative cells (Fig.40 a and 
b). Osteoclastogenic stimulus promoted the recruitment of the precursor cells and 
osteoclastic differentiation (Fig.40 b). Multinucleated cells and positive for TRAP 
staining were considered well differentiated into osteoclasts (Fig.40 d).  Moreover, 
osteoclastogenic medium induced an increase in the Cathepsin K (CTSK) mRNA 
expression after 5 days (Fig.40 e), an enzyme highly expressed in osteoclast that 
participates in extracellular matrix degradation. 
 CD34 CD45 Sca1 
Positive cells (%) 0.07±0.015 77.1±6.73 1.05±0.12 





           
Arrowheads indicate nuclei in osteoclast-like hematopoietic cells. T-test ** p<0.01. 
Augmentation 400x. Scale bar: 50 µm. 
Figure 40. Osteoclastogenic stimulus 
produced multinucleated TRAP-
positive cells. Bright field microscopy 
showed control cells (a) and lager 
multinucleated cells after 5 days of 
osteoclastogenic stimulus (b). Scarce 
or absence of TRAP stained cells were 
observed in the undifferentiated control 
cells (c), while multinucleated cells 
were positive for TRAP staining (d). 
CTSK expression increased after 5 
days of osteoclastogenic stimuli (e). 
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1.3.2. Calcitriol supplementation increases osteoclast differentiation 
 
We evaluated a physiological (10-11 M) and supraphysiological (10-9 M) 
concentrations of CTR during osteoclast differentiation of bone marrow 
hematopoietic cells and we observed that CTR supplementation increased the 
expression of CTSK as compared with osteoclasts (OC), consistent with a higher 
number of multinucleated TRAP positive cells (Fig.41). 
  
                    
 
Figure 41. CTR treatments increased 
osteoclastogenesis. Panel (a) shows 
undifferentiated cells. After osteoclastic 
stimuli TRAP+ multinucleated cells were 
observed (b). Treatment with CTR at 10-11 
M (c) and 10-9 M (d) increased osteoclastic 
differentiation and Cathepsin K expression 
(e). One-way ANOVA with Tukey test. a: 
p<0.05 vs undifferentiated control; b: 
p<0.05 vs OC. OC: Osteoclastogenic 




SECTION 2:  CALCIMIMETIC 
2.1. PTH-INDEPENDENT EFFECTS OF CALCIMIMETIC: IN VIVO STUDIES 
 
To separate the specific bone effects of calcimimetic from those triggered by the 
treatment decreasing PTH levels, we used rats that underwent total 
parathyroidectomy with PTH replacement to maintain blood calcium. After 28 days, 
animals were sacrificed and blood and bone (femurs) samples were collected for 
biochemical and bone histomorphometric analysis. 
 
2.1.1. Plasma biochemistry of rats with clamped PTH and normal renal 
function treated with calcimimetic 
Biochemical data are shown in Table 12. PTx rats showed lower plasma iCa and 
higher P levels than sham-operated rats (ap<0.05). PTH replacement (PTx-PTH) 
restored plasma iCa and P concentration to normal levels. The administration of 
calcimimetic (PTx-PTH-CM) did not modify plasma iCa and P levels significantly, 
however plasma calcium showed a tendency to decrease as compared with the PTx-
PTH group. Plasma 1,25(OH)2D3 levels were similar among Sham, PTx and PTx-
PTH groups, however PTx-PTH-CM rats showed significantly higher levels of 
1,25(OH)2D3 than this other groups (abcp<0.05 vs all groups). Plasma intact FGF23 
concentration was decreased in PTx rats as compared with Sham; and PTH 
replacement increased FGF23 concentration. PTx-PTH-CM group showed 
significantly lower plasma FGF23 concentration than PTx-PTH rats. 
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2.1.2. Calcimimetic effects in bone histomorphometry of rats with clamped 
PTH and normal renal function 
Bone volume (BV/TV) was similar in all groups (Fig.42 a). In PTx rats, the osteoid 
volume, osteoid surface and bone surface covered by osteoblasts (OV/BV, OS/BS 
and Ob.S/BS respectively) were significantly reduced as compared with the Sham 
group (Fig.42 b, c and d respectively). In addition, the bone surface covered by 
osteoclast was decreased in comparison with Sham rats (Fig.42 f) without changes 
in the eroded surface (Fig.42 e). PTH replacement (PTx-PTH) restored bone 
histomorphometric parameters to values similar than those found in sham-operated 
animals. The administration of CM (PTx-PTH-CM) did not alter bone parameters as 
compared with Sham and PTx-PTH, however a tendency to increase the osteoblast 










iCa (mM) 1.21±0.02 0.59±0.02 a 1.13±0.04 1.07±0.04 
P (mg/dl) 6.2±0.2 11.6±0.9 a 5.6±0.4 b 5.4±0.6 b 
1,25(OH)2D3 (pg/ml) 192±35 126±20 163±25 252±30 a,b,c 
FGF23 (pg/ml) 130±34 68±6a 129±20 b 88±13 c 
Table 12. Plasma biochemistry of rats with normal renal function. One-way ANOVA with 
Tukey test. a: p<0.05 vs Sham; b: p<0.05 vs PTx; c: p<0.05 vs PTx-PTH. 
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Figure 42. Bone histomorphometry parameters in rats with normal renal function. One-way 
ANOVA with Tukey test. a: p<0.05 vs Sham; b: p<0.05 vs PTx. Rats fed a 0.6%P, 0.6%Ca 
diet. 
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2.1.3. Effects of calcimimetic administration on bone in rats with renal 
insufficiency and clamped PTH 
As shown in Table 13, plasma concentration of creatinine was increased significantly 
in all 5/6Nx groups as compared with Sham rats (ap<0.05) with no differences among 
the other 5/6Nx groups. Plasma P, intact PTH and intact FGF23 concentration 
increased also in 5/6Nx rats as compared with Sham while plasma iCa levels 
decreased (ap<0.05). CM administration to 5/6Nx animals, decreased plasma intact 
PTH, 1,25(OH)2D3 and intact FGF23 concentration as compared with 5/6Nx group. 
In 5/6Nx rats with PTx, the PTH infusion in an amount 6-fold the normal replacement 
dose (5/6Nx-PTx-PTHx6) was sufficient to maintain plasma Ca and P at levels 
similar to those in 5/6Nx rats. The treatment with CM in 5/6Nx-PTx-PTHx6 rats 
(5/6Nx-PTx-PTHx6-CM) did not affect the plasma Ca concentration, and plasma 
biochemistry was similar to the 5/6Nx-PTx-PTHx6 group. PTH replacement by 9-fold 
induced a significant increase in plasma iCa and intact FGF23 concentrations as 
compared with 5/6Nx-PTx-PTHx6 group, while plasma 1,25(OH)2D3, and P levels 
remained similar to those with PTH replacement by 6-fold. CM administration did not 
alter plasma biochemistry between both 5/6Nx-PTx-PTHx9 groups. The amount of 
plasma PTH 1-34 in the 5/6Nx-PTx-PTHx6 groups was significantly lower than in 
5/6Nx rats. PTH replacement by 9-fold increased significantly the plasma 



















Creat (mg/dl) 0.49±0.03 0.88±0.06 a 0.9±0.05 
a 0.91±0.03 0.9±0.05 0.9±0.05 0.85±0.04 
iCa (mM) 1.21±0.02 1.10±0.02 a 1.00±0.02 a 1.02±0.03 a 1.08±0.06 1.15±0.07 1.17±0.06 
P (mg/dl) 6.2±0.2 8.73±0.39 a 7.35±0.32 a 7.77±0.43 6.32±0.40 7.58±0.80 7.94±0.76 
Intact PTH (pg/ml) 47±4.4 540±96 a 144±40 a,b n.a n.a n.a n.a 
PTH 1-34 (pg/ml) - 386±44 - 304±23 295±12 541±63 599±56 
1,25(OH)2D3 (pg/ml) 192±35 159±18 131±9.0 a 162±10 158±7 153±17 152±22 
FGF23 (pg/ml) 130±31 1522±217 a 826±178 a,b 471±105 491±87 1209±280 1005±140 
Table 13. Plasma biochemistry. Values are mean±SEM. T-test between paired treatments. a: p<0.05 vs sham, b: p<0.05 vs 5/6Nx. n.a.: infused PTH not recognized 
by the intact PTH assay. Sham rats fed a 0.6%P, 0.6%Ca diet. 5/6Nx groups fed a 0.9%P, 0.6%Ca diet. 
 
2.1.4. PTH-independent effects of calcimimetic in bone histomorphometry in 
uremic rats 
5/6Nx rats showed a significant reduction in BV/TV as compared with the sham 
group (p<0.001, Fig.43 a) and increased bone cell activity (Fig.43 b-h). Bone 
histomorphometric parameters in 5/6Nx rats treated with CM did not differ 
significantly from those in the 5/6Nx group treated with vehicle. 5/6Nx-PTx-PTHx6 
rats showed lower bone cell activity than the 5/6Nx group as assessed by the OS/BS, 
Ob.S/BS, ES/BS and Oc.S/BS (Fig.43 c, d, e and f respectively). In these conditions 
of relatively low PTH replacement (5/6Nx-PTx-PTHx6), CM administration increased 
significantly the osteoid surface (23.3±1.27 vs 13.9±2.39 %, p<0.05) and the bone 
surface covered by osteoblasts (11.7±1.44 vs 4.35±0.46, p<0.05). Similarly, in 
comparison with 5/6Nx-PTx-PTHx6, CM also increased the bone formation rate and 
mineralizing surface (Fig.43 g and h respectively). In parathyroidectomized 5/6Nx 
rats with PTH replacement by 9-fold the normal dose, bone turnover was higher than 
in 5/6Nx-PTx-PTHx6 rats and similar to 5/6Nx group. With the highest PTH infusion, 
the osteoanabolic action of calcimimetic was not observed, being the bone 




Figure 43. Bone histomorphometry in 5/6Nx rats with clamped PTH and calcimimetic 
treatment. Bars show mean±SEM. T-test. *: p<0.05; **: p<0.01; ***: p<0.001; n.s: no 
significant differences. 
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5/6Nx animals showed higher mineral apposition rate and mineralization lag time 
(Fig.44 c and e) and lower mineralizing surface related to osteoid surface and 
adjusted apposition rate (Fig.44 b and d) than Sham rats (p<0.05). However, CM 
administration did not induce significant changes in osteoid thickness, mineralizing 
surface related to osteoid Surface, mineral apposition rate, adjusted apposition rate, 
mineralization lag time or osteoid maturation time as compared with the 
corresponding vehicle treatment (Fig.44 a-f). 
 
 
Figure 44. Bone histomorphometry. Mineralization indices in 5/6Nx rats with clamped 
PTH and CM treatment. Bars show mean±SEM. T-test. *: p<0.05; n.s: non-significant. 
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Representative samples of Goldner’s trichrome staining of the undecalcified bone 
histology from the seven groups of rats are also shown in Figure 45. 
As CaSR activation triggers ERK1/2 phosphorylation, we investigated the CaSR 
downstream signaling in bone cells and we found that rats receiving CM showed 
increased phosphorylation of ERK1/2 in the osteoblasts, indicating a potential 
activation of the CaSR. ERK1/2 phosphorylation was observed in both, cytoplasm 




Figure 45. Representative photographs of Goldner’s trichrome staining and double calcein labeling in trabecular bone. In Sham animals, an 
almost quiescent state of bone cells was observed (a), with normal mineralization (b). In 5/6Nx rats, an increase in bone cell activity was 
observed (c), accompanied by an increase in bone formation (d). 5/6Nx rats treated with CM maintained a similar bone cell activity (e) and 
mineralization (f) than 5/6Nx rats. In Nx-PTx-PTHx6 animals, was detected a low bone turnover (g) and bone formation (h) respect to 5/6Nx 
group. Treatment with CM increased the number of osteoblasts and osteoclasts (i) as well as mineralization and bone formation (j). In Nx-PTx-
PTHx9 group was observed a similar bone turnover (k) and mineralization (l) than 5/6Nx group. In 5/6Nx-PTX-PTHx9 plus CM, bone cells 
activity (m) and bone formation (n) were similar to those observed in the 5/6Nx-PTX-PTHx9. Double-head arrows show the bone distance 



































Figure 46. The administration of CM triggered Erk1/2 phosphorylation in osteoblasts. Goldner’s staining of undecalcified bone sections shows 
cuboidal osteoblasts covering osteoid on the bone surface. Immunohistochemistry for phospho-Erk1/2 showed intense nuclear staining in 
osteoblasts in the Nx-CM, Nx-PTx-PTHx6-CM and Nx-PTx-PTHx9-CM groups and scarce nuclear staining in the bone cells of the other groups. 
To determine that the target cells are osteoblasts, serial undecalcified bone sections were also stained for osteocalcin. Running the 
immunohistochemistry without primary antibody in undecalcified bone samples showed no positive staining. Arrowheads indicate nuclear 
phospho-Erk1/2. Magnification 1000x. Scale bar: 20µm. 
  
 
Fig 47. Osteoblasts with positive phospho-Erk1/2 staining were counted in 3 random 
fields of each sample and were expressed as the percentage of total osteoblasts. T-
test. *** p<0.001. 
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2.2. IN VITRO STUDY OF THE CALCIMIMETIC EFFECT ON OSTEOBLASTS 
 
To further confirm the direct actions of CaSR in bone cells, we studied the effects of 
CaSR allosteric modulation by calcimimetic and calcilytic drugs in in vitro models of 
osteoblasts. 
 
2.2.1. Effects of the modulation of CaSR by calcimimetic and calcilytic in UMR-
106 cells 
To evaluate the direct effect of the positive allosteric modulation of CaSR on the 
osteoblastic phenotype of cell line UMR106, CM was added in the medium with a 
low Ca2+ concentration, which in turn mimics the in vivo effects of CM decreasing 
PTH with the resulting decrease in plasma Ca2+ concentration. Firstly, the presence 
of CaSR in UMR106 was proven by western blot and the addition of CM did not affect 
its expression (Fig.48 a). CaSR activation by CM led to an increase in ERK1/2 
phosphorylation (Fig.48 b), demonstrating that CaSR is functional and modulated by 
CM. After 48 hours of treatment, CM administration (100µM) significantly increased 
(ap<0.05 vs all groups) the expression of the osteogenic markers Runx2, Osterix and 
Osteocalcin (Fig.48 c, d and e respectively). 
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At contrary, the administration of the calcilytic Calhex 231 to UMR-106 cells inhibited 
the MAPK pathway, as assess by the reduction in ERK1/2 phosphorylation (Fig.49 
a). The decrease in the CaSR signaling was also accompanied by a down-regulation 
in the expression of the osteogenic genes Runx2, Osterix and Osteocalcin (Fig.49 
b, c and d respectively). 
Figure 48. CM addition activated CaSR downstream signaling and up-regulated osteogenic 
marker genes expression. Western blots of total protein extracts showed positive expression of 
CaSR in UMR106 cells (a) and induced ERK1/2 phosphorylation (b). The gene expression of 
Runx2 (c), Osterix (c) and osteocalcin (e) were up-regulated with the dose of 100 µM of CM. Bars 




Figure 49. Treatment with calcilytic decreased osteogenic genes expression in UMR-106 
cells. ERK1/2 phosphorylation was reduced by the treatment with Calhex 231 (a). CaSR 
inhibition with Calhex 231 induced a down-regulation of Runx2 (b), Osterix (c) and 
Osteocalcin (d). Bars show mean±SEM. ANOVA with Tukey test. a<0.05 vs Control. 
[Ca2+]=1.8 mM. 
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2.2.2. Effects of calcimimetic on osteoblastic differentiation and mineralization 
of human MSC 
Human bone marrow mesenchymal stem cells (MSC) were differentiated into 
osteoblasts in a medium with a low Ca2+ concentration (Ca 0.5 mM). Results show 
that CaSR was constitutively expressed in MSC (Fig.50 a). After 21 days, Ca2+ 
deposition (Fig.50 b) and the number of calcification nodules (Fig.50 c) were 
increased in osteoblasts cultured with CM. 
Consistently, the addition of CM also increased the expression of the early osteoblast 
markers Runx2 and Osterix (Fig.51 a and b respectively) and mature genes such as 
 
Figure 50. CM (100 µM) increases calcification of human MSC differentiated into osteoblasts. 
CaSR was expressed in MSC and Osteoblast-like MSC and CM did not significantly alter its 
expression (a). CM administration increased the calcium content in the mineralized matrix (b) 
and the number and size of the calcification nodules (c) after 21 days of osteogenic 
differentiation. One-way ANOVA with Tukey test. a: p<0.05 vs MSC; b: p<0.05 vs OB. Bars in 
microphotograph represent 100µm. 
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osteocalcin (Fig.51 c). Furthermore, CM addition enhanced the expression of BMP2 




Figure 51. Treatment with CM (100 µM) increases osteogenic genes expression of MSC 
differentiated into osteoblasts. One-way ANOVA with Tukey test. a: p<0.05 vs UC; b: p<0.05 
vs OB. UC: undifferentiated control. OB: Osteogenic medium. 
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2.3. IN VITRO EFFECTS OF CALCIMIMETIC ON OSTEOCLASTOGENESIS 
 
The direct effects of calcimimetic administration throughout osteoclastogenesis was 
also studied with a low calcium (0.5 mM Ca2+) in the culture medium. 
 
2.3.1. Calcimimetic effects on osteoclastic differentiation 
Firstly, we evaluated the role of different Ca2+ concentrations (low 0.5 mM vs normal 
1.25 mM) during osteoclastogenesis of bone marrow hematopoietic stem cells. 
Osteoclastogenic stimuli in normal Ca2+ conditions produced TRAP positive 
multinucleated cells (Fig.52 b), while with low Ca2+ (0.5 mM) (Fig.52 c) were not 
detected significant differences in TRAP staining as compared with undifferentiated 
cells (Fig.52 a). Furthermore, despite of some cells were multinucleated, rarely cells 
with more than 3 nuclei were found with low Ca2+ condition. Similarly, the pro-
osteoclastogenic stimulus did not increase the expression of CTSK (Fig.52 d), 
indicating that low Ca2+ may suppress osteoclastic differentiation. 
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Once the influence of low Ca was examined, we evaluate the effect of CM 
administration at 10 and 100 µM on osteoclastic differentiation. In low Ca conditions 
(Ca 0.5 mM), osteoclast differentiation did not induce an increase in the size of the 
multinucleated cells, which did not have more than 3-4 nuclei (Fig.53 a, b and c).  
Despite CM (at 100µM) significantly increased the expression of CTSK as compared 
with the group treated with osteoclastogenic medium (OC, Fig.53 d), CTSK 
expression was not more increased than in undifferentiated cells. 
Figure 52. Effects of low calcium on osteoclastogenesis. TRAP staining was negative in 
undifferentiated cells (a) and osteoclastogenic medium induced differentiation with Ca 1.25 
mM, as assessed by the increased number of multinucleated TRAP-positive cells (b). Low 
Ca prevented osteoclastic differentiation (c). CTSK expression (d) support these results. a: 
p<0.05 vs undifferentiated control. 
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increased with CM at 100 µM (e). CTSK expression was quantified in three replicas. 
OC: osteoclastogenic medium. b: p<0.05 vs OC. Arrows: osteoclasts. 
Figure 53. Effect of CM on osteoclastic 
differentiation of hematopoietic cells in 
low Ca2+ conditions. Control cells were 
TRAP negative and mononuclear cells 
(a). A scarce TRAP staining was 
observed in multinucleated cells, with no 
more than 3-4 nuclei (b). Treatment with 
CM by 10 (c) and 100 µM (d) did not 
induce significant differences in the 
number or intensity of TRAP-positive 
cells after 5 days. The expression of 
CTSK in osteoclasts was significantly 
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SECTION 3:  MAGNESIUM 
3.1. IN VIVO STUDY OF THE EFFECTS OF DIETARY MAGNESIUM 
SUPLEMENTATION ON BONE 
 
Despite the beneficial effects of Mg supplementation in renal disease had been 
reported in the last decades, there exist controversy about the actions of Mg on bone 
cells in vitro and in vivo. In this part of the results, the effects of dietary Mg 
supplementation on bone of uremic rats were examined. 
 
3.1.1. Plasma biochemistry 
5/6Nx rats were fed on diets with increased Mg content (0.1%, 0.3% and 0.6%) for 
14 days. At the moment of sacrifice all animals with 5/6Nx showed a lower body 
weight than sham rats without significant differences among them. Plasma 
biochemistry is shown in Table 14. The reduction of the renal mass in the 5/6Nx 
groups produced an increase in plasma creatinine levels as compared with the Sham 
group. Both Mg-supplemented diets prevented the increase in plasma creatinine 
levels, suggesting a protective renal effect of dietary Mg. The levels of plasma Mg 
increased in 5/6Nx rats as compared with Sham rats and significantly increased 
according to the Mg content in the diet although it was statistically significant alone 
with 0.6% Mg diet. Plasma P was increased in 5/6Nx rats fed on 0.1% Mg diet as 
compared with Sham animals. In comparison with these 5/6Nx rats, both 0.3% and 
0.6% Mg diets, decreased plasma P levels. In addition, iCa concentration was 
decreased in 5/6Nx rats as compared with Sham rats and 0.3% Mg showed similar 
iCa levels to those observed in Sham rats. Plasma PTH concentration was increased 
in the 5/6Nx+0.1% Mg group as compared with the Sham group. Rats on dietary Mg 
supplementation showed lower plasma PTH levels than 5/6Nx + 0.1% Mg, which 
were statistically significant with a 0.6% Mg diet. CTR concentration was reduced in 
all 5/6Nx groups as compared with Sham animals without significant changes among 
them and Mg diets. Plasma intact FGF23 increased in 5/6Nx+0.1% Mg as compared 
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Urinary parameters are shown in Table 15. Consistent with plasma biochemistry, 
creatinine clearance decreased in 5/6Nx groups as compared with Sham, and the 
reduction was lower in the 5/6Nx + 0.6% Mg. Urinary calcium was similar among all 
5/6Nx groups, however there was a significant increase respect to Sham animals 
group (p<0.05 vs Sham). According to plasma FGF23 and PTH levels, urinary P 
excretion, assessed by P/creatinine ratio and FEPi, increased in 5/6Nx + 0.1% Mg 
as compared with Sham animals. Dietary Mg supplementation (0.6% Mg) decreased 
the urinary P/Creat ratio. On the other hand, Mg content in the urine decreased in 
the 5/6Nx+0.1% Mg group as compared with Sham. In the 5/6Nx groups receiving 









Body Weight (g) 306±34 235±40 a 242±20 a 236±31 a 
Creat (mg/dl) 0.41±0.06 1.71±0.2 a 1.11±0.12 a,b 1.10±0.16 a,b 
Mg (mg(dl) 2.14±0.09 2.97±0.3 a 2.98±0.2 a,b 3.31±0.4 a,b 
P (mg/dl) 6.5±0.3 10.7±1.4 a 8.0±0.8 a,b 7.9±0.9 a,b 
iCa (mM) 1.20±0.01 1.07±0.03 a 1.19±0.02 b 1.13±0.03 a,b 
PTH (pg/ml) 21±7 529±171 a 401±170 a 79±46 a,b 
1,25(OH)2D3 (pg/ml) 318±29 110±23 a 120±25 a 89±25 a 
FGF23 (pg/ml) 218±147 100311± 158105 a 783±814 a,b 16253± 9121 a,b 
 
Table 14. Plasma biochemical analysis. Sham fed a 0.6% P, 0.6% Ca, 0.1% Mg diet. 5/6Nx groups 
fed a 1.2% P, 0.6% Ca and the indicated Mg percentage. Values show mean±SEM. ANOVA with 
Tukey test. a p<0.05 vs Sham; b p<0.05 vs 5/6Nx + Mg0.1%. 
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3.1.2. Bone histomorphometry  
Cancellous bone histomorphometry parameters were studied in the distal right 
femurs. We found that with respect to Sham animals, bone volume was decreased 
in 5/6Nx+0.1% Mg. Importantly, dietary Mg supplementation by 0.6% significantly 
prevented this loss of bone volume (Fig.54 a). Respect to Sham animals, osteoid 
volume and osteoid surface were also increased in 5/6Nx rats fed on basal Mg in the 
diet (0.1% Mg). Mg supplementation by 0.3% reduced both osteoid volume and 
osteoid surface. However, 5/6Nx rats fed on 0.6% Mg showed similar osteoid volume 
and osteoid surface than the 5/6Nx+0.1% Mg group (Fig.54 b and c). The high 
osteoid observed in the 5/6Nx+0.6% Mg was also associated with an increase in the 
osteoid thickness, suggesting that high Mg content in the diet might reduce bone 
mineralization (Fig.54 d). Bone turnover in 5/6Nx+0.1% Mg was higher than in Sham 
rats. The bone surface covered by osteoblasts was similar among all the 5/6Nx 
groups, (Fig.54 e). Additionally, the bone surface covered by osteoclasts was 
reduced in the 5/6Nx+0.6% Mg as compared with both, 5/6Nx+0.1% Mg and 









Creat Clearance 3.25±0.30 0.57±0.11a 0.68±0.14 a 1.16±0.21 a,b 
FEPi (%) 4.9±0.80 95.0±17.2 a 86.5±7.1 b 44.8±6.0 a,b 
P/Creat Ratio 0.68±0.06 6.12±0.83 a 6.11±0.70 a 3.47±0.44 b 
Mg/Creat Ratio 1.04±0.10 0.45±0.06 a 1.48±0.16 a,b 1.72±0.25 a,b 
Ca/Creat Ratio 0.05±0.01 0.11±0.07a 0.18±0.03a 0.15±0.04a 
Table 15. Urinary parameter analysis. a: p<0.05 vs Sham; b: p<0.05 vs 5/6Nx+Mg0.1%. Sham 
fed a 0.6% P, 0.6% Ca, 0.1% Mg diet. 5/6Nx groups fed a 1.2% P, 0.6% Ca and the indicated 




Figure 54. Dietary Mg alters bone histomorphometric parameters in 5/6Nx rats. a: p<0.05 vs 
Sham; b: p<0.05 vs Nx+0.1% Mg; c: p<0.05 vs Nx+0.3% Mg. Sham fed a 0.6% P, 0.6% Ca, 
0.1% Mg diet. 5/6Nx groups fed a 1.2% P, 0.6% Ca and the indicated Mg percentage. 
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Goldner’s trichrome representative pictures are shown in the Figure 55. 
 
 
3.2. IN VITRO STUDY OF THE EFFECTS OF MAGNESIUM ON OSTEOGENIC 
DIFFERENTIATION 
To examine the direct actions of Mg supplementation in bone cell differentiation and 
activity we used an in vitro model of osteogenesis. Thus, bone marrow MSC (from 
adherent fraction) were differentiated into osteoblasts. In addition, Mg content in the 
 
 
Figure 55. Effect of Mg suplementation on bone. Representative pictures of Goldner’s trichrome 
staining. Sham fed on a 0.6% P, 0.6% Ca and 0.1% Mg diet showed normal bone turnover (a). 
5/6Nx group fed on a 1.2% P, 0.6% Ca and 0.1% Mg showed increased number of osteoblasts 
(Ob) and osteoclasts (arrowhead), and increased osteoid and resorption surface (b). 5/6Nx rats 
on 0.3% Mg showed a decrease in osteoid volume (c) and dietary Mg by 0.6% resulted in an 
increased osteoid thickness (d). Arrowhead: Osteoclast. Ob: Osteoblasts. Magnification: 400x. 
 
173 
culture medium was increased with MgCl2 up to 1.2 or 1.8 mM. Basal Mg in the 
culture medium is 0.8 mM. 
3.2.1. Effects of moderately high concentrations of magnesium on 
osteogenesis and mineralization of rat bone marrow MSC 
 
After the addition of osteogenic stimuli for 21 days, MSC displayed osteoblast 
phenotype increasing the expression of osteogenic marker genes. Osteogenic 
medium supplementation with Mg2+ at 1.2 mM increased ALP activity by 4.2-fold 
while the addition of Mg2+ 1.8 mM elevated this activity by 6-fold vs basal Mg content 
(0.8 mM) (Fig.56 a). The increased ALP activity was consistent with higher matrix 
mineralization, assessed by Alizarin Red staining (Fig.56 b). 
 
 
Figure 56. MgCl2 supplementation increases mineralization of MSC differentiated into 
osteoblasts. Alkaline Phosphatase activity (a) was increased according to Mg 
concentration, as well as mineralization assessed by alizarin red staining (b). ANOVA with 
Tukey test. a: p<0.001 vs UC; b: p<0.001 vs OB; c: p<0.001 vs OB 1.2. UC: 
Undifferentiated control. OB: MSC under osteogenic stimuli for 21 days. 
pNPP: p-nitrophenyl phosphate. A.U.: arbitrary units. 
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In addition to an increased mineralization, MgCl2 supplementation achieved a 
significant increase in the expression of the osteogenic master genes such as  
Runx2, regulator of the early osteoblast differentiation, Osterix, transcription factor 
required for the transition of pre-osteoblasts to osteoblasts, and Osteocalcin, 
produced by mature osteoblasts (Fig.57 a, b and c respectively). These effects of 
MgCl2 on MSC osteogenesis were observed in dose-dependently. 
 
As FGF23 is released by mature osteoblasts and osteocytes, the amount of intact 
FGF23 in the supernatant could be also considered as a marker of osteoblast 
maturation. Culture medium with treatments was replaced and after 24h, 
supernatant was collected to determine FGF23 secretion during 24h after 21 days 
Figure 57. MgCl2 increases the expression of osteogenic markers. The treatment with Mg 
up-regulated the expression of Runx2 (a), Osterix (b) and Osteocalcin (c), as well as the 
concentration of intact FGF23 in the supernantant. ANOVA with Tukey test. a: p<0.001 vs 
UC; b: p<0.001 vs OB; c: p<0.001 vs OB 1.2. UC: Undifferentiated control. OB: MSC under 
osteogenic stimuli for 21 days. n.d: non-detected. 
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of osteogenic differentiation. As expected, undifferentiated cells did not secrete 
FGF23. In differentiated MSC into osteoblasts there was a light increase in the 
FGF23 secretion and after MgCl2 supplementation (1.2 and 1.8 mM) there was 
significant higher levels of FGF23 in the supernatant as compared with those 
osteoblasts cultured with basal Mg levels (Fig.57 d). 
3.2.2. Effects of the inhibition of magnesium transporters TRPM7 on 
osteogenic differentiation of MSC 
 
The inhibition of the Mg transporter TRPM7 by 2-APB produced a decrease in ALP 
activity (Fig.58 a) accompanied with a reduction of matrix calcification (Fig.58 b). 
 
 
Figure 58. Inhibition of the Mg channel TRPM7 with 2-APB decreases mineralization of MSC 
differentiated into osteoblasts. (a) Alkaline phosphatase activity. (b) Alizarin red staining. 
ANOVA with Tukey test. a: p<0.05 vs UC; b: p<0.05 vs OB 0.8 mM Mg. pNPP: p-nitrophenyl 
phosphate. A.U.: arbitrary units. 
176 
Moreover, as compared with those osteoblasts cultured with basal Mg2+ levels (0.8 
mM) TRPM7 inhibition by 2-APB administration diminished significantly the 
expression of the osteogenic marker genes Runx2, Osterix and Osteocalcin (Fig.59 
a, b and c, respectively). Similarly, 2-APB treatment reduced also FGF23 secretion 
(Fig.59 d). 
 
3.2.3. Mg supplementation increases proliferation of MSC during osteogenesis 
 
To investigate whether Mg supplementation increases cellular proliferation during 
MSC differentiation into osteoblasts, Cyclin D1 and PCNA protein levels were 
analyzed by Western blot after 21 days of treatment. The expression of both proteins 
Figure 59. TRPM7 inhibition by 2-APB administration decreased osteogenesis of MSC. 
ANOVA with Tukey test. a: p<0.05 vs UC; b: p<0.05 vs OB 0.8. 2-APB: 2-Aminoethoxydiphenyl 
borate. 
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was increased in osteoblasts as compared with undifferentiated cells (UC). In these 
conditions, MgCl2 supplementation (1.2 and 1.8 mM) enhanced dose-dependently 
the expression of these proliferation markers. It was interesting to note that 2-APB 
treatment (50µM), reduced significantly Cyclin D1 and PCNA protein expression, 
suggesting that Mg exerts its pro-proliferative effects intracellularly through this 
channel (Fig.60 a and b respectively). 
 
3.2.4. Effects of magnesium supplementation on Notch1 signaling in MSC 
 
To investigate the mechanism whereby MgCl2 supplementation increases the 
osteogenic differentiation of MSC, the potential role of two pro-osteogenic pathways, 
Wnt/β-catenin and Notch, was examined by confocal microcopy. 
Immunofluorescence analyses showed that osteogenic differentiation promoted the 
nuclear translocation of β-catenin, however as compared with basal Mg2+ treated 
cells (OB), the addition of MgCl2 to osteogenic medium did not further promote 
nuclear localization of β-catenin (Fig.61). 
Figure 60. MgCl2 supplementation promotes proliferation of MSC during osteogenesis. 
Treatment with Mg dose-dependently increased the amount of Cyclin D1 (a) and Proliferating 
Cell Nuclear Antigen (PCNA) (b) after 21 days of osteogenesis. At contrary, inhibition of the 
Mg channel TRPM7 decreased both Cyclin D1 and PCNA.  
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These results were also confirmed by western blot analysis of nuclear-enriched 
protein extracts (Fig.62) confirming that MgCl2 supplementation did not activate the 
canonical Wnt/β-catenin pathway. 
 
Figure 61. β-catenin nuclear translocation was not affected by MgCl2 supplementation. In 
undifferentiated MSC, β-catenin was found in the plasma membrane; and osteogenic medium 
increased the presence of β-catenin in the nuclei, however no significant differences were found 
with Mg treatments. OB: Osteogenic medium 21 days. DAPI: 4',6-diamidino-2-fenilindol.  
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With respect to Notch signaling, confocal microscopy analysis of Notch1 intracellular 
domain (NICD), using an antibody that only recognized the truncated (activated) 
NICD, showed that osteogenic differentiation of MSC with basal levels of Mg 
decreased the nuclear translocation of NICD as compared with undifferentiated 
MSC. However, MgCl2 supplementation promoted dose-dependently nuclear 
colocalization of NICD. At contrary, treatment with 2-APB reduced this nuclear 
translocation of the NICD that was clearly reduced (Fig.63 a). To check this co-
localization, green pixels (NICD) matching with blue pixels (DAPI) were analyzed 
using the Image J software (colocalization finder plugin). As shown in the fourth 
column (Fig.63 a, far right column), MgCl2 supplementation increased the green and 
blue pixels overlap, while 2-APB decreased it. 
 
Figure 62. Western blot of nuclear-enriched protein extracts for β-catenin. Osteogenic 
stimuli induced an increase in the amount of β-catenin in the nuclear-enriched extracts. 
Magnesium supplementation did not further increase the amount of nuclear β-catenin. TFIIB 
was used as housekeeping protein. 
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Additionally, these results were also confirmed by western blot of NICD in a nuclear-
enriched protein extracts (Fig.64). 
 
Figure 63. MgCl2 induces NICD nuclear translocation. Confocal microscopy analysis showed 
intense NICD-green nuclear staining in undifferentiated MSC. Mg addition increased the nuclear 
NICD translocation dose-dependently respect to differentiated osteoblast with basal Mg (OB 0.8 
mM). This presence was reduced in osteoblasts treated with 2-APB. UC: Undifferentiated 















The expression of HEY2, a well-known Notch target gene, was also quantified to 
further demonstrate the involvement of this pathway. Consistent with nuclear NICD 
analysis, the expression of HEY2 was decreased after osteogenic differentiation as 
compared with undifferentiated MSC, and the increase of Mg content in the 
osteogenic medium upregulated the mRNA expression of HEY2. Inhibition of the Mg 
transporter TRPM7 with 2-APB decreased HEY2 expression (Fig.65). 
 
 
Figure 64. NICD nuclear expression. Western blot analysis showed a decrease in NICD 
nuclear expression in the OB group respect to undifferentiated cells (UC) after 21 days of 
osteogenic differentiation. The addition of MgCl2 during osteogenesis increased dose-
dependently the amount of nuclear NICD. Treatment with 2-APB during osteogenesis 




Mg (mM)      0.8        0.8          1.2        1.8      0.8
UC        OB          OB OB OB
2-APB (µM)        - - - - 50
 
Figure 65. HEY2 mRNA expression was upregulated according to Mg concentration 
during osteogenesis. t-test. a: p<0.05 vs UC 0.8; b: p<0.05 vs OB 0.8; c: p<0.05 vs OB 
1.2; d: p<0.05 vs OB 1.8. 
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To gain in-depth knowledge with the relationship between Mg, osteogenesis and 
proliferation, we studied whether MgCl2 supplementation develops its actions 
preferably in MSC, osteoblasts-committed cells or both. Therefore, the effects of 
MgCl2 supplementation were evaluated after 24h on MSC or MSC plus osteogenic 
stimulus at early stage of osteogenic differentiation. Western blotting analysis 
showed that, in undifferentiated cells, the addition of MgCl2 for 24 h increased the 
nuclear protein expression of NICD (Fig.66 a). However, when MgCl2 was 
administered for 24 hours to MSC in presence of the osteogenic stimulus the levels 
of nuclear NICD remained similar to those found with basal Mg2+ content (Fig.66 b). 
Similarly, in differentiated osteoblasts for 21 days, the administration of MgCl2 or 2-
APB for 24h did not modify the nuclear NICD protein expression (Fig.66 c). Of note, 
high nuclear NICD protein amount was detected in undifferentiated MSC after 21 
days, while in differentiated osteoblasts the nuclear NICD was dramatically reduced.  
  
 
Figure 66. NICD nuclear protein 
amount assessed by western blot after 
24h of treatment with Mg or 2-APB in 
undifferentiated MSC with Mg 
supplementation or 2-APB treatment 
(a); at the time of osteogenic stimuli, 
early stage of differentiation (b); and at 
day 21 of differentiation, late stage of 
differentiation (c). UC: Undifferentiated 
control. OB: osteogenic medium. 
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3.3. IN VITRO STUDY OF THE MAGNESIUM EFFECTS ON OSTEOGENESIS IN 
DECELLULARIZED BONE SCAFFOLDS 
 
The role of magnesium on the osteogenesis of MSC cultured over decellularized 
bone scaffolds was also investigated. 
 
3.3.1. Scanning Electron Microscopy (SEM) 
 
To assess whether MgCl2 supplementation enhances the ability of MSC to 
repopulate rat bone scaffolds, decellularized rat long bones were cut into 5-10 mm 
pieces (Fig.67 a) and then placed in osteogenic medium with MSC and different Mg 
content during 21 days. In these decellularized bone scaffolds, SEM images showed 
osseous matrix as series of uniform and regular depressions corresponding to duct 
osteons (Fig.67 a). With basal Mg, bone scaffolds were covered by MSC 
differentiated into osteoblasts after 21 days. Abundant cells showed an irregular 
membrane with an unspecific distribution and presenting a stellate morphology 
(Fig.67 b). After Mg supplementation (1.2 mM), MSC formed an uniformly organized 
layer over the bone surface, of smooth aspect and with abundant cellular 
proliferation filling the osteon canals (Fig.67 c). In scaffolds treated with 1.8 mM Mg, 
bone surface was fully occupied by cells showing a continuous and regular layer of 
germinal bone tissue (Fig.67 d). 
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3.3.2. Transmission Electron Microscopy (TEM) 
 
Additionally, cellular layers from decellularized bone scaffolds were analyzed with 
TEM after 21 days of differentiation to accurately determine the osteogenic 
phenotype. During the osteoinduction of MSC with basal Mg levels, cells produced 
immature matrix, as it can be observed in the poorly organization of the collagen 
 
Figure 67. MgCl2 promotes MSC proliferation and cell atachment to bone scaffolds. 
Representative SEM microphotographs of decellularized rat bone (a) and MSC cultured 
into osteogenic medium with MgCl2 at 0.8 mM (b), 1.2 mM (c) and 1.8 mM (d). Note the 
surface of the bone scaffold covered by the well-organized cells with the higher Mg 
concentration. Bars are 800µm. 
a. b.
c. d.
Decellularized scaffold OB+Mg 0.8 mM
OB+Mg 1.2 mM OB+Mg 1.8 mM
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fibers (Fig.68 a). Mg supplementation up to reach 1.2 mM Mg increased the size of 
the cells, which showed abundant cytoplasm, resembling a phenotype similar to 
osteoblasts. In addition, cells showed well-structured layers, similar to the 
appositional growth found in bone, and osteoblasts were observed embedded into 
the bone matrix, which are considered osteocytes. These osteocytes showed 
membrane elongations similar to osteocytes and a more organized collagen matrix 
(Fig.68 b). With Mg 1.8 mM, the number of cells further increased, with presence of 
several osteocytes that showed longer membrane elongations and tunnels similar to 
bone canaliculi. Furthermore, it was observed well-organized collagen fibers similar 




Figure 68. MgCl2 enhances osteoblast differentiation. Representative TEM microphotographs 
of MSC differentiated into osteoblasts with Mg at 0.8 mM (a), 1.2 mM (b) and 1.8 mM (c). 
Note the dendrites of the osteocytes with Mg supplementation (Arrows). Asterisks indicate 
collagen fibers. 
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3.4. MAGNESIUM EFFECTS ON OSTEOCLASTOGENESIS IN VITRO 
 
Additionally, the effects of MgCl2 supplementation by 1.4 and 2.6 mM were examined 
on osteoclastogenesis in vitro. TRAP-positive multinucleated cells were observed 
with basal Mg concentration (0.8 mM) after 5 days of osteoclastogenic stimuli (OC) 
as compared with undifferentiated hematopoietic cells (UC) that were unstained 
(Fig.69 a-d). The addition of Mg to osteoclastogenic medium did not modify TRAP 
staining. Similarly, the expression of CTSK increased respect to undifferentiated 
cells after 5 days of osteoclastogenic stimuli, however increased Mg concentrations 
did not modify CTSK expression levels (Fig.69 e). 
  
                
 
Figure 69. Effects of MgCl2 supplementation 
on osteoclastogenesis. TRAP staining of 
undifferentiated hematopoietic cells (a) and 
hematopoietic cells with osteoclastogenic 
medium and Mg at 0.8 mM (b), 1.4 mM (c) and 
2.6 mM (d) during 5 days. CTSK gene 
expression is shown in (e). ANOVA with Tukey 
test. a: p<0.05 vs undifferentiated control. UC: 
undifferentiated control. OC: Osteoclasgenic 
medium. Arrows indicate osteoclasts. 
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SECTION 4: FGF23 
4.1 IN VIVO STUDY OF THE EFFECTS OF HIGH FGF23 IN BONE IN A RAT 
MODEL OF EARLY CKD 
We developed in our laboratory an animal model with increased plasma FGF23 
levels and without alterations of other mineral metabolism or renal parameters such 
as PTH, P, CTR or creatinine. We took advantage of the early increase of plasma 
FGF23 to separate it from other parameters that became significantly higher with 
more severe loss of renal function and end stage of renal disease. In this regard, we 
used heminephrectomized rats (right kidney, 1/2Nx) fed on a high P diet (1.2%) for 
three weeks. Sham animals without 1/2Nx fed on the same high P diet were used as 
control group. With these setting the effects of FGF23 in bone were studied in vivo. 
4.1.1. Plasma biochemical parameters 
Plasma biochemistry of Sham+1.2%P and 1/2Nx+1.2%P groups are shown in Table 
15. It is interesting to note that although plasma creatinine levels were different 
between Sham+1.2%P and 1/2Nx+1.2%P groups (0.52±0.01 vs. 0.66±0.02, 
***p<0.001), these ones were within the normal range of creatinine values. Plasma 
intact FGF23 levels were higher in 1/2Nx+1.2%P as compared with the 
Sham+1.2%P group (272±25 vs. 454±49.8, **p<0.01). Plasma P, iCa, 1,25(OH)2D3 
and PTH concentrations remained similar between both groups. Plasma ALP, a 
marker of osteoblast activity, also showed a non-significant increase in the 
1/2Nx+1.2%P group. A non-significant increase was observed in phosphaturia in 
1/2Nx+1.2%P rats as compared with Sham+1.2%P, consistent with the increased 
levels of plasma intact FGF23. Circulating sclerostin levels, a well-known inhibitor of 
the canonical Wnt pathway, was increased in 1/2Nx+1.2%P rats. 
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4.1.2. Bone histomorphometry parameters in early CKD rats 
After 21 days, trabecular bone of the right distal femurs were collected and prepared 
to analyze bone histomorphometry. A tendency to decrease bone volume was 
observed in the 1/2Nx+1.2%P group (Fig.70 a). Osteoid volume (Fig.70 b) and 
osteoid surface (Fig.70 c) were significantly higher in the 1/2Nx+1.2%P group as 
compared with Sham+1.2%P. Bone surface covered by osteoblasts was also higher 
in the 1/2Nx+1.2%P group than in Sham+1.2%P animals (Fig.70 d). The eroded 
bone surface was significantly higher in the 1/2Nx+1.2%P group as compared with 
Sham+1.2%P animals (Fig.70 e), however the bone surface covered by osteoclasts 






Creatinine (mg/dl) 0.52±0.01 0.66±0.02*** 
P (mg/dl) 6.63±0.36 6.77±0.40 
iCa (mM) 1.28±0.01 1.25±0.02 
PTH (pg/ml) 72.1±7.7 65.9±10.5 




ALP (U/l) 80.4±10.1 114±20.1 
Sclerostin (pg/ml) 127±8.16 198±12.1** 
FEPi (%) 31.9±7.49 50.2±7.03 
 




Figure 70. Hemi-nephrectomy produces an increase in bone cells activity. The bone volume 
showed a tendency to decrease in the 1/2Nx+1.2%P group (a). Increased bone remodeling was 
observed in 1/2Nx+1.2%P rats after 3 weeks, as assessed by the increased osteoid volume and 
surface (b and c respectively) and increased resorption surface (e); consistent with a higher 
bone surface covered by osteoblasts (d) and osteoclasts (f). T-test. * p<0.05; ** p<0.01; *** 
p<0.001 vs sham+1.2%P. 
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Representative microphotographs are shown in Figure 71. 
 
Importantly, despite of the decrease in bone volume was not statistically different, 
structural parameters showed significant changes in trabecular bone. In this respect, 
trabecular thickness and trabecular separation (Fig.72 a and b respectively) were 
higher in 1/2Nx+1.2% P rats as compared with Sham+1.2% P. Additionally, the 
trabecular number was reduced in the 1/2Nx+1.2% P group (Fig.72 c). No 
differences were observed in osteoid thickness (Fig.72 d) Altogether indicate an 
association between high levels of FGF23 and changes in bone microstructure. 
Representative pictures of Goldner’s staining are shown in Fig.72 e and f. 
 
Figure 71. Hemi-nephrectomy increases osteoclast and osteoblast activity. 1/2Nx+1.2% 
P rats showed higher bone surface covered by osteoblasts and higher osteoclast activity 
(b) as compared with Sham+1.2% P (a) Ob: Osteoblasts. Arrowhead: Osteoclast. 




Figure 72. Early increase in plasma FGF23 induces changes in trabecular bone. Goldner’s 
staining showed changes in bone microstructure in 1/2Nx+1.2% P rats (f) as compared with 
Sham+1.2% P (e). Bars are mean±SEM. t-test analysis * p<0.05; ** p<0.01; *** p<0.001. 
Augmentation: 40x. Scale bar: 500 µm. 
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4.1.3. Osteogenic gene expression in the bone of 1/2Nx rats 
To evaluate osteoblast maturation, total mRNA was isolated from the proximal tibias 
and the expression of osteogenic marker genes was analyzed. Runx2, Osterix and 
DMP1 mRNA expressions were down-regulated in the bone of 1/2Nx+1.2%P rats as 
compared with Sham (Fig. 73 a, b and c). Of note, SOST mRNA expression in the 
bones of the 1/2Nx+1.2%P rats was higher than in the Sham+1.2%P group (Fig.73 




Figure 73. Gene expression of osteogenic genes was down-regulated in bone lysates of 
1/2Nx+1.2%P rats except to sclerostin expression that was increased. T-test. *p<0.05 vs 
Sham+1.2%P **p<0.01 vs Sham+1.2%P; ***p<0.001 vs Sham+1.2%P. 
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4.2. IN VITRO STUDY OF THE EFFECTS OF FGF23 ON OSTEOGENESIS 
 
The direct actions of FGF23 were studied in osteoblastic differentiation. To prevent 
FGF23 degradation, we used a rat recombinant FGF23 with arginine 176 replaced 
by glutamine (R176Q). Rat recombinant intact FGF23 (R176Q) (from here 
abbreviated rFGF23) was added at a high concentration similar to that found in the 
plasma of experimental rat models with renal insufficiency. 
 
4.2.1. Evaluation of MSC differentiation into osteoblasts 
To confirm in vitro, the effects of FGF23 in bone cells we investigated whether the 
treatment with rFGF23 exerts direct effects on the osteogenesis of bone marrow 
MSC. First, we examined the differentiation of the MSC after 21 days of osteogenic 
stimulus. Mineralization assessed by alizarin red staining showed an intense red 
color in MSC differentiated into osteoblasts (OB) respect to undifferentiated MSC 
(UC) that were not stained (Fig.74 a). Osteogenic stimulus promoted also the cell 
recruitment and formation of calcification nodules observed in the bright-field 
microphotographs (Fig.74 b and c). 
 
 
Figure 74. Mineralization of MSC differentiated into osteoblasts. Osteogenic stimuli increased 
mineralization assessed by alizarin red staining (a). Representative microphotograph of 
undifferentiated MSC (b) and MSC differentiated into osteoblasts (c). ALP activity was 
increased in MSC differentiated into osteoblasts (d). Arrow: calcification nodule. UC: 
undifferentiated control. OB: Ostegenic medium 21 days. Magnification: 100x. 
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Additionally, to evaluate the degree of osteoblastic differentiation, the expression of 
well-known osteogenic marker genes was analyzed. The gene expression of Runx2 
(Fig.75 a), Osterix (Fig.75 b) and Osteocalcin (Fig.75 c) were increased, indicating 
osteogenic differentiation. Of note, MSC differentiated into osteoblasts after 21 days 
also increased the expression of the DMP1, an osteocyte marker gene (Fig.75 d). 
 
4.2.2. In vitro effects of high levels of FGF23 during MSC osteogenesis 
No significant differences were found in matrix mineralization (Fig.76 a) or calcium 
content (Fig.76 b) after the addition of rFGF23 at 15ng/ml to the MSC with 
osteogenic stimulus. However, rFGF23 addition throughout osteogenic 
differentiation decreased the ALP activity (Fig.76 c) and reduced the expression of 
 
Figure 75. Osteogenic stimuli during 21 days up-regulated the expression of mature 
osteoblast and osteocytes marker genes. Bars are mean±SEM. t-test ***p<0.001 vs UC. 
UC=Undifferentiated cells; OB= Osteoblast cells. 
196 





Figure 76. Rat recombinant FGF23 addition throughout osteogenic differentiation (21 days) 
decreases osteogenesis but not mineralization. Alizarin red staining showed similar 
mineralization in rFGF23-treated OB cells as compared with control OB (a). Quantification of 
eluted calcium from the mineralized matrix showed a tendency to decrease calcium content 
with rFGF23 treatment (b), consistent with a decrease in alkaline phosphatase activity (c). In 
addition, rFGF23 added throughout osteogenic differentiation down-regulated the expression 




4.2.3. Effect of high FGF23 in osteocyte-like MSC 
Furthermore, we considered of interest to evaluate the effects of high intact FGF23 
in mature osteoblasts and osteocytes derived from MSC. Therefore, MSC were 
cultured with osteogenic medium during 20 days to generate mature osteoblasts 
similar to osteocytes. Once maturated, rFGF23 was added at 15 ng/ml for 24h to 
evaluate an acute effect. After 24 h, rFGF23 addition to generated osteocytes 
significantly decreased the expression of gene expression of Osterix (Fig.77 a), 
Osteocalcin (Fig.77 b), DMP1 (Fig.77 c) and RANKL (Fig.77 d) while OPG remained 
similar (Fig.77 e). In this respect the ratio RANKL/OPG was decreased by rFGF23 
in mature osteoblasts and osteocytes (Fig.77 f). 
 
 
Figure 77. Effects of high rFGF23 addition in differentiated osteocytes after 24h of treatment. T-
test. Treatment with high rFGF23 decreased the expression of the osteogenic genes Osterix 
(a), Osterix (b) and Osteocalcin (c) in MSC differentiated into osteocytes after 24 hours. In 
addition, high dose of rFGF23 decreased RANKL expression (d), whereas did not affect OPG 
expression (e), decreasing the ratio RANKL/OPG. *p<0.05 vs OB; ***p<0.001 vs OB. 
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4.2.4. Effects of high  FGF23 on β-catenin nuclear translocation 
Consistent with the down-regulation of the osteogenic marker genes, rFGF23 
addition to mature osteoblasts inhibited nuclear translocation of β-catenin pathway 




Figure 78. High FGF23 decreases nuclear 
translocation of β-catenin. As shown in (a), 
there was a nuclear presence of β-catenin 
in osteocyte-like MSC. rFGF23 treatment 
for 24 hours considerably reduced the 
presence of β-catenin in the nuclei of the 
osteocyte-like MSC cells. The intensity of 
the green pixels into the nuclear area (blue 
pixels) confirmed these findings (b). 
Arrowheads: nuclear β-catenin. T-test. 
**p<0.01 vs OB cells. 
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4.3. EFFECTS OF FGF23 ON OSTEOCLASTOGENESIS IN VITRO 
The effects of a high dose of intact FGF23 were also analyzed in an in vitro model 
of osteoclastic differentiation from rat bone marrow hematopoietic stem cells 
4.3.1. Effects of high FGF23 on osteoclast differentiation 
To evaluate the effects of FGF23 on osteoclasts differentiation, rat recombinant 
intact FGF23 (R176Q) was added throughout differentiation at 0.1 and 10ng/ml. 
rFGF23 addition increased the number of TRAP-positive multinucleated cells (Fig.79 
a, b and c) and CTSK expression (Fig.79 d). 
 
 
Figure 79. rFGF23 addition increases osteoclastogenesis of hematopoietic cells. Bright field 
representative microphotographs of positive-TRAP multinucleated cells obtained after 5 days 
of osteoclastic stimuli (b). High rFGF23 produced larger positive-TRAP multinucleated cells 
(c). rFGF23 treatment also increased CTSK expression osteoclast-like hematopoietic cells 
(d). ANOVA with Tukey test. a: p<0.001 vs undifferentiated cells; b: p<0.001 vs Osteoclasts; 
c: p<0.01 vs Osteoclasts+rFGF23 0.1 ng/ml. UC: undifferentiated control. OC: Osteoclasts. 
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Moreover, rFGF23 increased the number of the osteoclast-like cells respect to OC 
cells (Fig.80 a, b p<0.001). High rFGF23 supplementation significantly reduced the 
number of nuclei per osteoclast (Fig.80 b). Of note, the treatment with high rFGF23 
increased the size of the osteoclast-like cells as assessed by the significantly higher 




Figure 80. High rFGF23 modified osteoclastogenesis of hematopoietic cells. rFGF23 added 
throughout osteoclastogenesis produced an increase in the number of the differentiated 
osteoclasts (a) and reduced the number of nuclei per osteoclast (b). Osteoclast size was also 
significantly greater in the osteoclasts treated with high rFGF23 (c and d). ANOVA with Tukey 
test. a: p<0.001 vs undifferentiated cells; b: p<0.001 vs Osteoclasts; c: p<0.01 vs 
















In this thesis we investigated the potential role of calcitriol, calcimimetic, magnesium 
and FGF23 in renal osteodystrophy. Firstly, each element will be discussed 
separately in an uremic context and subsequently all these parameters altered 
during CKD will be related. 
With respect to calcitriol, we investigated its bone effects independently of the 
actions on PTH secretion. We performed an animal model of renal insufficiency 
(5/6Nx rats) that underwent total parathyroidectomy and constant infusion of PTHx6 
(1-34 length). The recommended dose of calcitriol to treat SHPT varies between 0.5-
3 µg every 3 days186 (equivalent to 7.7-46.2 ng/kg per dose considering a total body 
weight of 65 kg), therefore our in vivo experiment with 20, 40 and 60 ng/kg weight 
ranged between medium to high dose of calcitriol. 
In these animals, the administration of calcitriol dose-dependently increased plasma 
Ca and P, according to the expected effects of calcitriol. It is important to note that 
in our model of 5/6Nx rats with clamped PTH, hypercalcemia could not affect PTH 
levels, which remained constant in these groups. In the group of rats treated with the 
highest dose of calcitriol an increase in plasma creatinine was observed. This fact 
could be explained by the exacerbation of the renal injury due to the 
hyperphosphatemia and hypercalcemia187. Plasma intact FGF23 levels increased 
according to the dose of calcitriol administered despite of the fact that PTH levels 
were clamped. The stimulation of FGF23 production and secretion by calcitriol have 
been widely described previously. In normal mice, administration of calcitriol 
significantly increased plasma FGF23 as early as 4 hours and this increase was 
associated with a higher FGF23 mRNA expression in bone. Furthermore calcitriol 
also increased FGF23 production in UMR cells dose and time dependently, and the 
treatment with actinomyzin D, an inhibitor of the RNA synthesis, prevented this 
effects indicating that calcitriol may trigger its actions at transcriptional level188.  Of 
note, Nguyen-Yamamoto et al have reported that the local production of calcitriol by 
bone cells, which express 1-α hydroxylase, also increase FGF23189. 
With respect to bone histology, in the 5/6Nx-PTx-PTH group treated with CTR 60 
ng/kg, a fall in the trabecular bone volume was observed, although osteoblast activity 
was not reduced. This fact might be explained by the high concentration of calcium 
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in plasma. In this way, the activation of the CaSR in osteoblasts by this extracellular 
calcium might lead to increased bone cell activity (discussed below). Additionally, 
plasma sclerostin levels increased significantly in the 5/6Nx-PTx-PTH treated with 
CTR 60 ng/kg as compared with the other 5/6Nx-PTx-PTH groups. Sclerostin is a 
well-known inhibitor of the Wnt/β-catenin pathway and bone formation contributing 
to the reduction of bone volume. The higher osteoblast activity was not accompanied 
by increased bone volume in the 5/6Nx-PTx-PTH treated with CTR 60 ng/kg, this 
fact may be due to the coexistence of bone anabolic and catabolic factors and 
additional studies are needed in order to clarify this controversial scenario. 
It has been reported that bone sclerostin synthesis is mediated by PTH signaling in 
vivo and in vitro190, however in our study we found that plasma sclerostin increased 
with clamped PTH, suggesting a sclerostin regulation independent of PTH changes. 
It is interesting to note that, despite its anti-anabolic actions in bone, sclerostin is 
involved in vitamin D metabolism since SOST-KO mice showed an increase of 
calcitriol and decreased levels of FGF23 while calcium and PTH remained similar to 
control191. Of note, plasma FGF23 concentration in this group was extremely high. 
In this respect, the negative effects of FGF23 on bone mineralization have been 
previously described192 and they will be discussed below. 
Respect to bone histomorphometry analysis, we observed that calcitriol 
administration by 20 and 40 ng/kg decreased the amount of osteoid, consistent with 
a tendency to decrease the mineralization lag time. We consider that these effects 
should be mainly influenced by the normalization in plasma phosphate and calcium 
levels. Previous studies have reported that knockout animal models for 1-α-
hydroxylase or VDR recovered mineralization abnormalities when they were fed on 
a rescue diet193–195. 
However, the administration of the highest dose of calcitriol induced an increase in 
the osteoid thickness consistent with a tendency to increase the mineralization lag 
time. Contrary to some previous authors that reported a pro-osteoclastogenic 
effect196, in our in vivo study (Nx5/6 and clamped PTH), calcitriol administration did 
not affect the bone surface covered by osteoclasts or the eroded surface suggesting 
an uncoupling of bone turnover.  
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The negative effects of excessive calcitriol on bone mineralization has been 
previously reported. Thus, knockout mice lacking the 24-hydroxylase shown 
increased levels of calcitriol, hypercalcemia and defective mineralization. Similarly, 
offspring from the crossing between 24-hydroxylase-KO and VDR-KO mice showed 
improved mineralization and changes in mineral parameters197. In 2012, Lieben et al 
reported that specific ablation of VDR in the gut conducted by the promoter of the 
villin gene produces an increase in plasma calcitriol with the subsequent 
maintenance of plasma calcium and phosphate levels, although these gut specific 
VDR-/- mice showed defective mineralization. In normal mice, administration of a high 
dose of calcitriol (0.5 µg/kg/day) produced the accumulation of osteoid and increased 
secretion of osteopontin, a mineralization inhibitor, and ANK, other well-known 
calcification inhibitor involved in pyrophosphate transport. Of note, specific ablation 
of VDR in osteocytes, conducted by the promotor of DMP1, prevented the defective 
mineralization triggered by the treatment with high calcitriol198. These studies support 
our results that suggest an inhibitory effect of calcitriol on bone mineralization. 
Moreover, we observed in vitro a hormetic dose-response of calcitriol on osteogenic 
differentiation. At the lowest doses of calcitriol we observed that calcitriol stimulated 
differentiation and mineralization, while at the highest concentrations calcitriol 
administration arrested osteoblastic differentiation and mineralization. The doses we 
used for the in vitro experiments varies between 10-8 to 10-12 M, while in vivo the 
dose we administered may induce a change in plasma calcitriol from 0.8x10-9 to 
2.4x10-9 M (considering a total blood volume of 15 ml per rat and a mean of 250 grs 
of total body weight). In this way, the doses assayed in vitro comprised a more 
extensive spectrum than those used in vivo. 
Calcitriol administration at 10-12 M increased the osteogenic gene expressions and 
did not affect matrix calcification, while concentrations at 10-10 M or higher blocked 
the osteogenic differentiation and mineralization of MSC. These effects are mediated 
at least partially by the inhibition of the Wnt/β-catenin pathway. In this respect, it has 
been reported that the inhibition of the Wnt/β-catenin pathway in osteocytes occurs 
in a murine model of progressive renal disease and also in CKD patients and was 
associated with increased expression of sclerostin and decreased bone volume57. 
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We also observed that supraphysiological doses of CTR increased the plasma levels 
of sclerostin in uremic rats with clamped PTH, which may lead to decreased bone 
volume. Furthermore, in vitro high CTR levels inhibited Wnt/β-catenin pathway and 
osteogenic gene expression. Altogether suggests a direct inhibitory effect of high 
calcitriol on osteogenesis. 
Of note, we also found that increased calcitriol down-regulated the expression of the 
VDR in MSC differentiated into osteoblasts. This fact may be due to a negative 
feedback produced by the chronic exposure to excessive calcitriol concentration to 
reduce the cellular sensitivity, as it occurs with the insulin receptor199. 
We also found that calcitriol administration increased the number of osteoclasts and 
the expression of CTSK. In this respect, the pro-osteoclastogenic effects of calcitriol 
in vitro have been already largely studied200–202. It has been reported that the effects 
of calcitriol on osteoclastogenesis are widely influenced by extracellular calcium, 
thus hypocalcemia is associated with an increase in the osteoclastic function in order 
to normalize plasma calcium levels198,203. However, in our animal model we did not 
observe differences in the bone surface covered by osteoclasts or the eroded 
surface, suggesting that others molecules must be involved in the regulation of 
osteoclast activity in vivo. 
In CKD patients, calcitriol is used to restore the calcitriol deficit, increase plasma 
calcium levels and treat SHPT. Healy MD et al, studied the bone effects of calcitriol 
treatment during six months in three patients with renal disease. They performed an 
iliac crest biopsy at the beginning of the study that revealed increased bone 
resorption and osteoid thickness. After treatment, osteoid accumulation and eroded 
surface were reduced, consistent with a reduction in plasma PTH levels204. Then, it 
was demonstrated that intermittent treatment with calcitriol for 12 months reduced 
bone turnover and reversed osteitis fibrosa in young patients undergoing 
hemodialysis and these results were largely attributed to the reduction in plasma of 
PTH concentration. Low PTH levels developed adynamic bone disease, however 
some patients with high PTH levels shown decreased bone formation, indicating that 
calcitriol may decrease osteoblast activity205. Additionally, a case report by Pahl M. 
et al showed that calcitriol treatment may decrease bone turnover in a patient 
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undergoing hemodialysis without affecting PTH levels206. Furthermore, this 
interpretation was also suggested by Ureña P. et al that reported a decrease in 
plasma bone specific alkaline phosphatase after treatment with calcitriol that was not 
accompanied by a decrease in plasma PTH in a hemodialysis patients. However, 
the suppressive effects of calcitriol on bone turnover were not observed in other 
hemodialysis patients, highlighting the complexity of the renal osteodystrophy207. 
Our results agree with those previous clinical studies that reported a direct 
suppressive effect of calcitriol on osteoblast activity. The principal findings in the 
study of the effects of CTR on bone are summarized in Figure 81. 
 
As abovementioned, calcitriol administration increases plasma calcium, and the 
effects of calcium through the CaSR might also influence bone turnover. Another 
 
Figure 81. Summary figure of the 
bone effects of calcitriol. Moderate 
doses of calcitriol increase bone 
mineralization and osteogenesis. 
However, high doses of calcitriol 
promote the accumulation of 
osteoid and increase the time of 
mineralization. In vitro, high doses 
of calcitriol block osteogenic 
differentiation. At least partially, 
these actions are mediated by 




part of this thesis was focused on the study of the in vivo and in vitro effects of the 
CaSR activation by calcimimetic in bone cells. 
In our in vivo experiments, calcimimetic administration to 5/6Nx rats produced the 
expected decrease in plasma intact PTH concentration. Despite this decrease in 
PTH, bone histomorphometry analysis showed that the bone surface covered by 
osteoblasts and osteoclasts remained similar between 5/6Nx and 5/6Nx+CM rats, 
suggesting that CaSR activation might exerts additional effects on bone. Recent 
studies using a murine model of reduced renal function by subtotal nephrectomy, 
have reported similar osteoblast and osteoclast activity in rats treated or not with the 
calcimimetic AMG416 (Parsabiv/Etelcalcetide) in spite of the differences in plasma 
PTH levels148. Wada et al reported that calcimimetic R-568 reduced PTH levels and 
ameliorated osteitis fibrosa in uremic rats. However, in this study bone cells activity 
was not different to that found in rats receiving vehicle208. In hemodialysis patients, 
Cozzolino M et al observed that the serum bone specific alkaline phosphatase 
activity increased in the subjects treated with cinacalcet as compared with those 
treated with paricalcitol after 28 days. These differences were explained by a lower 
PTH levels in treated patients with paricalcitol than with cinacalcet209; however these 
results would also agree with our hypothesis suggesting a direct effect of cinacalcet 
in bone cells. 
To separate the actions of calcimimetic in the parathyroid glands from those in bone, 
we performed the experiment in 5/6Nx rats with parathyroidectomy receiving a 
constant infusion of PTH 1-34 (moderate PTH6x or high concentration PTH9x). PTH 
infusion by 6-fold the necessary dose to maintain plasma calcium in a PTx rat with 
normal renal function maintained plasma calcium and phosphate concentration 
similar to those observed in 5/6Nx animals. However, plasma intact FGF23 levels 
were lower in the parathyroidectomized 5/6Nx rats with PTH replacement by 6x than 
in the 5/6Nx group treated with vehicle. Despite the fact that the infusion of PTHx6 
maintained the plasma mineral parameters, the bone cell activity was lower than that 
observed in the 5/6Nx group, suggesting that the amount of PTH 1-34 was 
insufficient. Actually, plasma PTH 1-34 levels were significantly lower in 5/6Nx-PTx-
PTH6x than in 5/6Nx group. Furthermore, it is known that circadian rhythms regulate 
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PTH210, which could not be mimicked in our animal model of clamped PTH. This 
aspect might also contribute to the differences between 5/6Nx and 5/6Nx-PTx-
PTH6x, since intermittent PTH pulses induce bone anabolic effects while continuous 
administration does not achieve to increase bone mass211. Other issue that 
complicates the explanation of the differences between both, 5/6Nx and 5/6Nx-PTx-
PTH groups is the existence of other biologically active fragments of PTH. It is 
assumed that the main biological activity of the PTH resides in the 1-34 fragment212. 
However, other fragments such as 7-84-PTH have demonstrated to inhibit the action 
of the intact (1-84) PTH213,214. In this way, the complexity of the actions and the 
presence of the several PTH fragments make difficult the comparison of an animal 
model with clamped PTH to animals with intact parathyroid glands. 
Despite the differences between both 5/6Nx and 5/6Nx-PTx-PTH6x, the model of 
parathyroidectomized 5/6Nx rats with PTH replacement was useful to separate the 
bone effects of calcimimetics from those dependent of the concomitant reduction of 
PTH levels. Interestingly, we found that 5/6Nx-PTx-PTH6x rats treated with 
calcimimetic increased bone turnover with respect to those treated with vehicle, even 
with similar biochemical parameters between them. These effects might be 
explained by the activation of the CaSR in bone cells by calcimimetic. 
Moreover, two additional groups of parathyroidectomized 5/6Nx rats receiving 
constant infusion of PTH 1-34 by 9-fold the necessary dose to maintain plasma 
calcium in a PTx rat with normal renal function were included, one of them receiving 
calcimimetic and the other one receiving vehicle. As expected, these animals 
showed increased osteoblast and osteoclast activity as compared with 5/6Nx rats 
and 5/6Nx-PTx-PTH6x rats. In these conditions of high PTH infusion, calcimimetic 
administration did not further increase bone turnover. As consequence of the 
elevated PTH infusion, these animals also increased plasma calcium levels; 
therefore, we consider that the bone effects of CaSR activation by calcimimetics in 
conditions of high plasma PTH and calcium are redundant being difficult to separate 
the effects of the high calcium on CaSR from those of calcimimetic. 
The relevance of CaSR activity on bone health was already evaluated by Xue Y. et 
al in rodents null for PTH and CaSR. In this sense, the anabolic effects of PTH were 
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reduced in PTH-/- CaSR-/- mice as compared with PTH-/- mice215. Likewise, another 
study showed that high dietary Ca increased bone formation in both wild type and 
PTH-/- mice, but these effects were absent in PTH-/- CaSR-/- double knockout 
mice216. Similarly, osteoblast specific ablation of CaSR attenuated the anabolic 
action of PTH217. These studies agree with our results that support a critical role of 
CaSR in bone cell activity. 
To confirm that the effects of calcimimetic were triggered directly in bone cells, we 
performed in vitro experiments. In this respect, firstly we checked that CaSR was 
expressed in the murine osteoblastic cell line UMR 106 and also in human bone 
marrow MSC. Furthermore, CaSR was functional, since Erk1/2 phosphorylation was 
modulated by calcimimetic and calcilytic addition. Yamaguchi et al reported that 
CaSR activation by calcium or its agonists, gadolinium or neomycin, increased 
osteoblast chemotaxis and proliferation as assessed by DNA synthesis129. In the 
same way, Chattopadhyay N. et al showed that high calcium led to an increased 
expression of Cyclin D1 in a primary culture of rat calvarial osteoblasts, and this 
effect was abolished after the expression of a dominant negative form of the 
CaSR218.  
At contrary, the administration of the calcilytic Calhex 231 inhibited the CaSR 
downstream signaling in UMR cells, as assessed by the decrease in ERK1/2 
phosphorylation. This inhibition of the CaSR signaling was accompanied by a 
reduction in the expression of osteoblastic genes, demonstrating the critical role of 
the CaSR on osteogenesis. It has been reported that activation of the CaSR by the 
calcimimetic R-568 or calcium increases the osteogenic differentiation of human 
mesenchymal stem cells from amniotic fluid and these effects were abolished by the 
treatment with the calcilytics Calhex-231 or NPS-2143219. This study supports our 
results that CaSR modulation potentially regulates osteogenesis. 
With respect to in vitro osteoclastogenesis our results showed that calcimimetic 
addition increases CTSK expression. Similarly, low calcium concentration used in 
this experiment generated osteoclast-like cells with a lesser number of nuclei (3-4), 
suggesting that CaSR activation might also participate in osteoclastogenesis. As 
described above, RANKL is a potent activator of osteoclastogenesis220. The actions 
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of RANKL are mediated via NFAT transcription factor activation221–223. NFAT2 
(NFATc1) pathway activation is regulated by the calcium/calmodulin signaling, which 
in turn leads to the activation of the phosphatase calcineurin and the subsequent 
dephosphorylation of NFAT2 leading to its nuclear translocation and the transcription 
of the NFAT2 target genes224. In this respect, the reduction in the calcium levels may 
also inhibit the Calcium/Calcineurin/NFAT signaling that might modulate 
osteoclastogenesis. However, more studies using calcimimetic at different calcium 
concentrations are needed to clarify the role of the CaSR on osteoclastogenesis and 
the signaling pathways involved in this process. 
The principal findings in these experiments are summarized in Figure 82. 
 
 
Figure 82. Summary figure shown the bone effects of calcimimetic. Activation of CaSR by 
calcimimetic decreases PTH production and secretion in the parathyroid glands while it 
maintains bone turnover. The bone actions of the calcimimetic are mediated through 
ERK1/2 signaling activation in osteoblasts that lead to increased osteogenic 
differentiation. Calcilytic administration reduces ERK1/2 phosphorylation and 
subsequently decreases the transcription of osteogenic genes. 
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In this thesis we also investigated the bone effects of Mg supplementation in the 
context of CKD using an animal model of vascular calcification. Mg salts are used in 
nephrology as phosphate binder, contributing to decrease hyperphosphatemia and 
vascular calcification157,160. In vitro, the beneficial effects of Mg on the prevention of 
phosphate-induced vascular smooth muscle cells calcification have been previously 
reported61,225–227. However, whether Mg supplementation promotes bone effects is 
unknown; similarly the role of Mg supplementation during the differentiation of bone 
cells is also unclear. In this respect, we investigated the bone effects of dietary Mg 
supplementation in an animal model of CKD-associated vascular calcification and 
our results showed that dietary Mg supplementation dose-dependently decreased 
plasma phosphate, FGF23 and PTH levels, increased plasma ionized calcium 
concentration and also prevented renal damage as assessed by the decrease in 
plasma creatinine levels.  
The normalization of plasma calcium and phosphate levels with the prevention of the 
renal damage in the 5/6Nx rats fed on dietary Mg supplementation decidedly 
intervene in the progression of SHPT. Furthermore, it has also reported that ionized 
Mg can bind the CaSR in parathyroid glands and reduce serum PTH production and 
secretion228. Therefore direct actions of Mg on parathyroid glands might also 
participate in the reduction of PTH levels. 
Of note, in spite of the reduced serum PTH levels in the 5/6Nx rats on dietary Mg 
supplementation, the bone surface covered by osteoblasts was similar among all 
5/6Nx groups. Additionally, the bone surface covered by osteoclasts was reduced in 
the group with higher content of Mg in the diet (5/6Nx+0.6% Mg) as compared with 
moderate doses of Mg in the diet (5/6Nx+0.1% Mg and 5/6Nx+0.3% Mg groups), 
consistent with a prevention of the loss of trabecular bone volume. The effects of the 
high PTH concentration on osteoclast activity are well-known229. Furthermore, PTH 
knockout mice displays a decrease in bone turnover accompanied by an increase in 
bone volume127. Several studies in animals have reported a deleterious effect of Mg 
deficiency on bone. Rude et al reported that Mg depletion in the diet by the 50% 
increased the number of osteoclasts in rats164, at least partially due to an increase in 
inflammation230. Furthermore, it has been reported recently that mild 
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hypermagnesemia is associated with a lower risk of hip fracture among patients 
undergoing hemodialysis231. This beneficial effects of Mg in bone may be derived, at 
least in part, by its direct actions on osteoblast activity. In this respect, our study is 
the first showing that dietary Mg supplementation decreases PTH levels while 
maintains osteoblast activity. 
In addition, the 5/6Nx+0.6%Mg group showed an increase in the osteoid thickness, 
suggesting that high Mg content in the diet may induce defective mineralization in 
CKD. In 1988, Moriniere et al showed no significant changes in any bone 
histomorphometric parameters after 8 or 20 months of treatment with Mg(OH)2, 
however showed clear tendencies to increase osteoid and decrease the resorption 
surface232. A coetaneous study by Gonella et al. showed that osteomalacia was 
prevented by decreasing Mg concentration in the dialyzed fluid233. These results 
highlight the importance of Mg levels on bone mineralization in CKD patients. 
To confirm whether the Mg effects are triggered directly in osteoblastic cells, we 
evaluated the effects of increasing doses of MgCl2 on the differentiation of bone 
marrow MSC into osteoblasts. We found that Mg supplementation in the culture 
medium increased matrix mineralization and expression of osteogenic master 
genes. These data support a direct effect of Mg on osteoblast differentiation. 
Furthermore, the addition of 2-APB, which blocks the Mg channel TRPM7234,235, led 
to the contrary effects, indicating that the effects of Mg are triggered intracellularly. 
Other authors have demonstrated the requirement of TRPM7 for growth and 
skeletogenesis236. 
We found that Mg supplementation activated the Notch signaling pathway, as 
assessed by the increased amount of NICD into nuclei of MSC differentiated toward 
osteoblasts. It has been reported that the activation of Notch signaling is differentially 
involved in bone development at different stages of osteoblast differentiation. On the 
one hand, Hilton et al demonstrated that Notch signaling preserves the MSC pool by 
suppressing osteoblast differentiation37. Similarly, Zanotti et al reported that specific 
overexpression of NICD in osteoblasts inhibits bone formation237. Nevertheless, the 
same authors reported that Notch activation in osteocytes increases trabecular bone 
formation in vivo38,40. Notch signaling activation has been also demonstrated in 
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osteocytes and its conditional activation in these cells promoted bone formation 
mainly by increasing bone mineralization. On the contrary, loss of function of the 
prenisilin γ-secretase by haploinsufficiency blocked osteoblast differentiation39. 
Recently, the potential role of Notch signaling in the process of fracture healing has 
been also elucidated, since the conditional ablation of Notch signaling in 
mesenchymal progenitor cells leads to inability for fracture union238. Altogether, 
these results highlight the importance of Notch in bone development. We observed 
in vitro, that the activation of the Notch signaling was presumably in the progenitor 
cells, due to the fact that differentiated osteocyte substantially decreased the protein 
amount of nuclear NICD, indicating that the pro-osteogenic effects of Mg 
supplementation may be triggered due to increased proliferation of the progenitor 
cell pool during differentiation. Taken together, our results suggest that Mg activates 
NICD nuclear translocation mainly in undifferentiated MSC but not in differentiated 
osteoblasts, maintaining the stemness and the pool for a more abundant 
osteogenesis. 
The finding of the differential effects of Mg on mineralization in vitro and in vivo might 
be due to differences in Mg concentration. 
In addition, we performed in vitro experiments to investigate whether Mg participates 
in the colonization and osteoblastic differentiation of MSC in bone scaffolds. We 
observed that bone scaffolds cultured into Mg-supplemented medium increased 
cellular proliferation and osteoblast were well-organized. Additionally, MSC 
differentiated into osteoblasts with Mg supplementation displayed an osteocyte-like 
shape, and even cytoplasmic processes of the osteocytes were identified by SEM. 
In this way the pro-osteogenic effects of Mg through Notch signaling activation may 
contribute, at least in part, to the colonization and osteogenic differentiation of MSC 
in osteoblasts. 
With respect to in vitro osteoclastogenesis, we found that Mg supplementation did 
not exert significant effects without differences in number of nuclei or CTSK 
expression. However, other authors have reported a potential role of Mg on 
osteoclast differentiation. Wu L et al, using higher Mg concentrations than those we 
used, demonstrated that increased levels of Mg extracts promote 
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osteoblastogenesis while inhibit osteoclastogenesis239. On the other site of the 
spectrum, other in vitro studies have reported that Mg deprivation enhances 
osteoclast differentiation240. With respect to these studies, we consider that Mg 
supplementation may not significantly affect osteoclastogenesis at the doses we 
investigated (1.4 and 2.6 mM), which are close to the physiological and lower than 
those previously assayed by other authors. 
The main results of the experiments of the effects of Mg on bone are highlighted in 
Figure 83. 
 
Finally, the role of FGF23 on bone development was also studied in this thesis. We 
developed an animal model in rats by reducing the functional renal mass (50%) and 
 
Figure 83. Summary figure of the bone effects of magnesium. In rats with renal 
insufficiency, Mg supplementation reduces plasma PTH levels while increases 
osteoblasts activity. In vitro, Mg addition increases the osteogenic differentiation of bone 
marrow mesenchymal stem cells by activation of the Notch signaling pathway. 
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fed with a high phosphate diet that increased plasma intact FGF23 without significant 
changes in other important parameters of mineral metabolism such as calcium, PTH, 
serum phosphate or calcitriol. As previously reported, FGF23 increased this early 
stage of renal insufficiency, even before plasma phosphate, calcium, PTH or 
calcitriol alterations84. 
Bone histomorphometric analysis revealed that in hemi-nephrectomized animals 
with high phosphate in the diet and high FGF23 (1/2Nx+1.2%P) there was an 
increased bone turnover and a tendency to decrease trabecular bone volume as 
compared with those receiving Sham operation and fed on the same diet. The bone 
effects of FGF23 have been already suggested previously. Sitara D et al developed 
a FGF23 and NaPi-IIa double knockout murine model to separate the FGF23 bone 
effects from those derived from phosphaturia. In this animal model, 
hyperphosphatemia was prevented, yet defective bone mineralization remained 
existent, indicating that, at least partially, FGF23 decreases bone mineralization241. 
The bone effects of elevated FGF23 have been also evaluated in Hyp mice (from 
hypophosphatemia, gene symbol Hyp), a well-established murine model for X-linked 
hypophosphatemia that present high levels of plasma intact FGF23242. Murali SK et 
al found that in osteoblasts FGF23 binds the FGFR3 and impairs mineralization by 
suppression of the tissue non-specific alkaline phosphatase (TNAP) and subsequent 
accumulation of pyrophosphate, a potent inhibitor of calcification243. In addition, they 
reported that FGF23 also increases osteopontin expression, a secreted protein that 
binds Ca and inhibits hydroxyapatite crystal formation. In this regard, the FGF23-
FGFR3 signaling in bone cells may directly impair mineralization in conditions of high 
FGF23192. 
In our study we found changes in bone turnover in the animals with higher plasma 
FGF23 levels, however we did not observed sign of defective mineralization. This 
difference with the previous studies may be due to the fact that the increase in the 
FGF23 levels in our animal model was not severe in order to avoid additional effects 
on mineral metabolism parameters such as plasma phosphate or ionized calcium. 
Furthermore, we observed that 1/2Nx-1.2%P animals showed significant changes in 
trabecular bone microstructure, a critical event in the development of renal 
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osteodystrophy244. Thus, bone abnormalities occur in an early stage of CKD and 
FGF23 may participate in its development. 
We also found that high plasma FGF23 levels were accompanied by high plasma 
sclerostin concentration. In this regard, increased sclerostin levels have been 
associated with decreased bone formation in long-term immobilized 
postmenopausal women245, which may be mainly due to an inhibition of the 
canonical Wnt/β-catenin pathway52,53. 
It is interesting to note that despite the increased osteoblast activity, the expression 
of osteogenic genes was reduced in 1/2Nx-1.2%P rats as compared with Sham-
1.2%P suggesting a delay in the maturation state of the osteocytes. This situation 
has been recently reported by others246 who suggest a stalled maturation of the 
osteocytes in young dialysis (CKD 5) and predialysis (CKD 2-4) patients. 
To further confirm the direct effects of FGF23 in osteoblasts, in vitro experiments 
were also performed. We observed that the addition of rat recombinant FGF23 
during MSC osteogenic differentiation also decreased the expression of osteogenic 
genes. These results agree with others that reported similar effects of FGF23 on 
osteogenesis. In this way, in vitro studies with rat calvaria cells over-expressing 
FGF23 have shown that elevated FGF23 decreases matrix mineralization and down-
regulates osteoblast marker genes. Furthermore, these effects were abrogated by 
administration of SU5402, a non-specific FGFR1 inhibitor178, indicating that the 
effects of FGF23 may be triggered presumably through FGFR signaling. 
Moreover, we observed that FGF23 administration to MSC differentiated into 
osteoblasts decreased the nuclear translocation of β-catenin after 24h, consistent 
with a decrease in the expression of osteogenic marker genes and an increase in 
SOST expression. These results are consistent with those observed in bone lysates 
of 1/2Nx-1.2%P rats, which also showed decreased osteogenic genes expression 
and increased SOST mRNA expression. It might suggest an involvement of FGF23 
and Wnt/β-catenin pathway during the development of bone alterations in early CKD. 
In a murine model of renal insufficiency (7/8Nx rats), it has been reported that an 
increase in the expression of Wnt inhibitors occurs as renal impairment progresses 
time-dependently in animals fed on a high phosphate diet associated with a 
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reduction in tibial bone mineral density. Uremic serum from these animals or FGF23 
plus α-klotho increased DKK, Secreted frizzled-related protein 1 (SFRP1) and the 
ratio phospho-β-catenin/total β-catenin247. 
On the other hand, we also investigated the effects of FGF23 on osteoclastogenesis 
by addition of rat recombinant FGF23 during in vitro osteoclastic differentiation of 
hematopoietic stem cells. Interestingly we found that FGF23 increased the number 
of osteoclasts, consistent with higher CTSK gene expression. The effects of FGF23 
on osteoclastogenesis have not been previously described and this study is the first 
demonstrating an effect of FGF23 on osteoclasts. Nevertheless, additional studies 
are needed to clarify the effects of FGF23 on the bone resorptive capacity of the 
osteoclasts in vitro. 
Of note, the osteoclasts treated with FGF23 became oversized and presented a 
lower number of nuclei as compared with control osteoclasts. In this respect, the 
increased enlargement of the osteoclasts in end stage renal disease has been 
previously reported by Kaye et al248. They found that osteoclasts increased the cell 
area in patients on dialysis, corresponding with a higher area of the lacuna248. It is 
important to note that FGF23 levels are extremely high in these patients and our 
results suggest that FGF23 may play a critical role in this process. In addition, the 
increased number of nuclei per osteoclast have been directly associated with the 
size of the resorption pit249,250. In this respect, our results indicate that FGF23 
increase the osteoclast enlargement, which may lead to increased bone resorption, 
as we observed in the in vivo experiment. However, the treatment with FGF23 
decreased the number of nuclei per osteoclasts that may also reduce the resorptive 
capability of the osteoclasts. Future experiments for evaluation of osteoclast 
resorption in vitro may help to clarify the role of FGF23 on osteoclast activity. 




Taken together, our studies shed some light on the complex scenario of CKD-MBD 
and suggest the development of clinical studies in the field of renal osteodystrophy 
that can lead to look for new therapeutical perspectives in the use of calcitriol, 
calcimimetic and Mg in the context of CKD and the consideration of FGF23 as an 
early biomarker of renal osteodystrophy. 
Interactions among these molecules may occur in vivo. Our results demonstrate that 
calcitriol has a hormetic dose-response in bone (i.e. it supports mineralization at 
lower doses and decrease mineralization at higher doses) that is not dependent of 
the PTH action. However, calcitriol administration dose-dependently increased 
plasma FGF23 concentration, which may also influence bone mineralization. 
 
Figure 84. Summary figure shown the bone effects of FGF23. In vivo, high plasma intact 
FGF23 decreases osteoblast-osteocyte transition and increases osteoclast activity. In 
vitro, high FGF23 concentration decreased osteogenic differentiation of bone marrow 
mesenchymal stem cells and these effects are, at least in part, mediated by the inhibition 
of the canonical Wnt-pathway. Furthermore, high FGF23 concentration increases 
osteoclastogenesis and osteoclast enlargement. 
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Additionally, treatment with high doses of calcitriol produced hypercalcemia, and 
high calcium may also activate the CaSR in bone cells. 
We highlighted a potential role of CaSR modulation on bone turnover. 
Physiologically, the gradual calcium concentration in the bone microenvironment 
may contribute to the coupling mechanism for bone resorption and bone formation. 
Thus, the increased calcium concentration in the area of resorption may participate 
in the activation and chemotaxis of osteoblasts, resulting in the classical situation of 
groups of bone-forming osteoblasts chasing bone-resorbing osteoclasts. This 
hypothesis agrees with previous studies that reported a role of the CaSR in 
osteoblast migration129. 
Mainly, positive allosteric modulation of the CaSR with calcimimetics is routinely 
used in hemodialysis patients in order to maintain plasma PTH levels within a non-
pathological range. In this population, bone abnormalities are common and the side 
effects of calcimimetics in bone cells may be beneficial in scenarios of low bone 
turnover. In this respect, adynamic bone is the prevalent form of renal 
osteodystrophy in CKD patients251,252, in which bone turnover is almost absent. Our 
results showed that calcimimetics maintain bone turnover despite the concomitant 
decrease in the plasma PTH levels in an animal model of renal insufficiency, and the 
treatment of SHPT with calcimimetic may prevent the development of adynamic 
bone. Clinical studies are needed to further clarify the actions of calcimimetics on 
bone turnover. 
Of note, Zaidi et al reported that divalent cations, including Mg, may regulate 
osteoclast differentiation through, at that time still hypothetical, calcium receptor253. 
Thus, besides the pro-osteogenic effects of Mg mediated through the activation of 
the Notch pathway, the additional effects derived from the activation of the CaSR by 
Mg should not be excluded, resulting in synergistic effects. Nevertheless, in 
presence of calcium and phosphate, high Mg may produce whitlockite instead of 
hydroxyapatite, 162. Whitlockite is the second most abundant mineral in bone254, and 
it has been reported that whitlockite has higher osteogenic potential than 
hydroxyapatite255. Hydroxyapatite and whitlockite ratio is fine-tuned in bone, albeit, 
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increased Mg or decreased pH block hydroxyapatite crystal formation in favor of 
whitlockite biomineralization and this fact may impede stable bone mineralization256. 
Another key finding in this thesis is the implication of FGF23 in bone abnormalities 
in an animal model with a 50% reduction of renal mass. 
Animals with higher intact FGF23 levels shown increased bone turnover and a trend 
to decrease trabecular bone volume was observed. These findings highlight the role 
of FGF23 in the early development of bone abnormalities. As indicated previously, a 
supraphysiological dose of CTR increase plasma FGF23 and sclerostin levels. In 
this respect, the extremely high FGF23 levels induced by the treatment with CTR 
may contribute at least partially to elevate plasma sclerostin, which in turn may lead 
to impaired mineralization and decreased bone volume. 
It is interesting to note that in vitro experiments demonstrate an anti-osteogenic effect 
of FGF23, which may not agree with the increased bone turnover observed in the in 
vivo model. However, our data demonstrated that FGF23 impaired osteoblast 
maturation. In addition, FGF23 directly enhances osteoclast differentiation, which 
may explain the increased turnover due to the coupling between bone cells. In view 
of these results, FGF23 may play an important role in the development of renal 
osteodystrophy at early stages of renal disease. However, our model did not 
replicate a progressive renal damage as the observed in the CKD population and 
clinical studies are needed to further clarify the involvement of FGF23 in early bone 
alterations. 
The results from the studies in this thesis indicate that bone is heterogeneously 
affected in CKD and this fact is clinically noticed since the spectrum of renal 
osteodystrophy is very broad in CKD patients. Historically, the most of the bone 
disorders associated with CKD have been related to the excessive plasma PTH 
levels, however other factors may also influence bone status. The administration of 
CTR to treat secondary hyperparathyroidism may also alter bone mineralization and 
osteogenesis, particularly if high doses are administered. Furthermore, excessive 
CTR elevates plasma FGF23 levels, which are very high in hemodialysis patients 
and also affects osteocyte maturation and osteoclastogenesis. On the other hand, 
patients that present hypomagnesemia may also develop low bone turnover 
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diseases or adynamic bone. Therefore, the maintenance of the plasma Mg levels 
within a narrow range or moderately elevated may be beneficial. Moreover, 
treatment with calcimimetic maintains bone turnover despite the concomitant 
decrease in plasma PTH by acting on the CaSR in osteoblasts. In this way, the 
treatment with calcimimetic may be useful to prevent adynamic bone disease in CKD 
patients. 
 
Taken together, we hope that our results may contribute to the understanding of the 
complex scenario of the bone and mineral disorders found in the context of renal 
diseases and may be helpful for the establishment of future studies in the search of 















1. In a rat model of renal insufficiency, Calcitriol administration at doses that do 
not promote hyperphosphatemia and hypercalcemia reduces the time of 
mineralization and osteoblast activity in a PTH-independent manner. 
2. In vitro, calcitriol inhibits osteoblast differentiation and mineralization and 
promotes osteoclast differentiation. 
3. In a murine model of renal insufficiency, treatment with calcimimetic 
maintains bone turnover despite the concomitant decrease in parathyroid 
hormone levels. 
4. Calcium sensing receptor modulation by calcimimetic and calcilytic 
regulates osteoblast differentiation and mineralization and may promote 
osteoclast differentiation. 
5. In a rat model of vascular calcification, dietary magnesium supplementation 
maintains osteoblast activity in bone and reduces the osteoclast activity in 
spite of the decrease in plasma parathyroid hormone concentration, 
however at high doses might promote defective mineralization. 
6. In vitro, magnesium supplementation promotes osteoblast differentiation 
and mineralization and do not significantly affects osteoclast differentiation. 
7. The increase in plasma FGF23 is associated with increased bone turnover 
and changes in trabecular bone microstructure in a murine model of early 
CKD. 
8. High FGF23 concentration decreases osteogenic differentiation by inhibition 
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Magnesium Chloride promotes 
Osteogenesis through Notch 
signaling activation and expansion 
of Mesenchymal Stem Cells
Juan M. Díaz-Tocados1,2,3,4, Carmen Herencia1,2,3, Julio M. Martínez-Moreno1,2,3, Addy Montes 
de Oca1,2,3, Maria E. Rodríguez-Ortiz4,5, Noemi Vergara1,2,3, Alfonso Blanco6, Sonja Steppan7, 
Yolanda Almadén1,3,8,9, Mariano Rodríguez1,2,3,4 & Juan R. Muñoz-Castañeda1,2,3,4
Mesenchymal stem cells (MSC) are osteoblasts progenitors and a variety of studies suggest that 
they may play an important role for the health in the field of bone regeneration. Magnesium 
supplementation is gaining importance as adjuvant treatment to improve osteogenesis, although 
the mechanisms involving this process are not well understood. The objective of this study was to 
investigate the effects of magnesium on MSC differentiation. Here we show that in rat bone marrow 
MSC, magnesium chloride increases MSC proliferation in a dose-dependent manner promoting 
osteogenic differentiation and mineralization. These effects are reduced by 2-APB administration, an 
inhibitor of magnesium channel TRPM7. Of note, magnesium supplementation did not increase the 
canonical Wnt/β-catenin pathway, although it promoted the activation of Notch1 signaling, which was 
also decreased by addition of 2-APB. Electron microscopy showed higher proliferation, organization 
and maturation of osteoblasts in bone decellularized scaffolds after magnesium addition. In summary, 
our results demonstrate that magnesium chloride enhances MSC proliferation by Notch1 signaling 
activation and induces osteogenic differentiation, shedding light on the understanding of the role of 
magnesium during bone regeneration.
Bone growth is a process required in a wide variety of conditions in which functional restoration of damaged bone 
is needed. There are pathological conditions such as polytraumatism, bone tumors, degenerative diseases, ortho-
pedic surgeries, osteonecrosis, osteotomy or non-union fractures where a combination of prosthesis implantation 
and enhanced osteogenesis is necessary1, 2. The standard treatment in some of these conditions require autolo-
gous or allogenic cancellous bone transplantation, supplemented with growth factors and/or progenitor cells. 
These alternatives have limitations such as surgical complications, elevated cost and/or immunogenic rejection3–5. 
Therefore, the search for new strategies to improve bone grafts has risen widely over the last years. An optimal 
biomaterial should be simple, biologically safe, biocompatible and with a high degree of interaction with the 
patient’s bone tissue to favor proliferation and differentiation of progenitor cells into an osteogenic phenotype.
Nowadays, there are many types of scaffolds such as calcium phosphate-based materials (extensively studied 
as bone scaffold for tissue engineering), polymeric (collagen, fibrin, alginate, silk, hyaluronic acid, or chitosan), 
composite (two or more distinct materials), metallic (magnesium or titanium) or third generation scaffolds that 
combine the aforementioned materials with stem cells, growth factors, cytokines, etc1.
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Magnesium (Mg2+) is particularly interesting because of its abundance in the organism, where it participates 
in numerous biological processes, like osteogenesis of progenitor cells. In addition, low Mg2+ concentrations 
have been associated with osteoporosis or osteopenia6. In biomaterial engineering, Mg-based implants have been 
used to enhance bone formation “in vivo”7–10. Due to corrosion resistance of Mg2+ alloys11, new formulas based 
on Mg2+ are being investigated. Currently, Mg2+ is used in combination with other materials as calcium and 
phosphate, or as Mg-coated structures to enhance osteogenesis. However, little is known about the mechanisms 
whereby Mg2+ salts affect osteogenesis and bone formation. It is known that Wnt/β-pathway and Notch sig-
naling are involved in bone marrow mesenchymal stem cells (MSC) osteogenesis12, 13. Although other works 
show that Notch signaling activation is also related to the maintenance of stemness14 even with the inhibition of 
osteogenesis15.
The characterization of the pro-osteogenic effects of Mg2+ will add knowledge on the biology of bone cells; 
thus, new or improved strategies can be developed aiming to enhance osteogenesis, and osseointegration of bone 
prosthesis.
The present study evaluates the effects of magnesium chloride on osteogenesis of bone marrow MSC and its 
capability to repopulate decellularized bone scaffolds. Moreover, the mechanisms whereby magnesium chloride 
triggers its pro-osteogenic effect are also investigated.
Results
Moderately high concentrations of Mg2+ increase osteogenesis and mineralization of rat 
MSC. Increasing Mg2+ concentrations (0.8, 1.2, and 1.8 mM) enhanced MSC osteogenesis (Fig. 1). In MSC 
differentiated into osteoblasts with 1.2 mM of MgCl2, alkaline phosphatase activity (ALP) increased by 4.2-fold 
(vs 0.8 mM) and by 6-fold with 1.8 mM of MgCl2, (Fig. 1a). Likewise, matrix mineralization, verified by Alizarin 
Red S, was more abundant in cells cultured with high Mg2+ concentrations (Fig. 1b).
The enhancement of mineralization was accompanied by a significant increase in the expression of oste-
ogenic master genes such as RUNX2 (Fig. 1c), regulator of the early osteoblast differentiation, OSTERIX 
(Fig. 1d), transcription factor required for the transition of pre-osteoblasts to osteoblasts, and OSTEOCALCIN 
(Fig. 1e), produced by mature osteoblasts. The addition of MgCl2 increased the expression of these genes in a 
concentration-dependent manner. As FGF23 is released by mature osteoblasts and osteocytes, the amount of 
FGF23 in the supernatant demonstrates the presence of mature osteoblasts. FGF23 production during 24 h was 
measured at 21 days of osteogenic differentiation. Undifferentiated cells did not produce FGF23 while in MSC dif-
ferentiated into osteoblasts with 1.8 mM of MgCl2 FGF23 levels were 31-fold increased as compared with 0.8 mM 
(Fig. 1f).
The inhibition of the Mg2+ transporter TRPM7 by 2-APB produced a decrease in ALP activity (Fig. 2a) as well 
as in matrix calcification (Fig. 2b). It also resulted in a significant down-regulation of the osteogenic marker genes 
RUNX2, OSTERIX and OSTEOCALCIN (Fig. 2c–e, respectively). Moreover, 2-APB treatment reduced FGF23 
secretion (Fig. 2f).
Protein levels of Cyclin D1 and PCNA, markers of cellular proliferation, were analyzed by Western blot. The 
expression of both proteins was increased in osteoblasts as compared with undifferentiated controls. The addi-
tion of Mg2+ to the medium induced a dose dependent increase in both PCNA and Cyclin D1 (Fig. 2g and h). 
Notably, the inhibition of the Mg2+ channel TRPM7 with 2-APB significantly reduced Cyclin D1 and PCNA 
protein expression.
Magnesium increases osteogenic differentiation through activation of Notch1 signaling in 
MSC. The Wnt/β-catenin and Notch signaling are pathways closely involved in bone development. The effect 
of Mg2+ on both pathways was explored. Immunofluorescence analyses revealed that osteogenic differentiation 
is associated with nuclear translocation of β-catenin. However, increasing MgCl2 concentrations in the culture 
medium did not produce a further increase the nuclear translocation of β-catenin (Fig. 3a and b).
Confocal microscopy analysis of Notch1 intracellular domain (NICD) showed that Mg2+ supplementation 
produced an increase in nuclear translocation of NICD (Fig. 4a). Osteogenic differentiation decreased the nuclear 
NICD as compared with UC while Mg2+ supplementation increased the presence of nuclear NICD. In OB cells 
treated with 2-APB the DAPI-NICD co-localization was almost inexistent. As it is observed in the last column 
of Fig. 4a as compared to 0.8 mM, after Mg addition there was an increase of green pixels (NICD) matching with 
blue pixels (DAPI), demonstrating nuclear colocalization of NICD protein. Similarly, Fig. 4b shows that a mod-
erate increase of Mg2+ in the osteogenic medium upregulated the mRNA expression of HEY2, one of the classic 
Notch target genes. The opposite effect was observed by the inhibition of the Mg2+ transporter TRPM7 with 
2-APB, which reduced the nuclear translocation of NICD (Fig. 4a) and Notch activation (Fig. 4b). To examine a 
likely direct effect of MgCl2, the nuclear expression of NICD was evaluated after 24 h of Mg supplementation on 
MSC or MSC plus osteogenic stimulus. The addition of MgCl2 for 24 h increased the nuclear protein expression of 
NICD as it was confirmed by western blotting (Fig. 4c). However, when MgCl2 was administrated for 24 hours in 
presence of an osteogenic stimulus the levels of nuclear NICD expression were similar to those found with basal 
Mg2+ content (Fig. 4d). The administration of MgCl2 for 24 h to differentiated osteoblasts or 2-APB treated cells 
for 21 days did not modify the nuclear NICD protein expression (Fig. 4e). A high NICD protein expression was 
also detected by immunoblotting of nuclear protein extracts from MSC and differentiated osteoblasts with Mg2+ 
supplementation after 21 days (Supplementary Figure S1). However, NICD expression was again highly induced 
in undifferentiated MSC. Taken together, these data suggest that Mg2+ activates NICD nuclear translocation on 
undifferentiated MSC but not in differentiated osteoblasts.
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Magnesium promotes maturation and distribution of osteoblast into decellularized scaf-
folds. Scanning Electron Microscopy (SEM). In decellularized scaffolds (Fig. 5a), osseous matrix was observed 
as series of uniform and regular depressions corresponding to ducts osteons (Fig. 5b). Whole bone surface and 
cavities were covered with a thin membrane with scarce cells. In the scaffolds recellularized with MSC and treated 
with basal levels of Mg2+ (0.8 mM) (Fig. 5c), bone matrix was covered with an irregular membrane with abun-
dant cells following an unspecific distribution and presenting a stellate morphology. After Mg2+ supplementation 
(1.2 mM), MSC formed a uniformly organized layer over the bone surface, of smooth aspect and with abundant 
Figure 1. Effects of MgCl2 supplementation on osteogenesis and mineralization of rat MSC. (a) ALP activity 
was significantly and dose-dependently increased by Mg2+ concentration. (b) Matrix mineralization verified by 
Alizarin Red S staining was higher according to Mg2+ levels. (c) Osteogenic marker genes Runx2, (d) Osterix 
and (e) Osteocalcin expression was up-regulated according to the increase in Mg2+ concentrations. (f) Intact 
FGF23 in the liquid supernatant was increased according to Mg2+ concentrations. FGF23 was not detected in 
liquid supernatant of UC. UC - undifferentiated cells, OB - osteoblasts. Bars show mean ± SEM. n = 4.
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cellular proliferation filling the osteon canals (Fig. 5d). In the scaffolds treated with 1.8 mM Mg2+, a continuous 
and regular layer of germinal bone tissue that fully occupied the scaffolds, was observed (Fig. 5e).
Transmission Electron Microscopy (TEM). Cellular layers on decellularized bone scaffolds were analyzed with 
TEM. During the osteoinduction of MSC with basal Mg2+ levels (0.8 mM), collagen-producing blastic cells were 
poorly organized and with immature matrix (Fig. 6a). After Mg2+ supplementation (1.2 mM), the number of 
Figure 2. Decrease in intracellular Mg2+ reduces osteogenesis, mineralization and proliferation during 
differentiation of rat MSC into osteoblasts. Inhibition of Mg2+ entry by blocking TRPM7 with 2-APB (50 µM) 
significantly decreased (a) ALP activity and (b) matrix mineralization as assessed by Alizarin Red S staining. 
Specific osteogenic marker genes (c) RUNX2, (d) OSTERIX and (e) OSTEOCALCIN were down-regulated 
by inhibition of Mg2+ entry with 2-APB. (f) FGF23 production was decreased by inhibition of the Mg2+ 
transporter TRPM7 with 2-APB. (g) Western blots show an increased stimulation of Cyclin D1 and (h) PCNA 
according to Mg2+ concentrations at 21 days of osteogenic differentiation. TFIIB was used as a loading control, 
UC - undifferentiated cells, OB - osteoblasts. Bars show mean ± SEM. n = 4. Vertical black line separates results 
from different gels using the same exposure and protein load (see Supplementary Figures S3–S4).
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osteoblasts increased and they were organized in layers, similar to appositional growth of bone, and more mature 
osteoblasts (osteocytes) were observed. These osteocytes showed bone canaliculi prolongation and a more organ-
ized collagen matrix (Fig. 6b). The highest concentration of MgCl2 (1.8 mM) produced a further increase in the 
number of osteoblast layers (appositional growth), with more mature osteocytes, large bone canaliculi and an 
organized deposition of collagen (osteoid matrix) (Fig. 6c).
Discussion
In the present study, we have investigated the potential effects of MgCl2 in bone marrow MSC during osteogenic 
differentiation including its effect on anchorage, cellular attachment and differentiation when they are cultured 
on decellularized bone scaffolds. As it is illustrated in Fig. 7, high concentrations of MgCl2 (1.2 mM or 1.8 mM) 
enhanced proliferation of rat bone marrow MSC in a dose-dependent manner, and increased the subsequent 
osteogenesis. These effects were not observed after inhibition of the Mg2+ channel TRPM7 by 2-APB, which 
confirmed the key role of intracellular Mg2+ in the osteogenesis of MSC. We evaluated the intracellular path-
ways whereby Mg2+ promotes osteogenesis of MSC, finding that MgCl2 addition did not increase canonical 
Wnt/β-catenin pathway activation, although this pathway was activated under osteogenic stimuli. It was inter-
esting to observe that MgCl2 supplementation induced the nuclear translocation of NICD and HEY2 expression. 
Our results show a direct effect of Mg2+ on Notch activation in MSC rather on differentiated osteoblasts from 
MSC (Fig. 4), suggesting a specific role of Mg2+ on the maintenance of stemness of MSC rather on osteogenic 
process. Furthermore, moderate concentrations of MgCl2 considerably promoted osteocyte maturation and 
enhanced cell attachment to the decellularized bone surface. Note that MgCl2 increased the effects of the osteo-
genic stimuli while conditioned medium with basal levels of Mg2+ only produced blastic cells, poorly organized, 
and without osteocytic phenotype.
The beneficial effects of several Mg2+ alloys on bone formation have been widely reported. The balanced com-
bination of Mg2+ with different elements such as calcium and phosphate or in Mg-coating prosthesis has demon-
strated osteoinductive effects7, 16. These effects are supported by the formation of a better structure. The structure 
and surface characteristic of the biomaterials/scaffolds are key for the attachment and function of the cells and, it 
may affect the absorption and/or integration of proteins; and in turn, the quality of the anchorage, influences the 
subsequent cellular responses and tissue regeneration. Minardi et al. suggested that Mg2+ provides the scaffolds 
with structural characteristics similar to those of bone, allowing anchorage and proliferation of progenitor cells9. 
Few studies have investigated the active effects of Mg2+ on osteogenesis. Recently, Zhang et al. have demonstrated 
that cement formed by a combination of calcium, phosphate and Mg2+ increased osteogenesis through a specific 
interaction between fibronectin and integrin α5β117. Of interest, the authors observed a significant increase in 
Mg2+ concentration (approx. 2.5 mM) after soaking these scaffolds with culture medium; this study support our 
results demonstrating that Mg2+ salts may enhance osteogenesis of progenitor cells. Yoshizawa et al. observed that 
supra-physiological concentrations of Mg2SO4 (10 mM) also promoted the expression of transcription factors 
related to COL10A1 expression18. Therefore, these findings suggest that Mg2+ salts promote bone formation in 
Figure 3. Mg2+ supplementation does not induce nuclear translocation of β-catenin. (a) Confocal microscopy 
showed translocation of β-catenin (green) to the nuclei in rat MSC cultured in osteogenic medium, but no 
significant differences were observed in groups with higher Mg2+ levels. (b) Western blot analysis of β-catenin 
for nuclear protein extracts. TFIIB was used as loading control. UC - undifferentiated cells, OB - osteoblasts. 
Original magnification: 400x.
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vitro. In fact, Mg2+ is abundant in the skeleton and it is an essential ion in bone development allowing physiolog-
ical, mineralization and osteogenesis of MSC19.
The Mg2+ channel TRPM7 is ubiquitously expressed and it is implicated in cellular Mg2+ homeostasis20. 
Expression and activity of TRPM7 are modulated by the availability of Mg2+ and Ca2+. High influx of Mg2+ 
Figure 4. Moderately high Mg2+ levels induce Notch signaling activation. (a) Confocal microscopy of NICD 
protein in undifferentiated MSC (UC 0.8 mM), differentiated osteoblasts with basal levels of Mg (OB 0.8) or 
plus Mg supplementation at 1.2 mM (OB 1.2) or 1.8 mM (OB 1.8 mM) and osteoblasts with Mg channel block 
(OB 0.8 + 2-APB). First column represents NICD immunostaining in green color; second column corresponds 
with nuclei staining with DAPI; the third column is a merge composition of green and blue staining while the 
last column shows green pixels that matches with blue pixels. (b) Gene expression of the Notch target gene 
HEY2. (c) Western blot for nuclear NICD in undifferentiated MSC after 24 h of stimulus with Mg2+. (d) Nuclear 
protein levels of NICD after 24 h of osteogenic stimulus with Mg2+ or 2APB. (e) NICD expression in MSC and 
differentiated osteoblast from MSC plus 24 h of Mg2+ stimulus after 21 days of treatment.
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stimulates gene expression of TRPM7 channel and promotes osteoblasts proliferation21. Other authors have 
demonstrated the requirement of TRPM7 for growth and skeletogenesis22. The results of these studies are in line 
with our findings, where TRPM7 inactivation by 2-APB inhibited osteogenesis of bone marrow MSC and sig-
nificantly reduced Notch1 signaling. The contrary effect was observed with the addition of moderate concentra-
tions of MgCl2, which promoted Notch1 signaling activation and increased osteogenesis of the MSC. The central 
role of this pathway during osteogenesis has been described already13, 23, although other works highlights too an 
inhibition of this pathway during osteogenesis15. The interrelationship among Notch1 signaling pathway, Mg2+ 
and osteogenesis is unknown; taken together, our in vitro and in vivo results suggest that Mg2+ supplementation 
Figure 5. MgCl2 supplementation promotes attachment and osteogenesis of MSC on decellularized bone 
scaffolds. (a) Macroscopic picture of rat decellularized bone scaffolds used in this study. Pictures show 
SEM images of (b) decellularized bone scaffold, (c) re-cellularizated scaffolds after 21 days of osteogenic 
differentiation with basal Mg2+ (0.8 mM), where spindle-shaped cells attached to the scaffold were observed. 
Mineralization, cell attachment and proliferation were enhanced dose-dependently as it is showed in (d) Mg2+ 
1.2 mM and (e) Mg2+ 1.8 mM. Scale bar 800 µm.
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promotes Notch activation tissue-specifically in MSC increasing the pool of osteoprogenitor cells susceptible to 
be differentiated into osteoblasts in the presence of osteogenic stimuli.
In a recent study, it is demonstrated that the inhibition of Notch pathway in MSC leads to a lesser proliferation 
and osteogenic capability avoiding fracture healing24. Zanotti et al. have observed that Notch effects in the skele-
ton are cell-context-dependent finding different effects on immature osteoblasts or osteocytes25. These and other 
works highlight the potential dimorphic effects of Notch signaling in bone homeostasis26.
Finally, and with respect to Mg2+ supplementation more studies, considering other important parameters 
for bone turnover such as PTH or vitamin D, should be led to evaluate with precision the in vivo effects of Mg2+ 
supplementation on the mineralization or the osteoid production in the bone.
In addition, we studied the effect of Mg2+ on cell organization and osseointegration of progenitor cells on 
rat decellularized bone. Our results reveal that the supplementation with Mg2+ improves cell attachment and 
increases osteogenic differentiation of MSC cultured on decellularized bone. Transmission electron micros-
copy analysis showed that Mg2+ supplementation increased proliferation and maturation of MSC differenti-
ated into osteocytes with the presence of cytoplasmic prolongations between osteocytes (bone canaliculi) and a 
well-organized osteoid matrix with a large number of layers similar to the appositional growth observed in bones. 
Figure 6. Rat bone marrow MSC differentiated into osteoblasts displayed phenotypic characteristics of 
osteocyte with MgCl2 supplementation. Pictures show TEM images of a MSC after 21 days of osteogenic stimuli 
with Mg2+ 0.8 mM, b 1.2 mM and c 1.8 mM. Scale bar 5 µm. *Collagen fibers; Arrows: Bone Canaliculi.
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Similarly, using scanning electron microscopy analysis, it was shown that Mg2+ induced proliferation, differen-
tiation and a more organized distribution of the osteocytes coating the surface of decellularized bone, allowing 
mineralization and formation of new bone. These data indicate that the bone tissue formed on decellularized rat 
bone after Mg2+ supplementation has a better internal distribution with highly organized structures. Several stud-
ies have shown that Mg2+ ions may enhance cell attachment and promote bone formation. Moreover, previous 
studies have demonstrated that Mg2+ ions support the initial cell adhesion of MSC and increase proliferation and 
activation of integrins27. Recently, Galli et al. also showed that the immersion of threaded screws in a solution of 
MgCl2 (10 mg/ml) leads to enhanced osteogenesis and improves osseointegration
28.
The data reported in this study could represent a new, feasible and economic strategy to improve bone for-
mation in different types of scaffolds. In addition, these results also suggest that local administration of moder-
ately high levels of Mg2+ could be suitable to promote osteogenesis in pathologies in which bone formation is 
necessary.
This approach would significantly impact the orthopaedic field, and further provides new targets to improve 
the quality of the materials currently available.
Methods
Isolation of rat bone marrow MSC. All experimental protocols were reviewed and approved by the Ethics 
Committee for Animal Research of IMIBIC in accordance with the ethical guidelines of the Institution and the 
EC Directive 86/609/EEC for animal experimentation. Twenty male Wistar rats were euthanized by aortic punc-
ture under general anesthesia with pentobarbital sodium (50 mg/kg) and midazolam (4 mg/kg/i.p). Tibiae and 
femurs were cut at the epiphyses and subsequently perfused with alpha minimal essential medium (αMEM; 
Sigma-Aldrich CO, St. Louis, MO, USA) containing FBS (15%; Lonza Inc., Walkersville, MD, USA), ultraglu-
tamine (1%; Lonza), penicillin (100 U/mL) and streptomycin (100 µg/mL). Single-cell suspension was generated 
by filtration through 70 µm cell strainer (BD Biosciences, San Jose, CA, USA). MSC were isolated according 
to their plastic adherence properties. Following centrifugation and washing with αMEM, bone marrow cells 
were cultured in 25 cm2 flasks (NUNC A/S, Roskilde, DE, USA) with αMEM containing FBS (15%), ultraglu-
tamine (1%), penicillin (100 U/mL), streptomycin (100 mg/mL) and basic fibroblast growth factor (bFGF; 1 ng/
mL; PeproTech EC Ltd., London, UK) in a humidified atmosphere with 5% CO2 at 37 °C. Fresh α-MEM with FBS 
(10%), ultraglutamine (1%), penicillin (100 U/mL), streptomycin (100 µg/mL) and bFGF (1 ng/mL) was added 
after 24 h and changed every 3 days. Once 85–90% confluence was reached, cells were collected using Trypsin-
EDTA (Lonza) and seeded in 6-well plates (NUNC) at 13000 cells/cm2. Treatments were started as described 
below when cells reached 90% confluence.
Osteogenic differentiation of MSC and treatments. MSC were cultured for 21 days in αMEM with 
FBS (10%), ultraglutamine (1%), penicillin (100 U/mL), streptomycin (100 µg/ml) and osteogenic stimuli based 
on dexamethasone (1 µM; Sigma-Aldrich), β-glycerol phosphate (10 mM; Sigma-Aldrich) and ascorbic acid 
(0.2 mM; BAYER, Barcelona, Spain). Basal Mg2+ concentration in the medium was 0.8 mM. In order to increase 
the Mg2+ content in the pro-osteogenic medium, MgCl2 (Carlo ErbaReagentiSpA, Milano, Italy) was added to 
achieve final Mg2+ concentrations of 1.2 mM and 1.8 mM during the osteogenic stimulus. Fresh medium alone 
or osteogenic medium supplemented with MgCl2 was replaced every 3 days. Furthermore, 2-APB (50 µM; Tocris 
Bioscience, Bristol, UK) was added to the osteogenic medium containing 0.8 mM of Mg2+ during differentiation 
to determine the effects of inhibiting the Mg2+ channel TRPM7. To examine a direct effect of Mg2+ supplemen-
tation (1.2 and 1.8 m, or 2-APB) for 24 hours on undifferentiated MSC or at the different stages of differentiation 
(early or mature osteoblasts obtained from MSC) the NICD expression was also analyzed by western blot. All 
experiments were repeated at least three times.
RNA isolation and quantitative RT-PCR. Total RNA was extracted with TRI reagent (1 mL; 
Sigma-Aldrich) and quantified by spectrophotometry (ND-1000, Nanodrop Technologies, Wilmington, 
DE, USA). cDNA was synthesized from 1 µg of total RNA with a first strand cDNA synthesis kit (Qiagen, 
Figure 7. Summary figure. Magnesium supplementation enhances proliferation of MSC. Mechanistically, 
magnesium ions enter into MSC through TRPM7 channel, increasing Notch Intracellular Domain (NICD) 
nuclear translocation. Proliferation of MSC contributes to a subsequent osteogenesis. Inhibition of TRPM7 
channels by 2-APB decreases the osteogenic potential of magnesium.
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Hilden, Germany) in the presence of random hexamers in a final volume of 20 µl at 25 °C for 10 min, fol-
lowed by 42 °C for 15 min and 95 °C for 3 min. PCR SYBR Green kit (Qiagen N.V., Hilden, Germany) was 
used to quantify mRNA expression levels. Primers for PCR were synthesized with Oligo software. RUNX2 
(Forward 5′CGG-GAA-TGA-TGA-GAA-CTA-CTC3′ Reverse 5′CGG-TCA-GAG-AAC-AAA-CTA-GGT3′), 
OSTERIX (Forward 5′GTA-CGG-CAA-GGC-TTC-GCA-TCT-GA3′ Reverse 5′TCA-AGT-GGT-CGC 
-TTC-GGG-TAA-AG3′), OSTEOCALCIN (Forward 5′TCT-GAG-TCT-GAC-AAA-GCC-TTC-ATG3′ Reverse 
5′TGG-GTA-GGG-GGC-T GG-GGC-TCC3′), and 18-S (Forward 5′GTA-ACC-CGT-TGA-ACC-CCA-TT3
′Reverse 5′CCA-TCC-AAT-CGG-TAG-TAG-CG3′). Primers for HEY2 (Forward: 5′TCC-AAT-GCT 
-CAT-AAA-GTC-CGT3′ and Reverse: 5′ TCT-GCA-AAT-GAC-AGT-GGA-TCA3′) were purchased from IDT 
Integrated DNA Technologies (Leuven, Belgium). The expression level of these genes was evaluated by quantita-
tive RT-PCR (Light cycler, Roche Diagnostics, Basel, Switzerland) with the 2−∆∆Ct method, using ribosomal 18 S 
RNA as housekeeping control.
Protein extraction and Western blot analysis. Cytosolic protein was isolated from cells in lysis buffer 
A, containing Hepes (10 mM), KCl (10 mM), EDTA (0.1 mM), EGTA (0.1 mM), DTT (1 mM), PMSF (0.5 mM), 
Protease Inhibitor Cocktail (15 µL/mL; Sigma-Aldrich), Igepal CA-630 (0.5%; Sigma-Aldrich), pH 7.9. The sus-
pension was centrifuged, and the supernatant (cytosolic extract) was stored. Nuclear extracts were obtained by 
incubating the pellet obtained from the cytosolic extract in lysis buffer B, containing HEPES (20 mM), NaCl 
(0.4 M), EDTA (1 mM), EGTA (1 mM), DTT (1 mM), PMSF (0.5 mM), Protease Inhibitor Cocktail (15 µL/mL), 
pH 7.9. Protein concentration was determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). 
To determine specific protein contents, 20 µg of nuclear cell lysates were analyzed by immunoblotting using anti-
bodies against proliferating cell nuclear antigen (PCNA; 1:100; Santa Cruz Biotechnology INC, Dallas, TX, USA), 
Cyclin D1 (1:500; Cell Signaling Technology Inc., Danvers, MA, USA) and cleaved Notch 1 (Val1744) (1:200; Cell 
Signaling Technology) as primary antibodies, and horseradish peroxidase-conjugated goat anti-mouse (1:10000; 
Santa Cruz Biotechnology) and goat anti-rabbit (1:10000; Santa Cruz Biotechnology) as secondary antibodies. 
Transcription factor II B (TFIIB; 1:1000; Cell Signaling Technology) was used as loading control.
Alkaline phosphatase activity quantification. 2 µg of cytoplasmic cell lysates were incubated in 
p-nitrophenol phosphate (2 mM; Sigma-Aldrich) for 30 min at 37 °C. The reaction was stopped by adding NaOH 
(3 M), and alkaline phosphatase (ALP) activity was measured by quantifying absorption at 405 nm. ALP activity 
was expressed as µmol of hydrolyzed p-nitrophenol phosphate per min and per mg of protein versus undifferen-
tiated control cells.
Alizarin red S staining. Matrix mineralization was detected by alizarin red S staining. Cells were washed 
twice with PBS, fixed with para-formaldehyde (2%) and sucrose (1%) for 15 min and subsequently washed 3 times 
with PBS. Then, cells were stained with alizarin red S pH 4.1 (40 mM; Sigma-Aldrich) for 20 min, and washed 
4 times for 5 min with water at pH 7. Finally, water was removed and samples were dried at room temperature. 
Plates were scanned in a WIFI OKI Scanner (Madrid, Spain).
Immunofluorescence analysis. For immunofluorescence analysis cells were cultured upon glass covers-
lips in 6-well plates. After 14 days of treatment, cells were fixed with cold methanol for 20 min and subsequently 
washed with PBS. Fixed cells were incubated with the antibodies diluted in BSA (1%; Sigma-Aldrich) in PBS. 
Primary antibodies against cleaved Notch 1 (Val1744) (1:50) and β-catenin (1:75; BD Biosciences, San Jose, CA, 
USA) were incubated for 1 h at 4 °C. Subsequently, cells were washed with PBS and incubated with Alexa Fluor 
488 anti-mouse (1:500; Invitrogen Ltd., Paisley, UK) diluted in BSA (1%) in PBS. Cell nuclei were visualized with 
the nuclear dye 4′,6-diamino-2-phenylindole dihydrochloride (DAPI) (Invitrogen). Pictures were obtained at 
40X in Axio Observer Z1 Inverted Confocal microscope (LSM5 Exciter Zeiss, Jena, Germany). ImageJ software 
(National Institutes of Health, Bethesda, MD, USA) was used to analyze the confocal images.
FGF23 secretion quantification. Supernatants from cultures were collected and pooled, and intact fibro-
blast growth factor 23 (FGF23) secretion was determined by using a specific ELISA kit (Kainos Laboratories, 
Tokyo, Japan).
Rat femurs decellularization and scaffolds preparation. Bone scaffolds were obtained as it has been 
previously reported by Shahabipour29. Briefly, rat femurs and tibiae were cut longitudinally in 5 mm pieces. 
Subsequently, bone pieces were boiled 4 times for 5 minutes to remove fat tissues. Pieces were stored overnight at 
−20 °C before decellularization. Bone specimens were thawed at room temperature, washed with PBS and placed 
in liquid nitrogen for 2 minutes. Then, pieces were maintained in distilled water at room temperature and washed 
with PBS. The freeze-thaw process was repeated five times to lysate the cells. Bone scaffolds were decellularized 
in SDS (2.5%) for 24 hours at 37 °C with gentle shaking. Then, bone specimens were washed with PBS twice for 
15 minutes to remove SDS, washed in ethanol (70%) and maintained in PBS for 30 minutes with shaking at room 
temperature.
Scanning Electron Microscope (SEM). Decellularized bone fragments were cut in small pieces and 
washed in buffer solution for 15 minutes to remove debris. Then samples were kept in glutaraldehyde (2.5%). 
Decellularized bones without addition of MSC were also analyzed to ensure the decellularization process. Bone 
scaffolds were mounted on the SEM specimen stubs with carbon tape and were carbon-coated. Samples were 
analyzed and photographed with a Hitachi S520 SEM (Tokyo, Japan).
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Transmission Electron Microscope (TEM). Bone marrow MSC were cultured in the presence of differ-
ent concentrations of MgCl2 (0.8, 1.2 and 1.8 mM) on rat femur scaffolds. After 21 days of culture, the cellular 
layer was removed from the surface of the bone scaffolds and they were analyzed by electronic microscopy. For 
the ultrastructural study, randomly selected samples of decellularized bone scaffolds were primarily fixed in a 
glutaraldehyde (2%) solution in phosphate buffer (0.1 M) pH 7.4 overnight at 4 °C and then re-fixed in osmium 
tetroxide (1%) in phosphate buffer (0.1 M) pH 7.4 for 30 minutes. After dehydration in graded ethanol series and 
embedding in araldite, semi-thin and ultra-thin sections were cut with a LKB ultramicrotome. Ultra-thin sections 
were viewed and photographed in a Philips CM10 transmission electron microscope.
Statistical analysis. Differences between means for three or more groups were assessed by T-test. A 
P-value < 0.05 was considered significant. Statistical analyses were performed with the assistance of GraphPad 
Prism version 6.1 software (GraphPad Software, Inc., La Jolla, CA, USA).
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Dietary magnesium supplementation
prevents and reverses vascular and soft
tissue calcifications in uremic rats
see commentary on page 1034
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Although magnesium has been shown to prevent vascular
calcification in vitro, controlled in vivo studies in uremic
animal models are limited. To determine whether dietary
magnesium supplementation protects against the
development of vascular calcification, 5/6 nephrectomized
Wistar rats were fed diets with different magnesium
content increasing from 0.1 to 1.1%. In one study we
analyzed bone specimens from rats fed 0.1%, 0.3%, and
0.6% magnesium diets, and in another study we evaluated
the effect of intraperitoneal magnesium on vascular
calcification in 5/6 nephrectomized rats. The effects of
magnesium on established vascular calcification were also
evaluated in uremic rats fed on diets with either normal
(0.1%) or moderately increased magnesium (0.6%) content.
The increase in dietary magnesium resulted in a marked
reduction in vascular calcification, together with improved
mineral metabolism and renal function. Moderately
elevated dietary magnesium (0.3%), but not high dietary
magnesium (0.6%), improved bone homeostasis as
compared to basal dietary magnesium (0.1%). Results of
our study also suggested that the protective effect of
magnesium on vascular calcification was not limited to its
action as an intestinal phosphate binder since magnesium
administered intraperitoneally also decreased vascular
calcification. Oral magnesium supplementation also
reduced blood pressure in uremic rats, and in vitro medium
magnesium decreased BMP-2 and p65–NF-kB in TNF-a–
treated human umbilical vein endothelial cells. Finally, in
uremic rats with established vascular calcification,
increasing dietary magnesium from 0.1% magnesium to
0.6% reduced the mortality rate from 52% to 28%, which
was associated with reduced vascular calcification. Thus,
increasing dietary magnesium reduced both vascular
calcification and mortality in uremic rats.
Kidney International (2017) 92, 1084–1099; http://dx.doi.org/10.1016/
j.kint.2017.04.011
KEYWORDS: dietary magnesium; hypertension; mineral metabolism; phos-
phate binder; vascular calcification
Copyright ª 2017, International Society of Nephrology. Published by
Elsevier Inc. All rights reserved.
T
he role of magnesium (Mg) in the prevention of
cardiovascular disease (CVD) is a subject of growing
interest. The American Medical Association has
included recommendations on Mg intake to prevent CVD.1
Epidemiologic, prospective, and recent meta-analysis studies
have favorably associated Mg intake with a decreased risk of
CVD.2–6 Taking into account the pleiotropic effects of Mg,
several plausible mechanisms have been proposed to explain
its cardiometabolic benefits, including its effects on
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inflammation, lipid metabolism, and endothelial function.4 In
animal studies, Mg deficiency accelerated atherosclerosis,
while Mg supplementation suppressed its development.7
CVD, particularly the development of vascular calcification
(VC), is a major cause of morbidity and mortality in patients
with chronic kidney disease (CKD). Experimental and clinical
studies have shown that high serum phosphate (P) is a critical
factor in the development of VC8 and CKD.9,10 Phosphate
binders are used to control serum P in uremic patients, and
Mg-containing phosphate binders have been shown to be
effective.11,12
Recent data show a clear association between low serum
Mg levels and mortality in CKD patients.13 Also, serum Mg
concentrations have been inversely associated with cardio-
vascular events in CKD.14 In nondiabetic hemodialysis pa-
tients, hypomagnesemia is associated with VC of hand
arteries independently of the serum concentration of calcium
(Ca) and P.15 Mitral annular calcification and an increase in
carotid intima-media thickness were strongly associated with
low Mg values in hemodialysis patients.16,17 Conversely, a
moderate increase in serum Mg may have beneficial effects on
VC and mortality rates in CKD patients. Long-term Mg
supplementation has been reported to reduce carotid intima-
media thickness and may retard progression of vascular
disease.18
We and others have shown in in vitro studies that Mg
reduces calcification of vascular smooth muscle cells
(VSMCs) cultured in high-P medium19–22 and also decreases
hydroxyapatite crystal growth.23 Inhibition of Mg transport
into cells prevents the protective effect of Mg on VSMC
calcification, indicating that Mg is taken up by the cells and
exerts its beneficial effect through active intracellular pro-
cesses. In vivo, Mg may also protect against VC by decreasing
serum P.16 Furthermore, Mg modulates metabolic de-
rangements associated with uremia such as insulin resistance
and oxidative stress, both of which have been shown to
enhance VC in rats with renal failure.24
Controlled in vivo studies addressing the influence of di-
etary Mg on uremic VC are lacking. Moreover, changes in
mineral metabolism parameters elicited by Mg supplemen-
tation have not been described in detail in the uremic setting.
Our study was aimed at investigating the effect of different
levels of dietary Mg intake on the prevention and treatment of
VC in uremic rats. In addition, we analyzed bone effects of
Mg supplementation and also evaluated whether the effects of
Mg are dependent on its effect as a phosphate binder. To
address these objectives, an experimental model of 5/6 ne-
phrectomy in Wistar rats was used because it resembles the
mineral abnormalities associated with uremia.
RESULTS
Experiment 1: effect of dietary Mg intake on the development
of VC
Parameters of mineral metabolism. The first part of the
study was designed to assess the effect of different dietary Mg
intake on the prevention of VC in uremic rats (Figure 1). The
body weights of all groups before 5/6 nephrectomy and sham
operation were not different. At killing, body weight in the
sham group was greater than that in the nephrectomy groups,
but among nephrectomy groups body weight did not differ.
The results of serum biochemistry in the study groups are
shown in Table 1. As expected, the concentration of serum
creatinine was increased in nephrectomized rats compared
with sham-operated rats. Among nephrectomized rats, serum
creatinine was greatest (P < 0.05) in rats ingesting the lowest
(normal) Mg diet (0.1%). Nephrectomized rats fed Mg 0.1%
had higher serum Mg levels than sham-operated rats fed Mg
0.1% (P < 0.05). Among nephrectomized rats, a progressive
increase in serum Mg concentration was observed as dietary
Mg was increased from 0.1% to 1.1%. Serum P was greater in
nephrectomized than in sham-operated rats (P < 0.05). In
nephrectomized rats, serum P was greatest in rats on the Mg
0.1% diet. As expected, nephrectomized rats showed a decrease
in ionized calcium (iCa) concentration that was accentuated by
the Mg 0.1% diet, which also had the highest value of serum P.
In nephrectomized rats the elevated parathyroid hormone
(PTH) values progressively decreased as dietary Mg was
increased from 0.1% to 0.9%, at which point normal PTH
values were observed. Serum calcitriol values were decreased in
nephrectomized rats compared with sham-operated rats and
were similar among nephrectomy groups with different intakes
of Mg. Fibroblast growth factor 23 (FGF23) values were greater
in nephrectomized than in sham-operated rats; however,
among nephrectomized rats, the pattern of FGF23 increase as
dietary Mg was increased was not uniform.
Urine Ca, P, and Mg concentrations were corrected for
urine creatinine (Table 2). Creatinine clearance (CrCl) was
greater in the 5/6 nephrectomy groups that received Mg
Figure 1 | Experimental design. (See text for details.) CTR, calcitriol;
Mg, magnesium; Nx 5/6, 5/6 nephrectomy; P, phosphate.
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supplementation compared with those that did not (Table 1).
In rats fed Mg 0.6%, 0.9%, and 1.1%, CrCl was similar and
significantly greater than 0.3%, which in turn was greater
than in rats on Mg 0.1%. Urinary Ca was greater in the Mg
1.1% group than in the rest of the nephrectomized rats. Urine
P and the fractional excretion of P were greatest in the
nephrectomy plus Mg 0.1% and nephrectomy plus Mg 0.3%
groups, which had the highest PTH values. The fractional
excretion of P was also greater in the nephrectomy plus Mg
groups than in the Mg 0.1% sham group. Urine Mg excretion
was less in the nephrectomy plus Mg 0.1% group than in the
sham plus Mg 0.1% group. Urine Mg excretion was increased
in the nephrectomy plus 0.3%, 0.6%, and 0.9% Mg groups,
which also had the highest serum Mg values.
Tissue Ca and P content. Tissue Ca and P were evaluated
both by direct measurement and histology (Figure 2). The Ca
content of the aorta in nephrectomized rats fed a Mg 0.1%
diet (13.6  2.2 mg/g tissue) was more than 80 times greater
than in sham-operated rates fed a Mg 0.1% diet (Figure 2a).
In nephrectomized rats, the change from 0.1% to Mg 0.3%
was associated with a 15-fold reduction in the Ca content in
the aorta (1.06  0.31 mg/g tissue). The increase in aortic P
content after nephrectomy was even greater, with values of
37.8  6.8 mg/g tissue in nephrectomized rats on a Mg 0.1%
diet compared with 0.04  0.02 mg/g in sham-operated rats
(Figure 2b). The decrease in aortic P content with an increase
in Mg intake was similar to the reduction observed in Ca.
Moreover, in the nephrectomy groups, an increase in dietary
Mg intake from 0.3% to 0.6% reduced the aortic Ca and P
content to levels similar to sham-operated rats. Histological
staining for CaP showed widespread distribution of CaP in
the aorta in the nephrectomy plus Mg 0.1% group. Increasing
dietary Mg in the nephrectomy groups essentially prevented
CaP deposition as assessed by histology (Figure 2c). The
osteochondrogenic markers Runx2 (Figure 2d) and BMP-2
(Figure 2e) were significantly increased in the nephrectomy
plus Mg 0.1% group compared with sham-operated animals.
The expression of these markers decreased significantly after
14 days with 0.3% and 0.6% dietary Mg supplementation.
Calcification in the stomach was similar to that seen in the
aorta. In nephrectomized rats on the Mg 0.1% diet, stomach
Ca content was 2.3  0.4 mg/g tissue, whereas on the Mg
0.3% diet, the Ca content was only 0.06  0.01 mg/g tissue.
Values for the stomach content of P paralleled those of Ca. An
additional increase in dietary Mg intake did not further
reduce Ca deposition in the stomach (Supplementary
Figure S1).
With respect to bone status, Figure 3 shows that compared
with sham-operated rats, uremic rats fed Mg 0.1% presented
a decrease in bone volume and an increase in osteoid volume,
osteoid surface, osteoid thickness, osteoblasts, and osteoclast
surface. Increasing Mg supplementation to 0.3% significantly
changed some bone parameters, reducing osteoid volume and
osteoid surface compared with rats on the Mg 0.1% diet and
Table 1 | Experiment 1: effect of dietary magnesium on the development of aortic calcification (mean ± SEM)
Parameter
Sham D Mg 0.1%
(n [ 10)
Nx D Mg 0.1%
(n [ 14)
Nx D Mg 0.3%
(n [ 10)
Nx D Mg 0.6%
(n [ 10)
Nx D Mg 0.9%
(n [ 10)
Nx D Mg 1.1%
(n [ 10)
Body weight (g) 306  34.9 235  40.6a 242  20.2a 236  31.1a 233  31.1a 226  19.5a
Creatinine (mg/dl) 0.41  0.06 1.71  0.2a 1.11  0.12a,b 1.10  0.16a,b 1.04  0.06a,b 1.20  0.2a,b
Magnesium (mg/dl) 2.14  0.09 2.97  0.3a 2.98 0.2a,b 3.31  0.4a,b 4.43 0.4a,b 4.58  0.4a,b
Phosphate (mg/dl) 6.5  0.3 10.7  1.4a 8.0  0.8a,b 7.9  0.9a,b 7.9  0.5a,b 7.8  0.4a,b
Ionized calcium (mM) 1.20  0.01 1.07  0.03a 1.19  0.02b 1.13  0.03a,b 1.16  0.02a,b 1.18  0.02b
PTH (pg/ml) 21  7 529  171a 401  170a 79  46a,b 23  17b 29  7b
Calcitriol (pg/ml) 318  29 110  23a 120  25a 89  25a 125  32a 143  18a
FGF23 (pg/ml) 218 (147) 10,0311 (158105)c 783 (814)c,d 16,253 (9121)c,e 20,546 (5437)c,e 5740 (6001)c,e
FGF23, fibroblast growth factor 23; Mg, magnesium; Nx, nephrectomy; PTH, parathyroid hormone.
aP < 0.05 versus sham þ Mg 0.1%.
bP < 0.05 versus Nx þ Mg 0.1%.
cP < 0.01 versus sham plus Mg 0.1%.
dP < 0.01 versus Nx plus Mg 0.1%.
eP < 0.05 versus Nx plus Mg 0.1%.
Table 2 | Experiment 1: effect of dietary magnesium on the development of aortic calcification, urine chemistry in the study
groups (see text for details)
Parameter Sham D Mg 0.1% Nx D Mg 0.1% Nx D Mg 0.3% Nx D Mg 0.6% Nx D Mg 0.9% Nx D Mg 1.1%
Creat. clearance 3.25  0.30 0.57  0.11a 0.68 0.14a 1.16  0.21a,b 1.63  0.22a,b,c 1.13  0.13a,b
Ca-to-creat. ratio 0.05  0.01 0.11  0.07 0.18  0.03 0.15  0.04 0.15  0.04 0.35  0.12a,b
P-to-creat. ratio 0.68  0.06 6.12  0.83a 6.11  0.70a 3.47  0.44b 1.97  0.30b 2.40  0.64b
Mg-to-creat. ratio 1.04  0.10 0.45  0.06a 1.48  0.16a,b 1.72  0.25a,b 1.86 0.20a,b N/A
Frac. excretion of P (%) 4.9  0.80 95.0  17.2a 86.5  7.1a 44.8  6.0 (ab) 21.7  3.4a,b 36.4  12.7a,b
Ca, calcium; creat., creatinine; frac., fractional; Mg, magnesium; N/A, not applicable; Nx, nephrectomy; P, phosphate.
aP < 0.05 versus sham plus Mg 0.1%.
bP < 0.05 versus Nx plus Mg 0.1%.
cP < 0.05 versus Nx plus Mg 0.3%.
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Figure 2 | Effect of dietary magnesium (Mg) intake on the development of aortic calcification. (a) Aortic calcium (Ca) content in the study
groups. (b) Aortic phosphate (P) content in the study groups. (c) von Kossa–stained sections from the study groups. Levels of mRNA (d)
Runx2 and (e) bone morphogenetic protein 2 (BMP-2) in the aortas of sham-operated animals and uremic rats with different Mg content in
the diet. aP < 0.001 versus sham group; bP < 0.01 versus sham group; cP < 0.05 versus sham group; dP < 0.001 versus all groups; þþþP < 0.001
versus Mg 0.1%. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. To optimize viewing of this image, please see the online version of
this article at www.kidney-international.org.
JM Diaz-Tocados et al.: Mg prevents vascular calcification bas i c re sea r ch
Kidney International (2017) 92, 1084–1099 1087
with a lesser osteoid thickness. However, the number of
osteoclasts was similar to that of uremic rats with Mg 0.1%. A
higher dietary content of Mg (0.6%) maintained the high
number of osteoblasts despite the marked reduction in PTH
levels, and the osteoid volume increased to the same level as
in rats fed Mg 0.1%. Osteoclasts were reduced to the same
level as sham-operated rats. Figure 4 shows Goldner’s
trichrome stain with representative bone samples of each
experimental group. These changes are also observed in bone
histological staining (Figure 4).
Effect of Mg on vascular calcification independent of the
serum phosphate. To evaluate whether the beneficial effect
of Mg on VC was exclusively due to phosphate binding or a
direct effect of Mg, we compared VC in nephrectomized rats
fed a diet containing high P plus Mg supplementation versus
normal P and no Mg supplement (P 1.2% þ Mg 0.6% vs. P
0.7% þ Mg 0.1%). The objective was to obtain rats with the
same reduction in serum P without the addition of Mg. The
results showed that a reduction in dietary P produced a
decrease in serum P concentration that was similar to that
obtained by Mg supplementation (0.6%) (Figure 5a). Despite
similar serum P, the content of Ca and P in the aorta was
significantly less in the group of rats fed P 1.2% þ Mg 0.6%
than P 0.7% þ Mg 0.1% (Figure 5b and c). These
results suggest that Mg may have a direct protective effect
against VC.
Whether the benefit of Mg supplementation was only due
to P binding was further evaluated by analysis of data pre-
sented in the previous experiments. In this secondary analysis
in nephrectomized rats with similar elevation in serum P
concentration, the degree of VC reduced by dietary Mg was
assessed. Among rats with dietary Mg supplementation, only
rats with serum P concentration within the 50th to 95th
percentile were selected (7.28–12.86 mg/dl). These rats were
compared with rats on Mg 0.1% with the same range of
serum P concentration. By design, the mean serum P was
high and similar for all groups (Figure 6a). The Ca and P
contents in the aorta were significantly reduced in rats
receiving Mg supplementation in the diet (Figure 6b and c).
These data provide supporting evidence that dietary Mg
supplementation reduced VC by other mechanisms besides
the reduction of the serum P levels.
Figure 3 | Effect of dietary magnesium (Mg) supplementation on bone homeostasis. Bone histomorphometric analysis of distal femurs.
(a) Bone volume to tissue volume (BV/TV). (b) Osteoid volume–to–bone volume ratio (OV/BV). (c) Osteoid surface–to–bone surface ratio
(OS/BS). (d) Osteoid thickness (O.Th). (e) Osteoblast surface–to–bone surface ratio (Ob.S/BS). (f) Osteoclast surface–to–bone surface ratio
(Oc.S/BS). aP < 0.05 versus sham; bP < 0.05 versus Mg 0.1%; and cP < 0.05 versus Mg 0.3% .
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Finally, to demonstrate the effect of Mg independent of its
phosphate binder action we administered Mg i.p. in
our model of vascular calcification. Compared with
vehicle-treated rats, rats receiving i.p. Mg had higher serum
Mg concentration, comparable to that obtained by oral
loading (diet containing Mg 0.6%). The addition of parenteral
Figure 4 | Histological slides of trabecular distal femurs stained with Goldner’s trichrome stain. (a) Sham. (b) 5/6 nephrectomy (Nx 5/6) þ
phosphate (P) 1.2% þ calcitriol (CTR) þ magnesium (Mg) 0.1%. (c) Nx 5/6 þ P 1.2% þ CTR þ Mg 0.3%. (d) Nx 5/6 þ P 1.2% þ CTR þ Mg 0.6%.
Green: calcified bone; red: osteoid. Original magnification 200. To optimize viewing of this image, please see the online version of this
article at www.kidney-international.org.
Figure 5 | Effect of dietary magnesium (Mg) on vascular calcification independent of phosphate (P), part 1. Levels of (a) serum P,
(b) aortic calcium (Ca), and (c) aortic P in 5/6-nephrectomized rats with low P in the diet (P 0.7% þ Mg 0.1%) versus dietary Mg supplementation
with high P (P 1.2% þ Mg 0.6%). aP < 0.05 versus 5/6-nephrectomized rats with low P in the diet. Mean serum P levels in sham animals
were 6.5  0.3 mg/dl, not statistically different in comparison with the other groups.
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Mg did not significantly modify serum phosphate, ionized
calcium, or serum creatinine (Table 3). I.p. administration of
MgSO4 significantly reduced aortic content of calcium
(Figure 7a) and phosphate (Figure 7b). This is also shown by
von Kossa staining (Figure 7c).
Changes in blood pressure. Blood pressure (BP) values
measured in sham-operated and nephrectomized rats on P
1.2% þ Mg 0.1% or P 1.2% þ Mg 0.6% diets are shown in
Figure 8. Independent of diet, nephrectomized rats had
higher BP than did sham-operated rats. Among nephrec-
tomized rats, the higher-Mg diet resulted in significantly
lower values of both systolic and diastolic BP.
Experiment 2: Effect of dietary Mg intake on progression
of VC
The second part of the study was designed to determine
whether in nephrectomized rats on a normal Mg diet (0.1%)
with established VC the progression of VC could be halted or
even reversed by increasing the dietary Mg intake (Figure 1).
Survival rates in rats with calcification during the 42 days of
Mg supplementation are shown in Figure 9. At day 28,
mortality rate in rats fed Mg 0.1% was greater than 50% (11
of 21), while the mortality rate in rats on the Mg 0.6% was
only 28% (5 of 18; P < 0.04) (Figure 9a). By day 42, none of
the rats fed Mg 0.1% survived (0 of 3); by contrast, 75% of
the rats (3 of 4) fed Mg 0.6% were alive at day 42 (P < 0.03)
(Figure 9b).
Blood chemistry from rats at days 14 and 28 is shown in
Table 3. At day 28, serum Mg levels remained unchanged in
rats fed a normal-Mg diet, but they were increased in rats fed
Mg 0.6%: 3.1  0.2 mg/dl versus 2.3  0.2 mg/dl (P < 0.05).
From days 14 to 28, in rats fed Mg 0.1%, the serum Ca
decreased, and both PTH and serum P increased (Table 4). In
rats fed Mg 0.6%, the serum iCa, PTH, and P did not change
from days 14 to 28.
At day 28, the aortic Ca content was significantly lower in
rats receiving Mg 0.6%, (7  0.9 mg/g tissue) than in rats fed
Mg 0.1%(14.9  1.9 mg/g tissue). Furthermore, the aortic Ca
content observed at day 28 in the rats fed a high-Mg diet (7 
0.9 mg/g tissue) was also significantly lower than at day 14:
14.3  2.1 mg/g tissue, indicating that higher dietary Mg
intake not only halted but also reversed VC (Figure 10a).
The aortic P content showed the same trend as aortic Ca;
the values in the group on a high-Mg diet at day 28
were lower than in the Mg 0.1% group at days 14 and 28
Figure 6 | Effect of dietary magnesium (Mg) on vascular calcification independent of phosphate (P), part 2. Levels of (a) serum P,
(b) aortic calcium (Ca), and (c) aortic P in 5/6-nephrectomized rats with different dietary Mg supplementation and with serum P ranging from
mean to 95th percentile. aP < 0.05 versus all groups.
Table 3 | Biochemical parameters related to the effect of
MgSO4 i.p. on renal function and vascular calcification
Parameter Sham D Mg 0.1% Nx D veh Nx D MgSO4
Magnesium (mg/dl) 2.4  0.09 2.8  0.29 3.4  0.59a,b
Phosphate (mg/dl) 4.95  0.51 9.74  1.13a 8.25  1.15a
Ionized calcium (mmol/l) 1.20  0.028 1.07  0.099a 1.05  0.039a
Creatinine (mg/dl) 0.43  0.016 0.88  0.211a 1.04  0.229a
Mg, magnesium; Nx, nephrectomy; veh, vehicle.
aP < 0.05 versus sham plus Mg 0.1%.
bP < 0.05 versus Nx plus veh.
bas i c re sea r ch JM Diaz-Tocados et al.: Mg prevents vascular calcification
1090 Kidney International (2017) 92, 1084–1099
(37.8  4.23 mg/g tissue and 51  6.5 mg/g tissue, respec-
tively) (Figure 10b). Results of von Kossa–stained sections of
the aorta were consistent with mineral quantification. Thus,
marked deposition of brown-stained pigments were evident
in the rats fed normal Mg, while the rats fed high Mg showed
a staining that was less marked than both with Mg 0.1% in the
diet at 14 or 21 days (Figure 10c).
The beneficial effect of higher dietary Mg intake on tissue
calcification was also evident in the stomach and lung
(Figure 11). An increase in dietary Mg resulted in significantly
lower Ca content in both the lung (1.3  0.2 vs. 10.4  3.4
mg/g tissue) and the stomach (2.6  0.4 vs. 9.3  1.4 mg/g
tissue). After supplementation with Mg, the P content in the
stomach and lung changed in parallel with Ca.
As reported above, 3 of the 4 rats alive in the high-Mg
group at day 28 remained alive at day 42. The biochemical
profile (creatinine, iCa, and Mg) of these 3 surviving rats was
similar to that of the rats on high Mg at day 28, but they had
significantly lower serum P (6.2  0.7 mg/dl) and PTH (12 
3 pg/ml). Aortic calcification in these rats was similar to the
values found at day 28 (7.4  2.1 mg/g tissue). Notably, both
gastric Ca (0.4  0.2 mg/g tissue) and pulmonary Ca (0.6 
0.1 mg/g tissue) were much lower at day 42 than at day 28
(2.6  0.4 mg/g tissue).
In vitro studies
As shown in Figure 12, stimulation of human umbilical vein
endothelial cells (HUVECs) with tumor necrosis factor alpha
(TNF-a) increased both mRNA (Figure 12a) and protein
expression of bone morphogenetic protein 2 (BMP-2)
(Figure 12b). Treatment with Mg resulted in a dose-
dependent decrease in mRNA and protein expression of
BMP-2 in HUVECs exposed to TNF-a. Changes in the nu-
clear p65 fragment of NF-kB paralleled those of BMP-2
(Figure 12b).
DISCUSSION
The results from the present study in uremic rats demonstrate
that dietary Mg supplementation reduces VC and other soft
tissue calcification. We found that high dietary Mg in 5/6-
nephrectomized rats produced a significant decrease in
serum P and PTH that only partially explains the reduction of
VC; for the same level of serum P, VC was significantly
reduced in Mg-supplemented rats. The beneficial effects of
Mg on VC are partly mediated by an effect independent of its
Figure 7 | Effect of i.p. administration of magnesium (Mg) on vascular calcification. (a) Calcium (Ca) and (b) phosphate levels in aortic
tissue, respectively, in sham-operated þ Mg 0.1% rats, 5/6-nephrectomized (Nx) rats on a diet containing 1.2% P and 0.1% Mg with calcitriol
replacement and receiving vehicle (Nx þ Veh), and Nx þ MgSO4 (vehicle þ MgSO4 i.p., 30 mg/kg body weight). (c) von Kossa staining from
aortas. aP < 0.001 versus sham; þþP < 0.01 versus Nx þ Veh. To optimize viewing of this image, please see the online version of this article at
www.kidney-international.org.
Figure 8 | Changes in blood pressure. Values in mm Hg of systolic
blood pressure, diastolic blood pressure, and mean arterial pressure
(MAP) in the 5/6 nephrectomy þ phosphate 1.2% þ calcitriol þ
magnesium 0.1% group (Mg 0.1%, black bars), the 5/6
nephrectomy þ phosphate 1.2% þ calcitriol þ magnesium 0.6%
group (Mg 0.6%, white bars), and the healthy rat group (sham, gray
bars). aP < 0.001 and bP < 0.01 versus Mg 0.1% group.
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phosphate binder action. Moderate (0.3%) but not higher
(0.6%) supplementation of Mg had a positive effect on bone
histomorphometry. Improvement in VC was also associated
with a reduction in BP and protection of renal function.
Moreover, in uremic rats that had developed VC, the addition
of Mg to the diet appeared to decrease calcifications and
mortality.
In nephrectomized rats on a normal Mg 0.1% diet, CrCl
was lower than in nephrectomized rats fed higher Mg con-
centrations. Hyperphosphatemia with marked vascular and
soft-tissue calcification probably contributed to the wors-
ening of renal failure. Increasing dietary Mg to 0.3% resulted
in a lower serum P and the virtual elimination of aortic and
stomach calcification, and this was associated with better
control of renal function. Further increases in dietary Mg
intake progressively decreased PTH, with eventual normali-
zation of its values. In the nephrectomy plus Mg 0.6% group,
normalization of PTH was observed even though mild
hyperphosphatemia persisted. Dietary Mg supplementation
reduces P absorption, which is a key factor for control of
hyperparathyroidism; in addition, there is a direct inhibitory
effect of Mg on parathyroid cell function.25–28 We are not
aware of any previous study resulting in a marked reduction
in PTH by Mg loading or hypermagnesemia in uremic ani-
mals with secondary hyperparathyroidism enhanced by P
loading. The hyperphosphatemia should have been reduced
by the high dietary Mg intake because Mg is an effective P
binder.29,30 The increase in serum iCa concentration in rats
ingesting Mg supplements may be explained by the reduction
in serum P concentration, which increases the calcemic effect
of PTH.31,32 Furthermore, with dietary Mg supplements bone
resorptive activity is maintained despite the reduction in PTH
levels. Finally, it should be considered that with oral Mg,
there is a chelant effect on phosphate increasing calcium
availability that in the presence of calcitriol might promote its
absorption. Moreover, this concept is also supported by the
data in Table 3, which demonstrate that serum phosphate was
not reduced by i.p. magnesium and iCa remained decreased.
Serum calcitriol values were lower in nephrectomized than in
sham-operated rats, but were not different among nephrec-
tomized rats. As such, calcitriol should not have resulted in
differences in intestinal Mg, Ca, and P absorption and PTH
and FGF23 values. In nephrectomized rats, FGF23 values
were much greater than in sham-operated rats, but among
nephrectomized rats, no discernible reason could be ascer-
tained for the wide variation in FGF23 values.
Our data show an inverse association between soft-tissue
calcification and creatinine clearance. Calcification was
reduced by the Mg 0.3% diet, and this was associated with
improvement in renal function. Further increase in dietary
Mg had limited additional beneficial effect on calcification,
but it improved renal function. This suggests that the bene-
ficial effect of Mg on renal function may not be fully
Figure 9 | Kaplan–Meier curves of survival in uremic rats with
calcifications fed normal (0.1%) or moderately high (0.6%)
magnesium (Mg) diets. (a) Survival at 14 to 28 days in the 5/6
nephrectomy þ phosphate 1.2% þ calcitriol þ Mg 0.1% group (11 of
21 dead, continuous line) and 5/6 nephrectomy þ phosphate 1.2% þ
calcitriol þ Mg 0.6% group (5 of 18 dead, interrupted line). aP < 0.05.
(b) Survival from 28 to 42 days in the 5/6 nephrectomy þ phosphate
1.2% þ calcitriol þ Mg 0.1% group (continuous line) and the 5/6
nephrectomy þ phosphate 1.2% þ calcitriol þ Mg 0.6% group
(interrupted line). All rats on the Mg 0.1% diet (3 of 3) were dead at
this time, whereas 75% of rats on the Mg 0.6% diet survived (3 of 4;
P < 0.05).
Table 4 | Experiment 2: effect of dietary magnesium on
reversibility of aortic calcification, biochemical parameters in
the study groups at killing (see text for details)
Parameter Day 14
Day 28
Mg 0.1% Mg 0.6%
Magnesium (mg/dl) 2.4  0.17 2.3  0.25 3.1  0.23a,c
Ionized calcium (mmol/l) 1.22  0.04 1.06  0.06a 1.20  0.03c
PTH (pg/ml) 284  55 1401  312b 177  79c
Phosphate (mg/dl) 10.9  1.00 16.7  2.73b 11.3  0.01d
Creatinine (mg/dl) 1.9  0.15 1.8  0.2a 1.9  0.22
Mg, magnesium; PTH, parathyroid hormone.
aP < 0.05 versus day 0.
bP < 0.001 versus day 0.
cP < 0.05 versus Mg 0.1% at day 14.
dP < 0.01 versus Mg 0.1% at day 14.
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explained by the reduction in calcification. Recent studies by
Sakaguchi et. al10 show that an excess load of P has a negative
effect on renal function, and Mg directly protects the kidney
from the deleterious effect of high P. In our experimental rats,
dietary supplementation of Mg may have protected kidney
function through a reduction in intestinal absorption of P,
thus preventing a potential deleterious effect of high P on
renal tubular cells.
Two different methods were used to evaluate calcification
of the aorta and stomach: direct measurement of Ca and P
after tissue dissolution in formic acid and histological staining
for CaP. Both methods yielded similar results. In nephrec-
tomized rats fed Mg 0.1%, extensive calcifications were seen
in the aorta and stomach. If dietary Mg is increased to 0.3%
or higher, aortic and stomach calcifications were 20- to 40-
fold less than on the Mg 0.1% diet, and values were not
different from sham-operated rats. In addition, we also found
that dietary Mg supplementation prevented the expression of
an osteochondrogenic phenotype of VSMC induced by
uremia and a high-P diet (Figure 2d and e). Similar results
have been obtained in previous in vitro and animal studies in
which Mg inhibited calcification in VSMC.20,22,33,34 Clinical
studies have also suggested that Mg supplementation may
have a favorable effect on VC and disease.14,22 In vivo, it is
difficult to separate the direct effect of dietary Mg intake on
calcification from that on the reduction in serum P. However,
even though serum P was reduced in rats fed the
Mg-supplemented diets, high levels of serum phosphate
persisted even with the highest Mg diet.
In uremic rats fed P 1.2% and Mg 0.1%, serum PTH was
elevated and bone histology showed features of high bone
turnover. Bone histology appears to be improved with 0.3%
dietary Mg supplementation; osteoid accumulation was
reduced compared with that in rats fed Mg 0.1%, and bone
homeostasis improved. However, despite a marked reduction
on PTH in rats receiving the Mg 0.6% diet, osteoblast activity
was maintained while osteoclast activity was reduced. At the
same time, osteoid volume and thickness increased, suggest-
ing a decrease in mineralization activity. Moreover, these data
suggest a stimulating effect of high Mg on osteoblastogenesis
independent of PTH.
Moreover, regression of extraskeletal calcification was
observed in rats fed a high-Mg diet that had persistently
elevated serum P. In addition, comparison of rats with similar
serum P levels and fed different levels of dietary Mg showed
that the protective effect of dietary Mg on VC was not
exclusively due to the P-binding effect. For a similar serum P
concentration, more Mg in the diet was associated with less
vascular accumulation of Ca and P.
Results from our study with parenteral Mg administration
demonstrate that Mg reduces, in part, VC independently of its
actions as a phosphate binder. The experiments in which Mg
was administered parenterally provide compelling evidence of
a protective effect on VC independent of any phosphate-
binding actions. However, the reduction of VC was less
accentuated after Mg given i.p. than in the diet. Overall, it
seems that oral Mg supplementation offers advantages over
parenteral Mg administration because it combines direct and
Figure 10 | Effect of dietary magnesium (Mg) on reversibility of aortic calcification. (a) Aortic calcium (Ca) content at days 14 and 28 in rats
fed normal (0.1%) and moderately elevated (0.6%) Mg. (b) Aortic phosphate (P) content at days 14 and 28 in rats fed normal (0.1%) and
moderately elevated (0.6%) Mg. (c) von Kossa staining of the aorta at days 14 and 28 in rats fed normal (0.1%) and moderately elevated (0.6%)
Mg. eP < 0.01 versus all groups; **P < 0.01 versus Mg 0.1% at day 14; þþþP < 0.001 versus Mg 0.1% at day 28. To optimize viewing of this
image, please see the online version of this article at www.kidney-international.org.
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indirect (P-binding) effects; the administration of Mg i.p. did
not help to control serum P or Cr.
Our study also shows that in uremic rats, a high-P diet
promotes VC, which is associated with an increase in BP.
Dietary Mg supplementation was accompanied by a
reduction in BP that could be explained by the marked
diminution in VC. However, our experimental design does
not allow for the determination of whether the decrease in
BP is due to decreased VC, improved renal function, or
both. In addition, other mechanisms, such as a direct effect
of Mg on BP, cannot be excluded. There are a number of
studies showing an association between low serum Mg
concentration and hypertension.35,36 The effect of Mg
supplementation on hypertension is controversial, and
clear evidence from randomized controlled clinical trials is
lacking.37
In vitro studies were performed to evaluate the protective
effects of Mg on VC independent of its phosphate-binder
action. Our results also support a beneficial effect of Mg
at the endothelial level. TNF-a–stimulated endothelial
microparticles, which are rich in BMP-2, have been shown
to enhance VSMC osteogenesis and calcification.38 Our
data, showing that exposure to Mg prevents the increased
expression of BMP-2 and p65–NF-kB by TNF-a, provides
an additional mechanism by which Mg may protect against
inflammation and VC. With respect to inflammation, the
decrease of p65–NF-kB induced by Mg suggests an anti-
inflammatory effect, which could be also related to less
VC. Other groups have shown in vivo39 and in vitro40 that
Mg supplementation also decreases NF-kB levels.
In our study, the regression in VC promoted by Mg
occurred with a parallel decrease in serum biochemical
parameters related to secondary hyperparathyroidism. PTH
Figure 11 | Effect of dietary magnesium (Mg) on reversibility of
soft-tissue calcification. (a) Pulmonary mineral content at days 14
and 28 in rats fed normal (0.1%) and moderately elevated (0.6%) Mg.
(b) Gastric mineral content at days 14 and 28 in rats fed normal (0.1%)
and moderately elevated (0.6%) Mg. ***P < 0.001 versus Mg 0.1% at
day 14; *P < 0.05 versus Mg 0.1% at day 14; þþP < 0.01 versus Mg
0.1% at day 28; and þP < 0.05 versus Mg 0.1% at day 28.
Figure 12 | In vitro effect of magnesium (Mg) on human umbilical
vein endothelial cells (HUVECs) exposed to tumor necrosis factor
alpha (TNF-a). Stimulation of HUVECs with TNF-a increased both (a)
mRNA and (b) protein expression of BMP-2 and nuclear p65 fragment
from NF-kB. Treatment with Mg resulted in a dose-dependent
decrease in mRNA and protein expression of BMP-2 in HUVECS
exposed to TNF-a. ***P < 0.001 versus control; *P < 0.05 versus
control; þþP < 0.01 versus TNF-a; and #P < 0.05 versus TNF-a þ
Cl2Mg 1.4 mM. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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levels were significantly lower in rats at day 28 than day 14.
Partial regression of cardiac and pulmonary calcifications41
and complete resorption of abdominal soft-tissue
calcification42 have been described in hemodialysis patients
after parathyroidectomy. Thus, the marked suppression of
PTH observed in our uremic rats after dietary Mg supple-
mentation may have influenced VC regression. The
contribution of high PTH levels on vascular and
coronary calcifications in uremic rats has been described by
Neves et al.43
In addition to improving the parameters of mineral
metabolism, Mg could also have promoted regression of VC
by direct mechanisms. Although the mechanistic pathways
involved in a regression of VC are not fully understood, a
Ca-sensing receptor–mediated effect has been postulated in a
study with calcimimetics.44 Mg is able to interact with
Ca-sensing receptor; it may share some common mechanisms
with calcimimetics in its capacity to prevent VC.28 Urinary Ca
excretion as assessed by Ca-to-Cr ratio tended to increase in
rats with dietary Mg supplementation, and it reached statis-
tical difference in the group of rats receiving the highest
percentage of Mg in the diet (1.1%). In this group of rats,
PTH was low and tubular reabsorption of Ca was likely
reduced as a result. In addition, there are clinical and
experimental data suggesting that Mg load reduces distal
tubular reabsorption of Ca through TRPV5.45
Our study shows for the first time that dietary Mg intake is
able to reverse already-established vascular and soft-tissue
calcifications. Certainly, the data suggest that a 0.6% Mg
diet may reverse VC. However, it should be emphasized that
VCs were not measured in the same rats. Therefore, with this
experiment a definite reversal of VC cannot be demonstrated.
The experimental rat model has limitations, especially the
short period of time to achieve vascular and soft-tissue
calcifications; however, the model reproduces with precision
the changes in renal function, mineral metabolism, hyper-
tension, and VC observed in patients with advanced renal
failure. Despite the severity of the process, moderate dietary
Mg supplementation was able to not only prevent the
development of VC but also halt its progression. The results
obtained in this model should help to generate hypotheses for
testing in prospective clinical trials. A noninterventional study
by Sakaguchi et al.13 showed that in hemodialysis patients,
hypomagnesemia was a significant predictor of mortality.
To date, there is not an effective therapeutic approach to
achieve VC regression. There have been previous reports in
the literature about the use of compounds and chelating
agents such as sodium thiosulfate to treat or slow the pro-
gression of calcifilaxis.46–48 Calcimimetics have also been
reported to be useful for the treatment of VC in animal
models.49 In the ADVANCE study, the administration of
cinacalcet plus low-dose vitamin D to hemodialysis patients
resulted in attenuation of VC.50 Serum P concentration also
decreases when using calcium-free P binders to treat VC; the
protective effect of sevelamer or lanthanum carbonate have
been widely described.51,52 Several studies in animal models
have shown that the use of bisphosphonates reduces arterial
calcifications in nephrectomized rats.53,54 Clinical studies in
CKD patients have also shown a beneficial effect of
bisphosphonates on VC.55 Although there is an association
between low Mg levels and CVD, a beneficial effect of Mg
supplementation has not been adequately tested in clinical
trials.56,57 The CALMAG study reported the efficacy of Ca and
Mg salts as a P binder in hemodialysis patients. De Francisco
et al. concluded that the administration of Mg had a good
tolerability profile, suggesting that Mg supplementation is
safe.30 Other clinical trials with Mg supplementation have
been performed in the context of type 2 diabetes58 and
depression,59 demonstrating the efficacy and safety of Mg
supplementation. Moreover, our study shows that the bene-
ficial effect of Mg was observed in rats on the most moderate
Mg-supplemented diet (0.3%).
In conclusion, we have shown that in 5/6-nephrectomized
rats, increased dietary Mg prevents and even reverses vascular
and other soft-tissue calcification, and has positive effects on
mineral metabolism parameters, BP, renal function, and
mortality. These beneficial effects of Mg are partly mediated
independently of its action as a phosphate binder.
METHODS
Animals
Healthy 9- to 10-week-old male Wistar rats without any genetic
modifications weighing 250 to 300 g were used. This strain was
chosen on the basis of its feasibility to reproduce CKD features.
Animals were purchased from Charles River (Wilmington, MA) and
individually housed in 33.5  56  19 cm cages with 450 cm2 floor
area per rat while applying a 12-hour light-dark cycle. Before
entering the study, rats were given ad libitum access to a standard
diet (Ca 0.8%, P 0.6%, and Mg 0.1%). Appropriate measures were
taken to ensure animal welfare and to address the basic behavioral
and physiological needs of rats. Killing was accomplished by aortic
puncture and exsanguination under general anesthesia (20 mg/kg
thiopental sodium i.p.). All experimental protocols were reviewed
and approved by the Ethics Committee for Animal Research of the
University of Cordoba, and all rats received humane care in
compliance with the guiding principles in the Guide for the Care and
Use of Laboratory Animals, Eighth Edition.
5/6 nephrectomy
Uremia was induced by 5/6 nephrectomy, a 2-step procedure that
reduces the original functional renal mass by five-sixths. On the basis
of our previous studies, animals were anesthetized using xylazine
(5 mg/kg i.p.) and ketamine (80 mg/kg i.p.). In the first step of the
nephrectomy, a 5- to 8-mm incision was made on the left medio-
lateral surface of the abdomen. The left kidney was exposed, and the
2 poles (two-thirds of renal mass) were ablated. The kidney was
inspected and returned to an anatomically neutral position within
the peritoneal cavity. The abdominal wall and skin incisions were
closed with sutures, and the rat was placed back into its home cage.
After 1 week of recovery, the animal was reanesthetized and a 5- to
8-mm incision was made on the right mediolateral surface of the
abdomen. The right kidney was exposed and unencapsulated, the
renal pedicle was clamped and ligated, and the kidney was removed.
The ligated pedicle was returned to a neutral anatomical position and
the abdomen and skin incisions closed with suture materials.
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Phentanyl (0.2 mg/kg) was used as an analgesic agent. An additional
group of nonuremic sham-operated rats that underwent the same
surgical manipulation without renal ablation was also studied.
Experimental design
The in vivo studies included 2 experiments: experiment 1 was
designed to study the effect of dietary Mg supplementation on
prevention of VC, and experiment 2 evaluated the effect of Mg on
reversibility of calcifications (Figure 1). Rats were randomly assigned
to different experimental groups to determine the effect of dietary
Mg on VC in rats with renal failure. The total number of animals
used was 108 in experiment 1 and 49 in experiment 2.
Experiment 1: effect of increasing dietary Mg intake on the
development of VC. One day after the second kidney surgery, rats
were fed a high-P diet (0.6% Ca and 1.2% P). The animals received
20 ng/48 h/rat i.p. calcitriol (Calcijex; Abbott, Madrid, Spain), to
control hyperparathyroidism and favor VC. Rats were randomly
divided into groups (n ¼ 10–14) that were fed diets with differing
Mg contents: 0.1%, 0.3%, 0.6%, 0.9%, and 1.1% for 14 days. Sham-
operated rats receiving a normal diet containing 0.1% Mg and 0.6%
P and without calcitriol administration were used as controls. All
animal feed was purchased from Altromin Spezialfutter (Lage,
Germany). Mg was added as magnesium carbonate.
Because the addition of Mg to the diet resulted in a reduction in
serum P, an additional protocol was designed to evaluate the separate
effects of dietary Mg and serum Pon VC. The objective was to analyze
aortic mineral content in rats with the same reduction in serum Pwith
and without the addition of dietary Mg. Additional experimental rats
were treated as in the previous experimental groups (with same dose of
calcitriol), but these rats were fed diets with a different P and Mg
content (a 5/6 nephrectomy group on a diet containing P 0.7% andMg
0.1% and a 5/6 nephrectomy group on a diet containing P 1.2% and
Mg 0.6%). Animals were placed in metabolic cages 3 days before
killing to collect 3 24-hour urine samples. After 2 weeks, all rats were
killed 24 hours after having received the last dose of calcitriol.
Following killing, the thoracic aorta and stomach were removed and
stored to measure Ca and P content.
An additional experiment was performed to evaluate the effect of
Mg given parenterally on vascular calcification. This experiment was
conducted to determine the effect of Mg independent of its
phosphate-binding action. The 5/6-nephrectomized rats on 1.2% P
diet and calcitriol replacement received 30 mg/kg MgSO4 diluted in
5% dextrose (n ¼ 10) or vehicle (n ¼ 10) over 14 days. MgSO4 was
administered every 12 hours to maintain constant high levels of
serum Mg. Rats in the control group following the same protocol
received vehicle (dextrose). At the end of the experiment, animals
were placed in metabolic cages before killing, and 24-hour urine
samples were collected. All rats were killed 24 hours after having
received the last dose of calcitriol. Following killing, blood and the
thoracic aorta were removed and stored to measure Ca and P content
and for von Kossa staining.
Experiment 2: effect of dietary Mg intake on reversibility of
VC. A second experiment was performed to determine whether the
VC observed in nephrectomized rats on normal Mg diet (0.1%)
could be reversed by increasing Mg supplementation. Thus, rats used
in this study were subjected to the same protocol described in
experiment 1: they were nephrectomized; fed a diet with 0.6% Ca,
1.2% P, and 0.1% Mg; and treated with calcitriol (20 ng/48 h/rat
i.p.). Rats (n ¼ 49) were monitored for 14 days to allow for the
development of soft-tissue calcification. At day 14, 10 animals were
killed to quantify calcification in the aorta and other soft tissues as
well as to measure biochemical parameters before starting Mg sup-
plementation. The remaining rats were randomly assigned to 2
experimental groups and placed on a diet with 0.6% Ca, 1.2% P, and
either normal (0.1%) Mg (n ¼ 21) or moderately high (0.6%) Mg
(n ¼ 18). The original design aimed to kill half of the rats in each
group 14 days later (day 28). However, due to high mortality (mainly
in the rats fed Mg 0.1%), only 7 rats on Mg 0.1% and 9 on Mg 0.6%
were killed. The remaining rats, 3 in the Mg 0.1% group and 4 in the
Mg 0.6% group, were monitored for an additional 14-day period for
a total of 42 days of experimental period. Then all the remaining rats
were killed (Figure 1). Following killing, the thoracic aorta, stomach,
and lungs were removed and stored.
Assessment of vascular and soft-tissue calcification
Vascular and soft-tissue calcification was assessed by microscopy and
by measurement of Ca and P tissue content. To avoid sampling bias,
the same section of the aorta from every animal was selected for each
assessment: the cranial one-third for histology and the middle one-
third for Ca and P quantification. The cranial part of the thoracic
aorta and samples of stomach and lung were fixed in 10% buffered
formalin and subsequently sectioned and stained by the von Kossa
method to assess mineralization according to standard protocols.
The extent of calcification (von Kossa staining) was evaluated blindly
by 3 independent observers. The middle part of the aorta was
demineralized in 10% formic acid, and the Ca and P contents were
measured in the supernatant. The organs (aorta, stomach, and lungs)
were placed into separate 30-ml tubes, and 20 ml 150 mM HCl were
added to each tube. The tubes were mixed by inversion for 24 hours
at room temperature, and Ca and P were measured in the acid
extract.60 Ca and P were measured in the aortas of killed rats and
those found dead.
Runx2 and BMP-2 expressions by RT-PCR
Total RNA from the thoracic aorta was extracted using the RNeasy
Fibrous Tissue Kit from Qiagen (Hilden, Germany). The expression
of mRNA was examined by quantitative real-time PCR (RT-PCR)
using the Light Cycler thermal cycler system (Roche Diagnostics,
Indianapolis, IN). RT-PCR was carried out in 1 step, using the
QuantiTect SYBR Green RT-PCR kit (Qiagen) following the manu-
facturer’s protocol. BMP-2 and Runx2 primers were designed with
Oligo 7 software (Oligosoft, Bangalore, India), and the sequences
were the following: Fwd-Runx2: 50-CGGGAATGATG AGAA
CTACTC-30 and Rwd-50-GCGGTCAGAGAACAAACTAGGT-30;
Bmp2: Fwd-50-AGGAGGCAAAGAAAAGGAACGGAC-30 and Rwd-
5’-GGAAGCAG CAACGCTAGAAGACAG-30. Results were normal-
ized to glyceraldehyde-3-phosphate dehydrogenase expression that
was used as a housekeeping gene. Glyceraldehyde-3-phosphate de-
hydrogenase sequence was the following: Fwd-50TGATGACATCA
AGAAGGTGGTGAAG-30and Rwd-50-TCCTTGGAGG CCATGT
GGGCCAT-30. Quantification of relative expression was determined
by the 2D(DCT) method.
Bone histology and histomorphometric analysis
After killing, right femurs were dissected and placed in 70% ethanol.
Subsequently, femurs were cut at the middle and distal bones,
dehydrated in alcohol, treated with xylene, and embedded in
75% methyl methacrylate, 25% dibutyl phthalate, and 2.5% weight/
volume benzoyl peroxide. Histomorphometric parameters were
evaluated in undecalcified 5-mm sections treated with modified
Masson-Goldner trichrome staining. Briefly, slices were fixed with
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50% ethanol under pressure, then were rehydrated and stained with
hematoxylin-ferric chloride 1:1, cleared with 1% HCl, and turned
blue with LiCO3. After rinsing with water, slices were stained with
Goldner trichrome dye for 20 minutes and then rinsed with 1%
acetic acid. Subsequently, samples were stained with safranin for 5
minutes and dehydrated with ethanol and mounted. Green-stained
areas were considered to be mineralized bone, and red-stained
areas measuring at least 1.5 mm were considered to be osteoid.
Bone histomorphometric parameters were assessed in cancellous
bone within the secondary spongiosa under 200 magnification as
previously described,61 and derived indices were determined by
standard calculations.62
Measurement of blood pressure in nephrectomized rats on
dietary Mg supplementation
The effect of dietary Mg supplementation (0.6%) on BP in
5/6-nephrectomized rats on a 1.2% diet was evaluated. The 5/6
nephrectomy was performed according to the protocol previously
described; after the second nephrectomized rats were randomly
assigned to receive diets containing P 1.2% plus Mg 0.1 % or P 1.2%
plus Mg 0.6%. At day 10, systolic, diastolic, and mean arterial
pressures were measured using a Panlab LE 5001 pressure meter
(Harvard Apparatus, Holliston, MA).
Biochemical determinations
Blood for biochemical analyses was obtained from the abdominal
aorta at the time of killing. Blood for measurements of iCa levels was
collected in heparinized syringes and measured immediately in a
Ciba-Corning 634 ISE Ca2þ/pH analyzer (Essex, UK). Serum was
separated by centrifugation and stored at –20

C until further anal-
ysis. Serum and urine creatinine, Ca, P, and Mg were measured by
spectrophotometry (BioSystems SA, Barcelona, Spain). Serum PTH
levels were quantified according to the vendor’s instructions using a
rat PTH (1–34) immunoradiometric assay kit (Immunotopics, San
Clemente, CA). Calcitriol was measured with a radioreceptor assay
(Immunodiagnostic Systems, Boldon, UK). FGF23 levels were
determined using an intact FGF23 enzyme-linked immunosorbent
assay kit (Kainos Laboratories, Tokyo, Japan). The collected urine
was centrifuged (1500 rpm for 5 minutes), volume was measured,
and an aliquot was saved for Ca, P, Mg, and creatinine measurement
(BioSystems SA).
In vitro studies
To investigate the influence of Mg on expression of osteogenic
proteins by endothelial cells, HUVECs (Cell Systems/Clonetics,
Solingen, Germany) were cultured at 37C, 5% CO2 with endothelial
cell medium (LONZA, Hopkinton, MA), plus endothelial cell growth
supplements (EGM, LONZA) and 10% fetal calf serum (Invitrogen
Molecular Probes, Eugene, OR). HUVECs from 2 to 9 passages were
used. HUVECs were stimulated by addition of TNF-a (Sigma-
Aldrich, St. Louis, MO) (20 ng/ml) over 36 hours. The optimal
concentration and time of TNF-a was established based on pre-
liminary results obtained from concentration- and time-dependent
effects of TNF-a on intracellular BMP-2 expression in HUVECs.
Two concentrations of Cl2Mg (1.4 and 2.6 mM), alone or in com-
bination with TNF-a, were also added. Treatments were performed
on 5 independent cultures.
Total RNA from HUVECs was extracted using Trizol reagent
(Sigma-Aldrich), and the expression of mRNA was examined as
described earlier.
BMP-2 and p65–NF-kB Western blots
Cytosolic proteins were isolated from cultured cells using lysis buffer
A, containing N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid
(10 mmol/l), KCl (10 mmol/l), ethylenediamine tetraacetic acid
(0.1 mmol/l), ethyleneglycol-bis-(b-aminoethylether)-N,N,N0,N0-
tetraacetic acid (0.1 mmol/l), dithiothreitol (1 mmol/l), phenyl-
methylsulfonyl fluoride (0.5 mmol/l), protease inhibitor cocktail (70
mg/ml; Sigma-Aldrich), Igepal CA-630 (0.5%), and pH 7.9. The
suspension was centrifuged, and the supernatant was stored. Protein
concentration was determined by the Bradford method (Bio-Rad
Laboratories, Munich, Germany). Once separated by electrophoresis
in Ready Gel Tris-HCl 4% to 20% (Bio-Rad Laboratories), proteins
were transferred to nitrocellulose membranes. Human anti–BMP-2
(sc-137087, Santa Cruz Biotechnology, Dallas, TX) and anti–p65-
NF-kB (sc-109, Santa Cruz Biotechnology) were used as primary
antibodies. Visualization of immune complexes was performed using
horseradish peroxidase-conjugated secondary antibody (goat anti-
mouse IgG-HRP, sc-2060, Santa Cruz Biotechnology) and the ECL
Advance Detection Reagents (GE Healthcare Bio-Sciences, Uppsala,
Sweden). Protein levels were quantified using the image analysis
software Quantity One 4.4.0 (Bio-Rad Laboratories) and were
normalized to b-actin levels.
Statistics
Values are expressed as the mean  SEM. Sample size and the power
of a contrast of hypothesis were calculated with statistical software
(GRANMO; IMIM, Barcelona, Spain). The difference between
means of more than 2 groups was assessed by analysis of variance
followed by Duncan’s post hoc analysis. Comparison of means from 2
different groups was evaluated by unpaired t-test. A P value of <0.05
was considered significant. Survival curves were analyzed by Mantel–
Cox test.
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SUPPLEMENTARY MATERIAL
Figure S1. Effect of dietary magnesium (Mg) on prevention of gastric
calcification. (A) Calcium gastric content in the study groups of
experiment 1. (B) Phosphate (P) gastric content in the study groups of
experiment 1. aP < 0.001 versus sham group; bP < 0.01 versus
sham group; þþþP < 0.001 versus Mg 0.1%; and þþP < 0.01 versus
Mg 0.1%.
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Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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2 the concomitant decrease in Parathyroid Hormone concentration 
3 Juan M. Díaz-Tocados1,2,3,4,#, María E. Rodríguez-Ortiz4,5,#, Yolanda Almadén1,6,7, Carmen 
4 Pineda3,8, Julio M. Martínez-Moreno1,2,3,4, Carmen Herencia1,2,3,4, Noemi Vergara1,2,3,4, M. 
5 Victoria Pendón-Ruiz de Mier1,2,3,4, Rafael Santamaría1,2,3,4, Cristian Rodelo-Haad1,2,3,4, 
6 Antonio Casado-Díaz1,3,9,10, Víctor Lorenzo11, Catarina Carvalho12,13,14, João M. 
7 Frazão13,14,15, Arnold J. Felsenfeld16, William G. Richards17, Escolástico Aguilera-Tejero3,8, 
8 Mariano Rodríguez1,2,3,4,*, Ignacio López3,8,+, Juan R. Muñoz-Castañeda1,2,3,4,+.
9
10
1Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain. 2Nephrology 
11 Service, Reina Sofia University Hospital, Cordoba, Spain. 3University of Cordoba, Spain, 
12
4Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, Madrid, 
13 Spain. 5Laboratory of Nephrology, Health Research Institute-Jiménez Diaz Foundation, 
14 Madrid, Spain. 6Internal Medicine Service, Reina Sofia University Hospital, Cordoba, Spain. 
15
7Spanish Biomedical Research Networking Centre consortium for the area of 
16 Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, 
17 Madrid, Spain. 8Department of Medicine and Animal Surgery, Cordoba, Spain. 9Clinical 
18 Management Unit for Endocrinology and Nutrition, Reina Sofia University Hospital. 10 
19 Network for Cooperative Research on Ageing and Fragility (RETICEF) & Spanish 
20 Biomedical Research Networking Centre consortium for the area of Frailty and Healthy 
21 Ageing (CIBERFES), Institute of Health Carlos III, Madrid, Spain. 11University Hospital of 
22 Tenerife, Nephrology Service, Canary Islands, Spain. 12 Braga Hospital, Department of 
Page 36 of 82


































































1 Nephrology, Portugal, 13Institute of Investigation and Innovation in Health (I3S), University 
2 of Porto, Portugal. 14National Institute of Biomedical Engineer (INEB), University of Porto, 
3 Portugal. 15Department of Nephrology, São João Hospital Center, Porto, Portugal. 
4
16Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and the 
5 David Geffen School of Medicine, University of California, Los Angeles, California, USA. 
6
17Amgen Research Thousand Oaks Ca, USA.
7
#These authors share the first authorship. +These authors share the last authorship.
8 Running title: PTH-independent Effects of Calcimimetics in Bone
9 *Correspondence: Mariano Rodríguez: marianorodriguezportillo@gmail.com. Maimonides 
10 Institute for Biomedical Research (IMIBIC). Nephrology Service, Reina Sofia University 
11 Hospital, Av. Menendez Pidal, Postal Code 14004, Cordoba, Spain.
Page 37 of 82



































































2 Calcimimetics (CMs) are used to decrease parathyroid hormone (PTH) secretion in uremic 
3 patients with secondary hyperparathyroidism. Decreased PTH should be associated with a 
4 reduction in bone turnover.  However, bone cells express calcium sensing receptor (CaSR) 
5 and the direct in vivo effect of CMs on these cells has not been defined. In this study, we 
6 evaluate the direct bone effects of CaSR activation by CM (AMG 641) in vivo and in vitro. 
7 Normal and 5/6 nephrectomized (Nx) rats were divided in subgroups that underwent 
8 parathyroidectomy followed by a constant subcutaneous infusion of PTH during treatment 
9 with vehicle or CM.
10 CM administration to normal rats with clamped PTH increased osteoblasts and osteoid 
11 volume. In Nx rats elevated PTH concentration led to reduced bone volume and increased 
12 bone turnover. CM administration to Nx animals decreased plasma PTH while bone cell 
13 activity remained similar to the vehicle Nx group. In Nx rats with PTH clamp (PTHx6), CM 
14 administration increased osteoblasts number, osteoid surface and bone formation as 
15 compared with vehicle. A higher dose of PTH1-34 (PTHx9) caused an increase in bone 
16 turnover that was not altered by the administration of CM. 
17 In UMR cells CM induced Erk1/2 phosphorylation and the expression of osteoblastic genes. 
18 The addition of a calcilytic resulted in the opposite effect. Moreover, CM promoted the 
19 osteogenic differentiation and mineralization of human bone marrow mesenchymal stem 
20 cells.
21 In conclusion, calcimimetic administration has a direct anabolic effect on bone that 
22 counteracts the concomitant decrease in PTH levels.  
23 Keywords: calcimimetic, parathyroid hormone, bone, CaSR, mineral metabolism, chronic 
24 kidney disease.
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2 Patients with renal insufficiency develop secondary hyperparathyroidism (SHPT).  High 
3 levels of parathyroid hormone (PTH) are associated with negative outcomes and play a key 
4 role in the development of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-
5 MBD). Excess PTH increases bone turnover and, as SHPT progresses, osteitis fibrosa 
6 develops1. However, due to bone resistance to PTH, normal or moderately increased PTH 
7 concentration is not sufficient to maintain normal bone turnover2. Therefore, an excessive 
8 suppression of PTH may exacerbate adynamic bone disease.
9 Calcimimetics (CMs) are used to reduce high PTH levels in dialysis patients3. CM’s act as 
10 positive allosteric modulator of the calcium sensing receptor (CaSR) expressed on the 
11 parathyroid gland 4 to reduce PTH levels, which is accompanied by decreased bone turnover 
12 as evidenced in clinical studies5,6. 
13 Bone cells also possess functionally active CaSR7 and a question that needs to be addressed 
14 is whether CMs have a direct effect on bone turnover independent of what would correspond 
15 to the reduction in PTH. In vitro studies have demonstrated that an increase in extracellular 
16 calcium (Ca) activates the osteoblast CaSR resulting in downstream cell signaling (Erk1/2 
17 phosphorylation) to induce osteoblast proliferation, osteoblastic gene expression and 
18 calcification8. This response is abrogated by the addition of a CaSR antagonist 8,9. 
19 Additionally, some authors indicate that CaSR is also expressed in osteoclasts, monocytes 
20 and osteoclast precursors10–12. In 1999, Kanatani M. et al showed  in vitro that CM 
21 administration inhibited osteoclastic differentiation in osteoclast precursor cells derived from 
22 spleen cells13. Despite all this information, the action of CM on bone independent of its 
23 modulation on PTH levels has not been investigated in the context of CKD. 
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1 Therefore, the aim of the present study was to evaluate a direct effect of CMs in vivo using 
2 normal and uremic rats in experimental models with parathyroidectomy (PTX) and clamped 
3 PTH level so the action of CMs on bone could be isolated from that of PTH. Additionally, 
4 the direct activation of the CaSR in osteoblasts by CMs was investigated in vitro.
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2 In vivo effects of CM in rats with normal renal function 
3 Biochemical parameters: 
4 As shown in Table 1, blood ionized Ca was decreased in PTX rats compared with sham-
5 operated rats (p<0.05). PTH replacement (PTX-PTH) restored the serum Ca concentration 
6 and the administration of calcimimetic (PTX-PTH-CM) did not decrease serum Ca levels. 
7 Serum P concentration was significantly increased in the PTX group as compared with 
8 Sham (p<0.05). PTX-PTH and PTX-PTH-CM rats had normal serum P concentration 
9 (p<0.05 vs PTX group). The decrease in serum 1,25(OH)2D3 was non-significant in PTX 
10 and PTX-PTH groups. In rats treated with CM the concentration of 1,25(OH)2D3 was 
11 increased (p<0.05 vs all groups) while plasma levels of FGF23 were reduced significantly 
12 (p<0.05) from 129±20 to 88±14 pg/ml.
13 Bone histomorphometry analysis: 
14 Bone Volume (BV/TV) was similar in all four groups (Fig. 1a). In PTX rats, osteiod 
15 volume, osteoid surface and the bone surface covered by osteoblasts (OV/BV, OS/BS and 
16 Ob.S/BS, respectively) were significantly reduced after 28 days (Fig. 1b, c, d). 
17 Additionally, the osteoclast surface was decreased without changes in the eroded surface 
18 (Fig. 1e and f). PTH replacement (PTX-PTH) restored bone histomorphometric parameters 
19 to values similar to those found in sham-operated animals. The administration of CM 
20 (PTX-PTH-CM) did not alter bone parameters as compared with Sham and PTX-PTH 
21 groups. Representative microphotographs are shown in Supplementary Figure S1.
22 In vivo effects of CM in uremic rats
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1 After 28 days of experimentation, body weight increased in all groups of Nx rats and body 
2 weight gain was no significantly different among the Nx groups. The gain in body weight 
3 observed in Sham rats was slightly higher than in Nx rats (Supplementary Figure S2).
4 Biochemical parameters: 
5 As shown in Table 2, serum concentration of creatinine was significantly increased 
6 (p<0.05) in all Nx groups with no differences among them. In parathyroidectomized Nx 
7 rats, PTH infusion in an amount 6-fold the normal replacement dose (Nx-PTX-PTHx6) was 
8 sufficient to maintain serum Ca at a level similar to Nx rats. However, a significant increase 
9 in iCa levels was observed in both Nx-PTX-PTHx9 groups (d p<0.05 vs Nx-PTX-PTHx6) 
10 that was not altered by the administration of CM.   The increase in serum P concentration 
11 observed in Nx rats was not altered by parathyroidectomy. CM administration in the Nx-
12 PTX-PTHx6-CM group maintained serum P at a level not significantly different from the 
13 Sham group. As expected intact rat PTH was elevated in 5/6 Nx rats and decreased with the 
14 administration of CM. Additionally, PTH1-34 levels in animals with PTH replacement 
15 were compared with PTH1-34 levels of Nx group. Table 2 shows that in Nx-PTX-PTHx6 
16 treated animals the PTH1-34 levels did not reach levels observed in the Nx group. 
17 However, in Nx-PTX-PTHx9, PTH1-34 levels increased significantly with respect to Nx 
18 and Nx-PTX-PTHx6 groups (d p<0.05 vs Nx-PTX-PTHx6). The serum level of 
19 1,25(OH)2D3 was similar in all groups. Finally, plasma FGF23 was higher in the Nx groups 
20 than in Sham animals (a p<0.05) and CM administration decreased FGF23 levels in Nx 
21 animals (b p< 0.05 vs Nx group). Nx- PTX- PTHx6 rats had lower FGF23 levels than those 
22 found in Nx group. Whereas a higher dose of PTH (Nx-PTX-PTHx9) increased FGF23 
23 levels significantly. In rats with PTH infusion, the addition of CM did not change FGF23 
24 levels.
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1 Bone histomorphometry analysis: 
2 Except for BV/TV which was reduced when compared with Sham rats (p<0.001) (Fig. 2a), 
3 all bone parameters were increased in Nx rats (Fig. 2b-h). In Nx rats with intact parathyroid 
4 glands treated with CM bone turnover was maintained despite a 4-fold reduction in PTH 
5 levels (from 540 to 144 pg/ml). 
6 In Nx-PTX-PTHx6 rats treated with vehicle, that had relatively low levels of 1-34 PTH bone 
7 turnover was reduced. The high dose of PTH (Nx-PTX-PTHx9) produced a significant 
8 increase in bone turnover when compared to Nx-PTX-PTHx6 vehicle group, resulting in 
9 higher values of osteoid volume (OV/BV), OS/BS, ObS/BS, ES/BS, OcS/BS, MS/BS and 
10 BFR/BS (Fig. 2). 
11 In the Nx-PTX-PTHx6 group CM administration (Nx-PTX-PTHx6-CM) increased osteoid 
12 surface (OS/BV), osteoblasts surface (Ob.S/BS) and osteoclasts surface (Oc.S/BS). With 
13 respect to bone formation, the addition of CM to Nx-PTX-PTHx6 rats produced an increase 
14 in mineralizing surface (MS/BS, 30.9±2.24 vs 21.3±5.00 %, p<0.05, Fig.2g) and BFR/BS 
15 (379±55 vs 253±81 %/year, p<0.01, Fig.2h) as compared to Nx-PTX-PTHx6-vehicle group. 
16 In conditions of very high PTH levels (Nx-PTX-PTHx9), CM administration (Nx-PTX-
17 PTHx9-CM) did not alter bone cell activity (Fig. 2). No differences in cortical bone area and 
18 thickness were observed among all animal groups (Supplementary Fig. S3 a and b).
19 With respect to mineralization, as compared with Sham animals, Nx group showed higher 
20 mineral apposition rate and mineralization lag time (a p<0.05 vs Sham group, Fig. 3a and 3b) 
21 and lower mineralizing surface related to osteoid surface and an adjusted apposition rate (Fig. 
22 3c and 3d, a p<0.05 vs Sham group). The Nx-PTX-PTHx9 group showed a significant 
23 increase in mineral apposition rate, mineralization lag time and osteoid thickness as 
24 compared with the Nx-PTX-PTHx6 group (Fig. 3a, b and e respectively). However, as 
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1 compared with the corresponding vehicle, CM administration did not induce significant 
2 changes in the mineralization parameters in any experimental condition (Fig. 3).
3 Representative samples of Goldner’s trichrome staining of undecalcified bone from the four 
4 groups of rats are shown in Fig. 4. In Sham animals, an almost quiescent state of bone cells 
5 with normal mineralization was observed. Nx groups showed an increased bone cell 
6 activity with high number of osteoblasts and osteoclasts on the bone surface, accompanied 
7 by an increase in b ne formation. CM treatment did not alter bone cell activity and 
8 mineralization was similar in Nx rats with intact parathyroid glands. In Nx-PTX-PTHx6 
9 animals a lower bone turnover and bone formation respect to Nx group was observed. In 
10 these conditions, treatment with CM increased the number of osteoblasts and osteoclasts as 
11 well as mineralization and bone formation. In Nx-PTX-PTHx9 group bone turnover and 
12 mineralization was similar to that observed in the Nx group, and CM administration did not 
13 modify bone cells activity and bone formation.
14 Figure 5 shows in consecutive bone slices, that CM increases the number of bone cells 
15 positive for phospho-Erk1/2 (both in cytoplasm and nuclei). To further confirm that the 
16 Erk1/2 phosphorylation was triggered in osteoblasts, staining for osteocalcin in consecutive 
17 slices was performed and matched. The phospho-Erk1/2 positive cells were also positive 
18 for osteocalcin staining illustrating that CM promotes Erk1/2 phosphorylation of 
19 osteoblasts. The phospho-Erk1/2 immunostaining was quantified and expressed as 
20 percentage relative to the total number of osteoblasts.
21 Modulation of CaSR, by CM and calcilytic, regulates the expression of osteoblast 
22 markers in UMR 106 cells
23 To evaluate the direct effect of positive allosteric modulation of CaSR on the osteoblastic 
24 phenotype, CM was added to UMR106 cells in a medium with a low Ca concentration (0.5 
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1 mM), which in turn mimics the “in vivo” effects of CM decreasing PTH with the resulting 
2 reduction in serum Ca concentration. The addition of CM did not modify significantly 
3 PCNA protein expression nor affected the CaSR expression in UMR 106 cells (Fig. 6a). 
4 CaSR activation by CM led to an increase in Erk1/2 phosphorylation (Fig. 6b), 
5 demonstrating that in these cells CaSR is functional and modulated by CM. Confocal 
6 microscopy showed nuclear translocation of phosphorylated Erk1/2 induced by CM 
7 (Supplementary Figure S4). After 48 hours of treatment, CM (100µM) significantly 
8 increased (p<0.05 vs all groups) the expression of the osteogenic markers Runx2, Osterix 
9 and Osteocalcin (Fig. 6 c, d and e respectively). Finally, negative allosteric modulation of 
10 the CaSR by the calcilytic Calhex 231 reduced the Erk1/2 phosphorylation (Fig. 7a) which 
11 was accompanied by down-regulation of the ostegenic gene expression of Osterix (Fig. 7b), 
12 Runx2 (Fig. 7c) and Osteocalcin (Fig. 7d) (a p<0.05 vs Control).
13 CM increases osteoblastic differentiation and mineralization of human bone marrow 
14 mesenchymal stem cells
15 Human bone marrow mesenchymal stem cells (MSC) were differentiated into osteoblasts in 
16 a medium with a low Ca concentration (Ca 0.5 mM). After 21 days, Ca deposition (Fig. 8a) 
17 and number of mineralization nodules were increased in osteoblasts cultured with CM 100 
18 M (Fig. 8b). Addition of CM increased the expression of the early osteoblast markers 
19 Runx2 and Osterix (Fig. 8c and d respectively) and mature osteoblast markers such as 
20 osteocalcin (Fig. 8e). Furthermore, CM addition enhanced the expression of BMP2 (Fig. 
21 8f), a well-known pro-osteogenic factor. Both, undifferentiated MSC and MSC 
22 differentiated into osteoblasts expressed CaSR (Fig. 8g). 
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2 The present study was designed to determine whether CMs directly affect bone cell activity. 
3 Our study showed that CM produced an increase in bone cell activity, as evidenced by in 
4 vivo and in vitro experiments. The CM effect was direct and independent of that from a 
5 reduction in PTH induced by CM. This explains the observation that in uremic rats with intact 
6 parathyroid glands the administration of CM maintained bone turnover despite the reduction 
7 of PTH level.
8 To evaluate a direct effect of CM on bone in vivo in Nx rats, it was necessary to clamp the 
9 serum PTH concentration using continuous delivery of PTH1-34 at 6 and 9- fold the 
10 replacement dose by subcutaneous miniosmotic pumps in previously PTX rats. The in vivo 
11 results demonstrated that CM increased bone cell activity. As compared with Nx group, the 
12 Nx-PTx-PTHx6 group presented a low bone cell activity which was likely due to relatively 
13 low levels of PTH as illustrated by the lower levels of PTH1-34. In this setting of low bone 
14 turnover (PTH6x), CM administration increased bone cell activity and bone mineralization. 
15 While osteoblast activity was higher in the Nx-PTX-PTHx6-CM group than in the Nx-
16 PTX-PTHx6 receiving vehicle, the bone volume remained similar. This could be explained 
17 by the increased osteoclast activity (Oc.S/BS) in the Nx-PTX-PTHx6-CM.
18 However, PTHx9 rats showed a very high bone turnover which was not further increased 
19 by CM administration. CM administration did not significantly affect cortical bone. More 
20 prolonged experiments may be required to assess whether CM has any effect on cortical 
21 bone.
22 With equal amounts of PTH infusion, in both normal and Nx rats, the administration of CM 
23 increased the bone surface covered by osteoblasts and the bone formation rate. In contrast 
24 to previous studies5,14,15, we did not find significant differences between vehicle or 
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1 calcimimetic administration in any PTH condition, indicating that the treatment with CM 
2 did not produce abnormal mineralization.
3 In normal renal function PTX rats with PTH infusion CM administration increased 
4 1,25(OH)2D3 levels, which likely results from reduced serum FGF23 levels in the PTX-
5 PTH-CM as compared with the PTX-PTH group. Furthermore, elevated 1,25(OH)2D3 
6 levels might also contribute to the increased bone anabolism observed in this group. In a 
7 previous article15 it was shown that serum levels of FGF23 may be markedly reduced when 
8 serum calcium concentrations decrease below 8-8.5 mg/dl (which corresponds to 1.0 – 1.06 
9 mM of ionized calcium). The reduction in FGF23 in the PTX-PTH-CM group could be 
10 related in part to the moderate reduction in serum calcium observed in these rats. Activation 
11 of the CaSR is known promote calciuria16. In our Nx rats with clamped PTH the production 
12 of FGF23 was not modified by CM because FGF23 synthesis is mainly determined by the 
13 reduction of renal function and by phosphate load.
14 In a previous study, Khoshniat S et al reported that extracellular calcium is necessary to 
15 promoted phosphate-dependent Erk1/2 signaling activation in osteoblasts in vitro. This 
16 occurs independent of CaSR and it is related with calcium phosphate precipitates which 
17 was associated with an increased expression of Osteopontin (OPN) and Matrix Gla Protein 
18 (MGP) that are  associated with a decrease in mineralization17. In our in vitro experiments 
19 in osteoblasts cultured with normal phosphate concentration, the addition of calcimimetic 
20 induced the Erk1/2 phosphorylation with an associated increase in both, osteogenic genes 
21 expression and matrix mineralization as assessed by the amount of calcium in the 
22 mineralized matrix. Thus, our data also support that the CaSR activation may not be 
23 involved in the decreased mineralization induced by calcium phosphate precipitates due to 
24 high levels of calcium and phosphate.
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1 To confirm the direct effect of the CM on osteoblasts, CM was added to UMR cells, an 
2 osteoblast cell line in culture. In these cells, the activation of CaSR by CM led to the 
3 phosphorylation of Erk1/2 triggering the expression of osteogenic genes. By contrast, in 
4 UMR 106 cells, the calcilytic compound Calhex 231 inhibited Erk1/2 phosphorylation and 
5 reduced the expression of osteogenic genes which further support the role of CaSR on 
6 osteoblast activity. Furthermore, when human bone marrow MSC were differentiated into 
7 osteoblasts and cultured with CM increased matrix mineralization together with an up-
8 regulation of osteogenic genes were observed. Taken together all these results indicate that 
9 positive allosteric modulation of the CaSR in bone cells participates in the maintenance of 
10 bone turnover.
11 Our results suggest that the activation of CaSR by CM in osteoblasts promotes bone 
12 turnover independently of PTH. In the context of CKD, our results are consistent with other 
13 studies. Wada et al reported that the calcimimetic R-568 reduced PTH levels and 
14 ameliorated osteoitis fibrosa in uremic rats. However, bone cell activity was not 
15 significantly different than in rats receiving vehicle18. In a similar animal model, over-
16 suppression of PTH by CM, produced no significant differences in the surface of bone 
17 covered by osteoclast, although the number of osteoblasts was significantly reduced19. 
18 Given the reduced bone responsiveness to PTH in uremia20, it is important to maintain  
19 PTH levels sufficiently high to sustain bone turnover. In this context, our results suggest 
20 that CaSR activation of bone cells with a CM may act to maintain bone turnover when PTH 
21 is reduced.
22 The relevance of CaSR activity on bone health was evaluated by Xue Y. et al in rodents 
23 null for PTH and CaSR. In these animals, the anabolic effects of PTH were more greatly 
24 reduced in PTH-/- CaSR-/- as compared with PTH-/-21. Likewise, another study showed that 
Page 48 of 82


































































1 high dietary Ca increased bone formation in both wild type and PTH-/- mice, but these 
2 effects were absent in PTH-/- CaSR-/- double knockout mice22. Similarly,  osteoblast specific 
3 ablation of CaSR attenuated the anabolic action of PTH14. All these findings support an 
4 important role of CaSR activation in bone cell activity. Conversely, a study by Dvorak et 
5 al23  reported  that constitutive activation of the bovine parathyroid CaSR in mature 
6 osteoblasts of mice without other systemic changes in serum Ca2+ and PTH led to bone loss 
7 through an increase in bone resorption. In this case, CaSR activation was not associated 
8 with an altered renal function or changes in mineral metabolism parameters such as P, 1,25-
9 OH2D3 or FGF23 which likely modulate bone activity; in addition, the role of CaSR on 
10 early osteoblasts was not quantified. Whether the structure and function of CaSR in 
11 parathyroid glands is the same that CaSR in bone is controversial. Regardless, additional 
12 studies still need to be performed to characterize specific aspects of the role of CaSR on 
13 bone cell activity in normal physiological states.  
14 A clinical study called Bonafide was conducted to assess bone histomorphometric changes 
15 after treatment with the calcimimetic cinacalcet in a cohort of dialysis patients. The study 
16 reported a reduction in PTH levels after 12 months of treatment. The reduction of PTH was 
17 accompanied by decreased bone turnover and bone formation. However, only a modest 
18 correlation between changes in PTH and the reduction in bone activity existed, suggesting 
19 that other factors besides the change in PTH may have influenced bone turnover. An 
20 excessive dose of  vitamin D at the beginning of the study might  have affected the results5. 
21 Of interest, a recent pre-clinical study which looked at the effect of the calcimimetic 
22 Parsabiv™ (Etelcalcetide) on SHPT in subtotal Nx rats showed that Etelcalcetide 
23 administration decreased plasma PTH levels, but histomorphometric analysis showed that 
24 the osteoblast and osteoclast bone surface remained similar to vehicle24.
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1 Extracellular Ca is the natural activator of the CaSR. In fact, high extracellular Ca has been 
2 shown to promote osteoblast maturation and proliferation8,25. The hypercalcemic effect of 
3 PTH may potentiate the bone anabolic effect of PTH.  The administration of CM to dialysis 
4 patients causes a reduction in PTH and a concomitant decrease in the plasma Ca 
5 concentration. It is important to know whether the action of CM on the CaSR could 
6 potentially compensate for the moderate reduction in plasma Ca concentration on bone 
7 cells. Thus, we performed an experiment to evaluate in vitro, the effect of CM on bone cells 
8 in the presence of a low Ca concentration. UMR106 cells and osteoblasts-derived from 
9 MSC cultured in low Ca conditions showed an increase in the expression of osteogenic 
10 genes when treated with CM. Moreover, the increased osteoblastic genes were associated 
11 with the activation of the Erk1/2 pathway. Of note, mineralization was enhanced in MSC 
12 differentiated into osteoblasts with CM suggesting an active role of the CaSR in 
13 mineralization. Our study is the first to demonstrate that despite low calcium, CM increases 
14 maturation, differentiation and mineralization of osteoblast-like cells. 
15 In conclusion, this is the first in vivo study to show that, in uremic rats, the administration of 
16 a calcimimetic directly increases bone cell activity and bone formation rate, an effect that is 
17 observed despite the concomitant decrease in PTH levels.  
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2 In vivo experiments
3 Male Wistar rats weighing 200-250 g were housed with a 12h/12h light/dark cycle and 
4 given ad libitum access to standard diet, 0.6% Ca, 0.6% phosphate (P) and tap water. 
5 Animal care and experimental procedures were approved by Research and Ethics 
6 Committees of IMIBIC/Reina Sofia University Hospital in accordance with Directive 
7 2010/63/EU of the European Parliament and with institutional guidelines for the care and 
8 use of laboratory animals and the Declaration of Helsinki. Human samples of bone marrow 
9 mesenchymal stem cells were collected after obtaining the corresponding signed informed 
10 consent.
11 Total PTX was performed as previously reported with the aid of a dissecting microscope26. 
12 One week after PTX, rats were anesthetized using sevofluorane (Abbott, Madrid, Spain) and 
13 blood (0.7 ml) was drawn by puncture of the jugular vein to measure serum Ca levels. PTX 
14 was considered successful in rats with ionized Ca levels below 0.8 mM.
15 In vivo effects of CM in rats with normal renal function 
16 Subsequently, a miniosmotic pump (ALZET model 2ML4 purchased from Charles River 
17 Laboratories, Barcelona, Spain) was implanted subcutaneously between the shoulders. The 
18 osmotic pump was loaded with rat PTH (rat PTH1-34 fragment, Sigma Aldrich Co., St Louis, 
19 MO, USA) diluted in isosmotic saline with 2% cysteine (pH 1.4) in aseptic conditions.
20 Two subgroups of PTX rats received the amount of PTH1-34 infused that allowed to maintain 
21 serum calcium close to the physiological range (PTH1-34, 0.022 µg/100g per hour) through 
22 the miniosmotic pumps, one of them in combination with calcimimetic AMG 641 (1.5 
23 mg/kg/48 h, subcutaneously) and the other one received vehicle. The physiological dose of 
24 PTH (0.022 µg/100g per hour) was previously defined by its ability to maintain a normal 
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1 range of serum ionized calcium values (1.15-1.25 mM) in PTX rats fed a 0.6% Ca and 0.6% 
2 P diet27 . 
3 In rats with normal renal function the following experimental groups were included: Sham 
4 operated (Sham, n=6), Parathyroidectomized rats (PTX, n=7), Parathyroidectomized rats 
5 plus PTH replacement (PTX-PTH, n=5) and Parathyroidectomized rats and PTH replacement 
6 plus CM (PTX-PTH-CM, n=6).
7 The calcimimetic AMG 641 was reconstituted in Captisol (Ligand Pharmaceuticals, Inc. San 
8 Diego, CA) 12% p/v, pH 3. The control animals received only Captisol as vehicle. The 
9 calcimimetic AMG 641 (chemical name: (1R)-N-((6-(methyloxy)-4′-(trifluoromethyl)-3-
10 biphenylyl)methyl)-1-phenylethanamine) is an arylalkylamine with a molecular weight of 
11 approximately 400 g/mol, the half-life is approximately 3-fold longer than cinacalcet and has 
12 a large volume of distribution. This compound triggers Erk1/2 phosphorylation in the 
13 absence of calcium; therefore, it would referred as an allosteric agonist rather than strict 
14 allosteric modulator19,28. The dose of AMG 641 administered to the rats has showed to be 
15 efficient to decrease PTH levels in Nx rats29. 
16 In vivo effects of CM in uremic rats
17 To assess the effects of the CM on bone in animals with renal insufficiency and intact 
18 parathyroid glands, a second experiment was performed in uremic rats. Uremia was induced 
19 by 2-step subtotal nephrectomy (Nx) as previously described26. After the second surgery, the 
20 standard diet was switched to a moderately high phosphate diet (0.6% Ca and 0.9% P) (Nx 
21 group). An additional group of Nx rats was treated with CM (1.5 mg/kg/48h; subcutaneously) 
22 (Nx-CM). To determine whether the administration of AMG641 (CM) exerts PTH-
23 independent effects on bone, several additional groups of Nx rats underwent total PTX 
24 receiving a constant infusion of a 6-fold (0.132 µg/100g per hour) or 9-fold (0.198 µg/100g 
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1 per hour) dose of rat recombinant PTH1-34 through ALZET osmotic pumps in combination 
2 with vehicle or CM (1.5 mg/kg/48 h, subcutaneously). Therefore, final experimental groups 
3 were the following: Sham (Sham, n=6), 5/6 Nephrectomized rats (Nx, n=7), 5/6 
4 Nephrectomized rats plus AMG641 (Nx-CM, n=6), 5/6 Nephrectomized plus 
5 Parathyroidectomy and PTH replacement x6 (Nx-PTX-PTHx6, n=8), 5/6 Nephrectomized 
6 plus Parathyroidectomy and PTH replacement x6 plus CM (Nx-PTX-PTHx6-CM, n=5), 5/6 
7 Nephrectomized plus Parathyroidectomy and PTH replacement x9 (Nx-PTX-PTHx9, n=5), 
8 5/6 Nephrectomized plus Parathyroidectomy and PTH replacement x9 plus CM (Nx-PTX-
9 PTHx9-CM, n=6). 
10 Body weight of Sham animals and the different experimental groups with reduced renal 
11 function was measured twice a week. On day 28, twenty-four hours after the last dose of CM 
12 had been administered, blood was obtained by aortic puncture under general anesthesia 
13 (sodium tiopenthal, i.p) and femurs were dissected to study bone histomorphometry.
14 Blood Biochemistry
15 Blood for measurements of ionized Ca levels was collected in heparinized syringes and 
16 immediately analyzed using a Ciba-Corning 634 ISE Ca2+/pH Analyzer (Ciba-Corning, 
17 Essex, England). Afterwards, serum was separated by centrifugation and stored at -20 C. 
18 Serum P and creatinine were measured by spectrophotometry (Biosystems SA, Barcelona, 
19 Spain). Serum concentrations of active vitamin D (1,25-OH2D3) were measured by 
20 radioimmunoassay (IDS kit, Boldon, UK) and Serum intact PTH levels were assayed using 
21 enzyme-linked immunosorbent assay (ELISA) kit (Immutopic, San Clemente, CA, USA). 
22 Infused PTH was not recognized by PTH assay. The plasma concentration of the PTH (1-34) 
23 fragment, was measured with a specific ELISA kit (Phoenix Pharmaceuticals, Inc. 
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1 Burlingame, CA, USA). Plasma levels of circulating intact FGF23 were determined using an 
2 ELISA kit (Kainos Laboratories, Tokyo, Japan).
3 Bone Histomorphometry
4 Bone mineralization was assessed only in uremic rats. Double calcein labeling (25 mg/kg) 
5 was administered at days 9 and 2 before sacrifice. At sacrifice, right femurs were dissected 
6 and placed in 70% ethanol. Subsequently, femurs were dehydrated in alcohol, cleared with 
7 xylene, and embedded in 75% methyl methacrylate, 25% dibutyl phthalate and 2.5% w/v 
8 benzoyl peroxide. Histomorphometric parameters were evaluated in undecalcified 5-μm 
9 sections of the distal bone treated with modified Masson-Goldner trichrome staining. Briefly, 
10 slices were fixed with 50% ethanol with pressure, then rehydrated and stained with 
11 hematoxylin-ferric choride 1:1, cleared with 1% HCl, and turned blue with LiCO3. After 
12 rinsing with water, slices were stained with Goldner trichrome dye for 20 minutes and then 
13 rinsed with 1% acetic acid. Subsequently, samples were stained with safranin for 5 minutes, 
14 dehydrated with ethanol and mounted. Green stained areas were considered as mineralized 
15 bone and red stained areas measuring at least 1.5 µm were considered as osteoid.
16 Bone histomorphometric parameters were assessed in cancellous bone within the secondary 
17 spongiosa (0.25mm distance from endocortical bone and growth plate) under 200x 
18 magnification using OsteoMeasure™ software (OsteoMetrics, Decatur, IL, USA) and 
19 derived indices were determined by standard calculations30. The bone dynamic parameters 
20 were calculated by measurement of the single and double fluorescent calcein labelling lines 
21 in undecalcified 10-μm serial sections. Analysis of cortical bone was performed in axial 
22 sections of the femoral midshaft according to the method reported by Erben RG31.
23 The following parameters were analyzed: BV/TV: Bone Volume/Tissue Volume, OV/TV: 
24 Osteoid Volume/Tissue Volume, OS/BS: Osteoid Surface/Bone Surface, Ob.S/BS: 
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1 Osteoblast Surface/Bone Surface, ES/BS: Eroded Surface/Bone Surface, Oc.S/BS: 
2 Osteoclast Surface/Bone Surface, BFR/BS: Bone Formation Rate/Bone Surface, MS/BS: 
3 Mineralizing Surface/Bone Surface, Osteoid Thickness (O.Th), Mineralizing Surface 
4 related to Osteoid Surface (MS/OS), mineral apposition rate (MAR), adjusted apposition 
5 rate (Aj.AR), mineralization lag time (Mlt) and osteoid maturation time (Omt), Ct.B.Ar: 
6 Cortical Bone Area, Ct.Th: Cortical Thickness.
7 Bone immunohistochemistry
8 Consecutive decalcified bone sections were used to analyse: Goldner´s trichrome staining, 
9 phospho-Erk1/2 immunostaining, osteocalcin immunostaining and absence of antibody. 
10 Bone slices from 5-μm sections were deacrylated in a 1:1 mixture of xylene and chloroform 
11 for 30 minutes and rehydrated with graded ethanol. Subsequently, samples were decalcified 
12 with 14% EDTA, pH 7.4 for 1 hour and rinsed with distilled water for 10 minutes. Then, 
13 immunohistochemistry was performed using the Novolink Polymer detection System kit 
14 (Leica Biosystems Newcastle Ltd, UK) according to the manufacturer’s instructions. Anti- 
15 phospho-p44/42 MAPK (4370, Cell Signaling Technology Inc., Danvers, MA) was used as 
16 primary antibody at 1:400. Anti-human/rat Osteocalcin antibody was purchased from R&D 
17 Systems (Minnesota, USA) and it was used at concentration of 10 g/ml. Finally, PBS was 
18 used to perform a negative immunostaining to substrate background. Image were taken in a 
19 Leica DM2000 LED microscope with a Leica MC190 HD camera using the Leica 
20 Application Suite 4.8.0 software.
21 In vitro experiments
22 To test the effects of the treatment with CM in mature osteoblasts, we used the rat 
23 osteosarcoma cell line UMR106 (ATCC, Manassas, VA, USA) which displays osteoblastic 
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1 properties. UMR106 cells were culture in calcium-free DMEM (Gibco™, Grand Island, NY, 
2 USA), supplemented with 10% FBS (Lonza Inc., Walkersville, MD, USA), 2mM 
3 ultraglutamine (Lonza), 1mM sodium pyruvate (Lonza), 20mM HEPES (Sigma-Aldrich), 
4 100 U/ml penicillin, 100µg/ml streptomycin and calcium chloride (Sigma-Aldrich) to adjust 
5 the calcium concentration at 0.5mM. Once cells reached ~90% confluence, CM (1 μM and 
6 100μM) or Calhex 231 hydrochloride (1 and 10 μM) were added to the medium. Protein 
7 samples were collected after 6 hours of treatment for western blot analysis. RNA samples 
8 were obtained after 48 hours of treatment for gene expression quantification.
9 Additionally, human mesenchymal stem cells (MSC) were obtained from excess bone 
10 marrow collected during diagnosis or routine follow-up of patients on the Hematology 
11 service of the Reina Sofía University Hospital. These MSC from the iliac crest were isolated 
12 by their plastic adherence properties. 750µl of total bone marrow aspirate were cultured in 
13 75cm2 flasks (NUNC A/S, Roskilde, DE, USA) with αMEM (Sigma-Aldrich) containing 
14 15% FBS, 2mM ultraglutamine, 100U/ml penicillin, 100µg/ml streptomycin and 1ng/ml of 
15 basic fibroblast growth factor, (PeproTech EC Ltd, London, UK) in a humidified atmosphere 
16 of 5% CO2 at 37ºC. Fresh α-MEM supplemented as above and with 10% FBS added after 24 
17 hours and replaced every 3 days. Once 85-90% confluent, cells were collected using Trypsin-
18 EDTA (Lonza), seeded into 6-well plates (NUNC A/S) at 13000 cells/cm2 and cultured with 
19 calcium-free DMEM supplemented as described above and under osteogenic stimuli based 
20 on 1µM dexamethasone (Sigma-Aldrich), 10mM β-glycerol phosphate (Sigma-Aldrich CO.) 
21 and 200µM ascorbic acid (Bayer, Barcelona, Spain). Additionally, 100µM of CM was added 
22 to osteogenic media with low Ca (0.5mM) throughout differentiation. After 21 days, protein 
23 and RNA samples were collected for analysis.
24 Protein extraction and Western blot analysis
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1 Total protein will be isolated from cells in a lysis buffer, containing 20mM Tris/HCl, 150mM 
2 NaCl, 1mM EDTA, 0.5mM PMSF, 70µg/ml Protease Inhibitor Cocktail (Sigma-Aldrich), 
3 0.5% Igepal CA-630 (Sigma-Aldrich), 1µl/ml Phosphatase Inhibitor Cocktail 2 and 1µl/ml 
4 Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich), pH 7.6. Suspension will be centrifuged 
5 and supernatant (protein extract) will be stored at -80ºC. Protein concentration will be 
6 determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). To determine 
7 specific proteins c ntent, 50µg of total protein will be analyzed by immunoblotting using 
8 antibodies for CaSR (ab19347, Abcam plc., Cambridge, UK) at 2µg/ml, p44/42 MAPK 
9 (4695, Cell Signaling Technology) at 1:1000, phospho-p44/42 MAPK (4370, Cell Signaling 
10 Technology) and PCNA (sc-56, Santa Cruz Biotechnology) at 1:200 were used as primary 
11 antibodies, and horseradish peroxidase-conjugated goat anti-mouse and goat anti-rabbit 
12 (Santa Cruz Biotechnology Inc., Dallas, TX) at 1:10000 were used as secondary antibodies. 
13 -actin (sc-47778, Santa Cruz Biotechnology) at 1:500 was used as loading control.
14 Gene expression quantification
15 Total RNA was extracted using TRI reagent (Sigma-Aldrich) and final concentration was 
16 quantified by spectrophotometry (ND-1000, Nanodrop Technologies, Wilmington, DE, 
17 USA). Isolated RNA samples were treated with DNase amplification grade (Sigma-Aldrich) 
18 and Real-time PCR was assayed with 50ng of DNAse-treated RNA using SensiFAST SYBR 
19 No-ROX One-Step Kit (Bioline, London, UK). Primers for PCR are shown in supplementary 
20 information (Supplementary Table S1). PCR amplification was performed using Lightcycler 
21 480 (Roche Molecular Biochemicals, Indianapolis, IN). The expression of target genes was 
22 normalized to the expression of with the 2-Ct method using GAPDH as housekeeping 
23 control.
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2 UMR cells were cultured on glass coverslips in 6-well plates. Once cells reached 90% 
3 confluence, cells were treated with CM (100 µM) or a similar volume of vehicle (DMSO) 
4 and after 6 hours, cells were processed for immunofluorescence staining of phospho-Erk1/2. 
5 Briefly, cells were rinsed with PBS, fixed with cold methanol for 20 minutes and 
6 subsequently rinsed with PBS three times. Fixed cells were incubated in the diluted antibody 
7 in 1% BSA (Sigma-Aldrich) and PBS. Phospho-Erk1/2 primary antibody (Cell signaling 
8 Technology Inc; dilution 1:500) was incubated O/N at 4ºC. Subsequently, cells were washed 
9 with PBS and incubated with Alexa Fluor 488 anti-rabbit (Invitrogen; 1:500 dilution) diluted 
10 in 1% BSA in PBS for 1 hour at RT. Nuclei were visualized with the nuclear stain 4’,6-
11 diamino-2-phenylindole dihydrochloride (DAPI; Invitrogen). Pictures were obtained at 400x 
12 in a Zeiss LSM 710 inverted confocal microscope (Carl Zeiss, Jena, Germany). ImageJ 
13 software (National Institutes of Health, Bethesda, MD, USA) was used to analyze the 
14 confocal images. Co-localization analysis was performed by quantifying the mean of 
15 intensity of fluorescence (phospho-Erk1/2-488) in each nucleus of the different treatments. 
16 Values are showed as fold change vs Control.
17 Measurement of calcium content in cultured cells 
18 After 21 days of osteogenic differentiation, cells were decalcified by incubation in HCl (0.6 
19 M) for 24 hours. Ca content in the supernatant was determined by the 
20 phenolsulphonephthalein method using a commercial assay (QuantiChrom™ Calcium Assay 
21 Kit, BioAssay Systems, CA, USA). Cells were washed 3 times with PBS (Sigma Aldrich) 
22 and protein content was extracted with a NaOH (0.1 M) SDS (0.1%) solution. Protein content 
23 was quantified as described above and the Ca content was normalized according to total 
24 protein.
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2 Values are expressed as the mean ± standard deviation (SD). The difference between means 
3 for two groups was assessed by T-test. One-way ANOVA test with tukey post hoc was 
4 used to analyze the statistical differences among three or more independent groups. Two-
5 way ANOVA test with LSD post hoc was used to examine the influence of PTH and CM 
6 on another variable. P<0.05 was considered significant. IBM SPSS Statistics software 
7 (IBM, Armonk, NY, USA) was used for Two-way ANOVA statistical analysis. GraphPad 
8 Software (GraphPad Software, Inc., La Jolla, CA, USA) was used for One-way ANOVA 
9 and T-test statistical analyses and graph performance.
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1  Table 1. Serum mineral and biochemical parameters in the experiment with rats with 
2 normal renal function.
3
4 Data are mean±SD. ANOVA with Tukey test. a: p<0.05 vs Sham; b: p<0.05 vs PTX; c: 










Ionized calcium (mM) 1.21±0.04 0.59±0.05a 1.13±0.09 1.07±0.10
Phosphate (mg/dl) 6.2±0.4 11.6±2.4a 5.6±0.89b 5.4±1.47b
1,25(OH)2D3 (pg/ml) 192±78 126±53 163±56 252±73abc
FGF23 (pg/ml) 130±76 68±16a 129±45b 88±34c
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0.9±0.08 0.9±0.11 0.9±0.11 0.85±0.10
Ionized calcium (mM) 1.21±0.04 1.10±0.05
a
1.00±0.04a 1.02±0.08 1.08±0.13 1.15±0.16 1.17±0.15
Phosphate (mg/dl) 6.2±0.4 8.73±1.03
a
7.35±0.78a 7.77±1.22 6.32±0.89 7.58±1.79 7.94±1.86




n.a n.a n.a n.a
PTH (1-34) (pg/ml) - 386±116 - 304±65 295±27 541±141c 599±137
1,25(OH)2D3 (pg/ml) 192±78 159±48 131±22 162±28 158±16 153±38 152±54




471±296 491±194 1209±626c 1005±343
Data are mean±SD. One-way ANOVA with Tukey post hoc test was used to analyze differences among Sham, Nx and Nx-CM groups. 
a: p<0.05 vs Sham; b: p<0.05 vs Nx. Two-way ANOVA test with LSD post hoc was used to compare the PTH and CM effects on Nx-
PTx groups. c: p<0.05 vs Nx-PTX-PTHx6; n.a.: not applicable.
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2 Figure 1. Effects of CM in the bone histomorphometric parameters of normal rats undergoing 
3 PTX and clamped PTH. After 28 days, the bone volume (a) remained similar in all groups. 
4 Parathyroidectomy decreased the osteoid volume (b), osteoid surface (c), osteoblasts (d) and 
5 osteoclasts (f) activity. PTH replacement reestablished bone remodeling that was similar to sham. 
6 Treatment with CM produce a tendency to increase osteoblast activity. Bars show mean±SD. One-
7 way ANOVA test with Tukey post-hoc. *: p<0.05; **: p<0.01. ●: Sham; ■: PTX; ▲: PTx-
8 PTH;▼: PTx-PTH-CM.
9
10 Figure 2. Effects of CM in bone histomorphometric parameters of Nx rats and Nx rats with PTX 
11 and PTH infusion. Nx induced a reduction in the bone volume (a), and increased bone turnover (b-
12 f). a p<0.05 vs Sham (One-way ANOVA test with tukey post hoc). In Nx rats, treatment with CM 
13 prevented the decrease in bone turnover. In Nx-PTx-PTHx6 the bone turnover was decreased 
14 while CM treatment (Nx-PTx-PTHx6-CM) increased bone cell activity. *: p<0.05; ** p<0.01 
15 (Two-way ANOVA test with LSD post hoc). The infusion of PTHx9 significantly increased bone 
16 turnover as compared with PTHx6. b p<0.01vs Nx-PTx-PTHx6 (Two-way ANOVA test with LSD 
17 post hoc). In conditions of very high PTH, the administration of CM (Nx-PTx-PTHx9-CM) did 
18 not produce a significant further increase in bone cell activity. Bars show mean±SD. n.s: not 
19 significant. ●: Sham; ▲: Nx; ▲: Nx-CM; ■: Nx-PTX-PTHx6; ■: Nx-PTX-PTHx6-CM; ▼: Nx-
20 PTX-PTHx9; ▼: Nx-PTX-PTHx9-CM.
21
22 Figure 3. Effects of CM on bone mineralization of Nx rats and Nx rats with PTX and PTH 
23 infusion. No significant differences were found between groups treated with vehicle or CM for 
24 osteoid thickness (a), mineralizing surface related to osteoid Surface (b), mineral apposition rate 
25 (c), adjusted apposition rate (d), mineralization lag time (e) or osteoid maturation time (f). a 
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1 p<0.05 vs Sham (One-way ANOVA test with tukey post hoc). b p<0.05 vs Nx-PX-PTHx6 (Two-
2 way ANOVA test with LSD post hoc). n.s: no significant differences. ●: Sham; ▲: Nx; ▲: Nx-
3 CM; ■: Nx-PTX-PTHx6; ■: Nx-PTX-PTHx6-CM; ▼: Nx-PTX-PTHx9; ▼: Nx-PTX-PTHx9-
4 CM.
5
6 Figure 4. Representative photographs of Goldner’s trichrome staining and double calcein labeling 
7 in trabecular bone. In Sham animals, an almost quiescent state of bone cells was observed (a), 
8 with normal mineralization (b). In Nx rats, an increase in bone cell activity was observed, note the 
9 high number of the cuboidal cells (osteoblasts, arrowhead) and multinucleated cells (osteoclasts, 
10 asterisk) on the bone surface (c), accompanied by an increase in bone formation (d). Nx rats 
11 treated with CM maintained similar bone cell activity (e) and mineralization (f) to Nx rats. In Nx-
12 PTX-PTHx6 animals low bone turnover (g) and bone formation (h) with respect to Nx group were 
13 detected. Treatment with CM increased the number of osteoblasts and osteoclasts (i) as well as 
14 mineralization and bone formation (j). In Nx-PTX-PTHx9 group a similar bone turnover (k) and 
15 mineralization (l) to the Nx group was observed. In Nx-PTX-PTHx9 + CM bone cells activity (m) 
16 and bone formation (n) were also similar to those observed in their corresponding vehicle group 
17 Nx-PTX-PTHx9. Mineralized tissue is stained in green while the non-mineralized bone (osteoid) 
18 is stained in red. The distance between calcein labels (Double-head arrows) shows the bone being 
19 formed during the time interval (7 days) indicating the mineralization status. Magnification: 200x. 
20 Scale bar: 100µm. Arrowheads: Osteoblasts. Asterisks: Osteoclasts.
21
22 Figure 5. The administration of CM triggered Erk1/2 phosphorylation of osteoblasts. Osteoblasts 
23 with positive phospho-Erk1/2 staining (b and c) were counted in 3 random fields samples and 
24 were expressed as the percentage of total osteoblasts (a). Goldner’s staining of undecalcified bone 
25 sections showed cuboidal osteoblasts covering osteoid on the bone surface. 
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1 Immunohistochemistry for phospho-Erk1/2 showed intense nuclear staining in osteoblasts in the 
2 Nx-CM (b), Nx-PTx-PTHx6-CM and Nx-PTx-PTHx9-CM groups (c) and scarce nuclear staining 
3 in the bone cells of the other groups. To determine that the target cells were osteoblasts, serial 
4 undecalcified bone sections were also stained for osteocalcin. Immunohistochemistry without 
5 primary antibody in undecalcified bone samples showed no positive staining. Arrows indicate 
6 nuclear phospho-Erk1/2. Magnification 1000x. Scale bar: 20µm.
7
8 Figure 6. Treatment with CM triggers CaSR downstream signaling and up-regulates osteogenic 
9 marker genes expression in low calcium conditions. Western blots of total protein extracts show 
10 positive expression of CaSR in UMR106 cell line and with CM there was a non-significant 
11 tendency to increase PCNA expression (a), while induced a manifested Erk1/2 phosphorylation 
12 (b). The gene expression of Runx2 (c), Osterix (d) and osteocalcin (e) was induced with the 
13 effective dose of CM. Bars show mean±SD. T-test. a: p<0.05 vs control; b: p<0.05 vs CM 1µM.
14
15 Figure 7. Inhibition of CaSR signaling by Calcilytics decreases osteogenesis in UMR-106 cells. 
16 Calhex administration at 10 M reduced Erk1/2 phosphorylation (a). In presence of Calhex there 
17 was a significant decrease of Osterix (b), Runx2 (c) and Osteocalcin (d) expression. 
18
19 Figure 8. Treatment with CM during osteogenic differentiation of MSC in low Ca medium 
20 increases mineralization and gene expression of osteogenic marker. Osteogenic differentiation 
21 induced matrix mineralization (a and b), and increased expression of osteogenic gene markers 
22 Runx2 (c), Osterix (d), Osteocalcin (e) and BMP2 (f). Both, MSC and MSC-derived osteoblasts 
23 expressed CaSR (g). Mineralization and osteogenic markers were further increased with CM 
24 addition. Low Ca was 0.5mM. [CM]= 100µM. Bars show mean±SD. T-test. a: p<0.05 vs MSC. b: 
25 p<0.05 vs OB. Magnification: 200x. Scale bar: 100µm.
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3 Supplementary Table S1. Sequences of the primers used for the RT-PCR. 
4 Supplementary Figure S1. Representative photographs of Goldner's trichrome staining in 
5 trabecular bone from Sham (a), PTX (b), PTX-PTH (c) and PTX-PTH-CM (d) groups with 
6 normal renal function. As compared with the Sham group, the PTX group shows a decrease in 
7 osteoid surface and in the number of osteoblasts and osteoclasts. PTH replacement increased 
8 osteoid surface and the osteoid surface covered by osteoblasts. As compared with PTX group the 
9 administration of CM maintained bone cell activity and mineralization. Magnification: 200x. 
10 Scale bar: 100µm. 
11 Supplementary Figure S2. Evolution of the total body weight of the different groups of rats 
12 during the experiment. * p<0.05 Sham vs all groups.
13 Supplementary Figure S3. Cortical bone analysis. Cortical Bone Area (Ct.B.Ar) (a) and Cortical 
14 Thickness (Ct.Th) (b) in the midshaft of the femurs were similar in all groups. 
15 Supplementary Figure S4. Treatment with CM triggers phospho-Erk1/2 nuclear translocation. 
16 Immunofluorescence analysis show increased amount phospho-Erk1/2 (Green) in the nuclei of 
17 UMR cells (Blue) after 6 hours of treatment with CM (a). The amount of green pixels in the nuclei 
18 was higher in cells treated with CM than in vehicle (b). T-test *** p<0.001. Scale bar: 50 µm.
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Figure 1. Bone histomorphometry normal renal function 
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Figure 2. Bone histomorphometry 5/6Nx_TV 
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Figure 3. Bone histomorphometry 5/6Nx_M 
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Figure 4. Representative microphotographs 
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Figure 5. Bone p-ERK1/2 IHC 
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Figure 6. UMR and CM 
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Figure 7. UMR and Calhex 
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Figure 8. MSC osteogenic differentiation and CM 
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SUPPLEMENTARY FIGURE S1. 
 
 
Supplementary Figure S1. Representative photographs of Goldner's trichrome staining in 
trabecular bone for Sham (a), PTX (b), PTX-PTH (c) and PTX-PTH-CM (d) groups with 
normal renal function. As compared with the Sham group, the PTX group shows a decrease 
in osteoid surface and in the number of osteoblasts and osteoclasts. PTH replacement 
increased osteoid surface and the osteoid surface covered by osteoblasts. Despite absence 
of PTH the administration of CM maintained bone cell activity and mineralization. 
Magnification: 200x. Scale bar: 100µm. 
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SUPPLEMENTARY FIGURE S2. 
 
 
Supplementary Figure S2. Evolution of the total body weight of the different groups of 
rats during the experiment. * p<0.05 Sham vs all groups. 
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SUPPLEMENTARY FIGURE S3. 
 
Supplementary Figure S3. Cortical bone analysis. Cortical Bone Area (Ct.B.Ar) (a) and 
Cortical Thickness (Ct.Th) (b) in the midshaft of the femurs were similar in all groups. 
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SUPPLEMENTARY FIGURE S4. 
 
Supplementary Figure S4. Treatment with CM triggers phospho-Erk1/2 nuclear 
translocation. Immunofluorescence analysis show increased amount phospho-Erk1/2 
(Green) in the nuclei of UMR cells (Blue) after 6 hours of treatment with CM (a). The 
amount of green pixels in the nuclei was higher in cells treated with CM than in vehicle (b). 
T-test *** p<0.001. Scale bar: 50 µm. 
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SUPPLEMENTARY TABLE S1. 
 
 Forward primer Reverse Primer 
Rat Runx2 5’-CGGGAATGATGAGAACTACTC-3’ 5’-CGGTCAGAGAACAAACTAGGT-3’ 
Rat Osterix 5’-GTACGGCAAGGCTTCGCATCTGA-3’ 5’-TCAAGTGGTCGCTTCGGGTAAAG-3’ 
Rat Osteocalcin 5’-TCTGAGTCTGACAAAGCCTTCATG-3’ 5’-TGGGTAGGGGGCTGGGGCTCC-3’ 
Rat GAPDH 5’-AGGGCTGCCTTCTCTTGTGAC-3’ 5’-TGGGTAGAATCATACTGGAACATGTAG-3’ 
Human Runx2 5’-CCGGAGTGGACGAGGCAAGAGTT-3’ 5’-AGCTTCTGTCTGTGCCTTCTGGG-3’ 
Human Osterix 5’-ATCTGCCTGGCTCCTTGGGACCCG-3’ 5’-TGCTTTGCCCAGAGTTGTTGAGTC-3’ 
Human Osteocalcin 5’-GCAGAGTCCAGCAAAGGTGCAGCC-3’ 5’-GCCTCCTGAAAGCCGATGTGGTCA-3’ 
Human BMP2 5’-AGGAGGCAAAGAAAAGGAACGGAC-3’ 5’-GGAAGCAGCAACGCTAGAAGACAG-3’ 
Human GAPDH 5’-TGATGACATCAAGAAGGTGGTGAAG-3’ 5’-TCCTTGGAGGCCATGTGGGCCAT-3’ 
 
Supplementary Table S1. Sequences of the primers used for the RT-PCR. 
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